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The receptor-type protein tyrosine phosphatases (RPTPs) of the R3 
subgroup play key roles in the immune, vascular and nervous system. They 
are characterised by an extracellular domain (ECD), comprised of multiple 
FNIII-like repeats, a transmembrane domain and a single intracellular 
phosphatase domain. Although their phosphatase domains have been 
Fstudied in detail the functional roles of their extracellular regions have not 
been clearly defined. Potential roles in ligand interaction, dimerisation and 
cell-cell contacts have been reported. Here I used a bimolecular 
fluorescence complementation (BiFC) assay in live cells to examine the 
molecular basis for the interaction of one of the R3 RPTP members, VE-
PTP, with VE-cadherin, and explored the potential of others to interact with 
this protein. The potential of R3 RPTPs to homo-dimerise via extracellular 
domains in live cells was also addressed. Quantitative BiFC analysis using 
sialophorin (SPN), an unrelated membrane protein, and a membrane 
anchored C-terminal Venus-YFP (Myr-VC) fragment as controls revealed a 
specific interaction between VE-PTP and VE-cadherin using constructs 
expressing only the extracellular and transmembrane domains. Use of a 
deletion mutant indicated that, in contrast to previous studies, removal of the 
17th FNIII-like domain of VE-PTP is not sufficient to disrupt this interaction. 
Other members of the R3 RPTP family (DEP-1, GLEPP1 and SAP-1) also 
exhibited the potential to interact with VE-cadherin suggesting that specificity 
of this protein-protein interaction is not determined by the ECD alone. The 
direct interaction of DEP-1 with VE-cadherin is likely to be of physiological 
relevance since both proteins are expressed in endothelial cells. GLEPP1 
and SAP-1 exhibited homo-dimerisation, whereas DEP-1 and VE-PTP did 
not form dimers via their extracellular and/or transmembrane domains. SPN 
was identified as a possible bona fide ligand for DEP-1 and their interaction 
is likely to be of physiological relevance since they were both shown to 
regulate T cell receptor activation. The interactions identified in the present 
study suggest a role for both the extracellular domain and transmembrane 
domain of R3-PTPs in interaction with VE-cadherin. The study also highlights 
the importance of using multiple controls in BiFC experiments and 

































1.1 Protein tyrosine phosphatases 
Over the past few decades there has been a great improvement in the 
techniques for studying protein structures and functions. As a result there 
has been a great focus on processes by which newly synthesised proteins 
become post-translationally associated with specific organelles or are 
modified by folding or addition of different associated constituents, such as 
metals and carbohydrates (Waters, 2016). Almost all proteins undergo post-
translational modifications (PTMs) that take place in different cellular 
compartments (e.g. nucleus, cytoplasm, endoplasmic reticulum and Golgi 
apparatus) and modulate functions of modified proteins. It has been 
proposed that overall structure and function of a mature protein in a cell 
could be influenced by PTMs (Blom et al, 2004). PTMs can be irreversible, 
such as proteolytic cleavage, or reversible, such as phosphorylation and 
glycosylation (Blom et al, 2004; Jensen, 2004). Protein modification by 
phosphorylation is considered a key event in many signal transduction 
pathways of biological systems and it mainly occurs on serine, threonine and 
tyrosine residues (Blom et al, 2004). For example, in cell signalling kinase 
cascades are turned on and off by the addition and removal of phosphate 
groups (Jensen, 2002; Jensen, 2004).  
Many fundamental cellular processes in human cells, such as 
communication between and within the cells, proliferation, differentiation, 
metabolic homeostasis, migration and regulation of gene transcription, are 
coordinated by tyrosine and to a lesser extent by threonine and serine 
phosphorylation. Although phosphorylation of tyrosine residues represents 
less than 1%, tyrosine phosphorylation plays an essential role in signal 
transductions that regulate these cellular processes among neighbouring 
cells in embryogenesis, organ development, tissue homeostasis and the 
immune system (Alonso et al, 2004; Conrads and Veenstra, 2005). It is a 
reversible and dynamic process governed by the opposing, yet coordinated, 
activities of protein tyrosine kinases (PTKs) and protein tyrosine 
phosphatases (PTPs) (Ostman et al, 1994; Mustelin et al, 2002; Chiarugi, 
2005). PTKs catalyse phosphorylation of protein, i.e. addition of a phosphate 
group, whereas PTPs are responsible for the removal of a phosphate group 
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(i.e. dephosphorylation), thus modifying biological function of their substrates 
(Figure 1). These two enzymatic reactions can have a variety of effects, 
including steric hindrance and either allosteric or conformational activation or 
inactivation (Hunter, 1995). It was generally considered that PTPs attenuate 
signal transductions generated by PTKs. However, numerous studies over a 
few decades demonstrated that PTPs have the potential to negatively 
regulate signalling by dephosphorylating autophosphorylation sites in PTKs 
themselves or phosphorylation sites in their downstream target as well as 
play a positive role by dephosphorylating an inhibitory site in a PTK, such as 
the C-terminal sites in Src family PTKs, thereby activating the kinase and 
promoting phosphorylation and signalling (Kohanski and Lane, 1986; Lin and 
Clinton, 1988; Ostergaard et al, 1989; Krebs, 1992; Thomas and Brown, 
1999; Kang and Kim, 2006; Tonks, 2013). Although much more research has 
been focused on PTKs it is emerging that PTPs play specific, active and in 
some cases even dominant roles in regulating the levels of tyrosine 
phosphorylation in cells and in the regulation of many physiological 
processes (Fischer et al, 1991). Dysregulation of PTPs gives rise to a variety 
of inherited or acquired human diseases, such as cancer and immune 
deficiencies (Alonso et al, 2004). Therefore PTPs represent an important 
protein family the study of which would shed more light into their specific 
physiological functions and regulations as well as enabling development of 











Figure 1. Phosphorylation/Dephosphorylation reactions. Protein tyrosine 
kinases catalyse the addition of phosphate groups (phosphorylation) by 
transferring the phosphate group from ATP to the hydroxyl group of a serine, 
threonine or tyrosine in the protein. Dephosphorylation is a reversal of 
phosphorylation catalysed by protein tyrosine phosphatases, which involves 
the removal of a phosphate group from a phosphorylated protein. 
 
1.1.1 Dephosphorylation mechanism 
Dephosphorylation of substrates by PTPs is a two-step mechanism (Figure 
2). The first step involves the formation of a covalent bond between a PTP 
and the phosphate group of the substrate phosphotyrosine. In this process 
the phosphate group is displaced from the substrate’s tyrosine, releasing the 
dephosphorylated protein. In the second step the subsequent PTP-
phosphate bond (phosphoester bond) is hydrolysed, regenerating the active 
PTP and releasing the phosphate group (Ostman et al, 2006). In this step a 
water molecule acts as a nucleophile, which is activated by an aspartate 
residue by abstracting one of its hydrogens. A glutamine residue ensures the 




















Figure 2. Two-step dephosphorylation mechanism. In the first step cysteine in the active site of a PTP acts as the attacking 
nucleophile, donating an electron to a phosphate group attached to a substrate, thus displacing the substrate and forming a 
thiophosphoryl enzyme intermediate (phospho-cysteine intermediate). The phosphoenzyme formation step is assisted by an 
aspartic acid, which protonates the P-O bond linking the phosphate group to the tyrosine with subsequent release of free substrate. 
In the second step the phosphoester bond in thiophosphoryl enzyme intermediate is hydrolysed, releasing free enzyme and 
inorganic phosphate. A glutamine residue coordinates a precise placement of the water nucleophile for efficient phosphoenzyme 
hydrolysis.   
   

















1.1.2 Classification of protein tyrosine phosphatases  
 
Protein tyrosine phosphatases (PTPs) represent a large and diverse 
superfamily of related enzymes encoded by 107 PTP genes in the human 
genome (Alonso et al, 2004). The PTPs can be grouped into four families, 
namely Class I, II and III cysteine-based PTPs and aspartic acid-based 
PTPs. Based on their structure and substrate specificity Class I cysteine-
based PTPs can be further divided into two major categories: the tyrosine-
specific or “classical” PTPs, which are specific for phosphotyrosine (pTyr)-
containing substrates and the dual specificity phosphatases (DSPs), which 
dephosphorylate pTyr and pSer/pThr and other substrates, such as lipids 
and mRNA. As demonstrated in Figure 3 classical PTPs, in turn, can be 
subdivided into intracellular non-transmembrane NT1-NT9 phosphatases 
and transmembrane receptor-like enzymes designated receptor types R1-R8 
based on sequence similarity (Andersen et al, 2001; Alonso et al, 2004; Barr, 
2010). This is a simplistic classification of phosphatases, which in reality is 
much more complex and diverse due to the use of alternative promoters, 
alternative mRNA splicing and post-translational modifications. Classical 
PTPs have one or two intracellular domains but only one membrane-
proximal domain (D1) is believed to be catalytic, comprising about 280 
residues. Nevertheless the structural integrity of the second PTP domain 
(D2) was shown to be important for the activity, specificity and stability of the 
RPTP as a whole and may provide docking sites for substrates and 
regulatory proteins (Tonks, 2006). The catalytic domain is defined by several 
conserved short sequence motifs, such as the signature sequence that 
functions as a phosphate-binding loop at the active site (Tonks, 2006). The 
specificity of the classical PTPs for the phosphotyrosyl residues could be 
partially explained by the depth of the active side cleft on the protein 
molecular surface. The depth of this cleft is determined by an invariant 
tyrosine residue from the pTyr loop. At the base of the cleft a cysteine (cys) 
residue is positioned within the PTP (i.e. catalytic) loop for nucleophilic attack 
on the phosphate moiety of the substrate (Salmeen et al, 2000). Non-
transmembrane PTPs (NTPTPs) are rich in protein-protein interaction 
domains, such as the SH2 domain (Alonso et al, 2004). In addition the 
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NTPTPs contain a wide variety of structural motifs flanking the catalytic 
domain that are important for regulating their PTP activity, either directly by 
interaction with the active site or by controlling substrate specificity (Garton 
et al, 1997). The transmembrane receptor-like phosphatases (PTPs) are 
characterised by an extracellular domain and a membrane-spanning α-helix 
transmembrane.  Many RPTPs display features of cell-adhesion molecules 
have been implicated in processes that involve cell–cell and cell–matrix 













Figure 3. Schematic representation of Classical PTPs. The classical protein tyrosine phosphatases (PTPs) can be categorised 
as non-transmembrane (NT) or receptor-like (R) proteins. Both categories are further subdivided into NT1-NT9 groups for non-
transmembrane phosphatases and R1-R8 groups for receptor phosphatases based on the structure similarities. Only the human 
PTPs are shown. The image was obtained and modified from Tonks (2006).    
Non-transmembrane PTP subgroups (NT) 
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1.2 Protein tyrosine phosphatases of R3 subgroup 
The focus of this thesis is on the receptor-type PTPs of R3 subgroup (R3 
RPTPs) (boxed in red in Figure 3). There are five RPTP members in this 
subgroup in humans and mice: density-enhanced phosphatase-1 (DEP-1), 
vascular endothelial protein tyrosine phosphatase (VE-PTP), glomerular 
epithelial protein 1 (GLEPP1), stomach cancer-associated protein tyrosine 
phosphatase-1 (SAP- 1) and protein tyrosine phosphatase receptor type Q 
(PTPRQ).  Only the first four members are tyrosine phosphatases. The 
PTPRQ protein, although it shares primary structure with the other R3 
RPTPs, is a phosphatidylinositol (PI) phosphatase and has little activity 
towards protein substrates (Yu et al, 2013; Jeon, 2015). Therefore, only VE-
PTP, DEP-1, SAP-1 and GLEPP1 transmembrane enzymes were 
investigated in this project. The schematic representation of these proteins is 
shown in Figure 4.  
All the members of the R3 subgroup of RPTPs share a similar structure, with 
an extended N-terminal extracellular portion containing multiple fibronectin 
type III-like domains (Figure 4), a transmembrane domain and a single 
catalytic domain in the cytoplasmic region, which contains a highly 
conserved active site with a cysteine residue and the flexible WPD (Trp-Pro-
Asp) loop (Murata et al, 2010; cited in Barr, 2010). In addition, all R3 RPTP 
members are highly glycosylated, containing multiple N-glycosylation sites in 
their extracellular region (Matozaki et al, 2010). 
The intracellular portion of these enzymes has been studied intensively and it 
has been shown that they share other features as well. For example, all 
members of this subgroup undergo tyrosine phosphorylation at the amino 
acid motif YxNᶲ (where x represents any amino acid and ᶲ a hydrophobic 
amino acid) in the COOH-terminal region (Matozaki et al, 2010; Murata et al, 
2010). For example, in SAP-1 two tyrosine residues at positions 945 and 953 
were demonstrated to be potential phosphorylation sites. Whereas Tyr1220 in 
GLEPP1 and Tyr1982 in VE-PTP were shown to be required for the 
phosphorylation of these phosphatases (Murata et al, 2010). DEP-1 was 
shown to be phosphorylated on residues Tyr1311 and Tyr1320 in response to 
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vascular endothelial growth factor (VEGF) (Spring et al, 2014). Src family 
kinases are important for the tyrosine phosphorylation of R3 RPTPs. This 
motif was shown to act as a binding site for the Src homology-2 (SH2) 
domains of Src family kinases (SFKs), leading to the dephosphorylation and 
consequent activation of Src by the catalytic domain of R3 RPTPs (Matozaki 
et al, 2010; Murata et al, 2010). The same motif has been shown to be 
involved in interaction with an adaptor protein Grb2, which forms a complex 
with a guanine nucleotide exchange protein, Son of sevenless (SOS), that in 
turn promotes the activation of the Ras/mitogen-activated protein kinase 
(MAPK) pathway (Murata et al, 2010). However, the functional significance 
for the interaction between Grb2 and R3 subgroup RPTPs remains unclear. 
In addition R3 RPTPs are expressed in a single or limited number of cell 
types and unambiguously at the apical surface of polarised cells. 
Interestingly, in the case of VE-PTP it has been shown that with increasing 
cell density more VE-PTP was detected at cell contacts but the overall 














Figure 4. Schematic representation of the R3 RPTPs. VE-PTP has 17 
fibronectin type III-like domains and SAP-1, GLEPP-1 and DEP-1 have eight 
fibronectin type III-like domains in their extracellular region. These enzymes 
are Ia membrane proteins that have a single transmembrane spanning 












1.2.1 Signal transduction pathways of R3 RPTPs  
Some RPTPs have been reported to regulate the activity of RPTKs through 
dephosphorylation. Ligand-binding to the extracellular domains of RPTKs 
was shown to induce their dimerisation, resulting in the subsequent 
autophosphorylation of their cytoplasmic domains and activation of the 
tyrosine kinase activity. Phosphorylated tyrosine sites in the RPTKs 
cytoplasmic domains serve as binding sites for specific downstream 
signalling molecules, which, upon complex formation, initiate a specific signal 
transduction (Sakuraba et al, 2013). A study by Sakuraba et al (2013) using 
a two-hybrid system with substrate-trapping R3 RPTP mutants demonstrated 
that the members of the R3 subgroup share some similarities in specificity 
towards some RPTKs but differences towards others. All four members 
appeared to interact with and dephosphorylate TYRO3 and EphB2 tyrosine 
kinases whereas protein tyrosine kinase RET was recognised only by DEP-
1, and EGFR1 and VEGFR2 kinases by SAP-1. However, the signal 
transduction pathways are not fully defined for all R3 RPTPs. It is interesting 
to note that VEGFR2 was identified as a substrate for SAP-1 in a study by 
Sakuraba et al (2013) whereas in a study by Chabot et al (2009) VEGFR2 
was identified as a bona fide substrate for DEP-1. DEP-1 was shown to 
specifically dephosphorylate tyrosine residues in the activation loop of 
VEGFR2 and, thus, play a regulatory role in the VEGFR2-mediated 
angiogenic signalling response. The proposed DEP-1 regulation of VEGFR2-
mediated signalling pathway is shown in Figure 5. It appears that DEP-1 
exerts both negative and positive regulation of VEGFR2 activity perhaps by 
dephosphorylating different tyrosine residues. Upon VEGF stimulation 
VEGFR2 undergoes dimerisation that allows trans/autophosphorylation of 
several intracellular tyrosine residues. Activated VEGFR2 then associates 
with numerous signal transducers, resulting in endothelial cell survival, 
proliferation and migration (Laramee et al, 2007). Activated VEGFR2 was 
shown to associate with VE-cadherin-β-catenin complex, where it is 
dephosphorylated by DEP-1 (Lampugnani et al, 2003). This results in 
impaired activation of the proliferative ERK1/2 pathway and, thus, in 
decreased endothelial cell proliferation (Chabot et al, 2009). A study by 
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Laramee et al (2007) demonstrated that upon VEGF stimulation VEGFR2 
also associates with and phosphorylates an adaptor protein Gab1. It has 
been suggested that the activated Gab1 links the DEP-1-activated Src 
(through dephosphorylation of the Src-inhibitory tyrosine residue Y529) to 
phosphatidylinositol3 kinase (PI3K) and subsequently activates Akt signalling 
pathway that promotes cell survival (Laramee et al, 2007; Chabot et al, 2009; 
Lampugnani et al, 2003). VE-PTP was also shown to interact with and 
dephosphorylate VEGFR2. However, unlike with DEP-1, this association is 
not direct but mediated by the Angiopoietin-1 (Ang1) receptor Tie-2 and it is 
accompanied by decreased VE-cadherin phosphorylation and the 
subsequent enhancement of lumenised vessel formation (Hayashi et al, 
2013). VE-PTP, Tie-2 and VEGFR2 appear to form a trimeric complex that, 
upon stimulation by VEGF and Ang1, translocates to junctions where Tie2 
and VEGFR2 are dephosphorylated and thus inactivated by VE-PTP. 
Downregulation of VE-PTP results in increased activation of VEGFR2 and 
Tie-2 and leads to VE-cadherin phosphorylation and formation of 
pathological vasculature (Hayashi et al, 2013). However, the exact signalling 
pathway that brings all these proteins together in regulation of VE-cadherin-
mediated angiogenesis is not yet defined. 
However, it is important to note that the above studies obtained their results 
using different methods. A study by Sakuraba et al (2013) used mammalian 
two-hybrid assay, which provides sensitivity and specificity in protein-protein 
interaction studies and allows the assayed proteins to undergo appropriate 
post-translational modifications in their native cellular context. However, 
caution must be taken when interpreting the results as an exogenous 
expression of hybrid “prey” and “bait” proteins could lead to either false 
positive or false negative results. For example, overexpression of proteins is 
common and can create the risk that the proteins interact merely due to their 
high concentration in the cell. Generation of hybrid proteins can also result in 
steric hindrance, preventing the association of the assayed proteins and thus 
giving rise to false negative interactions. On the other hand, fusion proteins 
can adopt altered conformations, which could result in exposure of an 
interaction domain that is normally hidden in the protein structure, facilitating 
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non-native interactions and resulting in false-positive signal (Lievens et al, 
2009). In contrast, a study by Chabot et al (2009) used substrate-trapping 
experiments which, although versatile and any type of cells, tissues or organ 
can be used, are prone to artifactual results since isolated PTPs can be 
promiscuous. In addition, both studies investigated the ability of a sigle PTP 
to dephosphorylate VEGFR2 (i.e. SAP-1 in the Sakuraba et al (2013) study 
and DEP-1 in the Chabot et al (2009) study). However, since these PTPs 
belong to the same R3 subgroup they could both have a potential to 
recognise the same substrate. 
A study by Shintani et al (2015) showed that R3 RPTPs could also be 
involved in insulin receptor (IR) signalling. Upon insulin stimulation the IR 
undergoes autophosphorylation. Activated IR subsequently phosphorylates 
and activates downstream signals, including PI3K and Akt (Saltiel and Kahn, 
2001). All four members of R3 subgroup have been shown to suppress 
activation of the IR by specifically interacting with and dephosphorylating 
Y960 in the juxtamembrane region and Y1146 in the activation loop of the IR 
(Shintani et al, 2015). Although all four phosphatases showed similar 
dephosphorylating activities towards IR, only DEP-1 was found to be 
expressed and co-localised with IR in insulin target tissues (i.e. skeletal 
muscle, liver and adipose tissue) and, thus, was the most likely member to 
regulate insulin signalling in vivo (Shintani et al, 2015). This is an interesting 
observation that raises some questions about substrate specificity. If all four 
members have a potential to bind directly to the same substrate (as in the 
case with insulin receptor) in vitro, then it remains unclear how the substrate 
specificity is determined in vivo. 
Despite many cellular targets involved in essential cellular activities, such as 
cell survival, proliferation and migration, the exact signalling events are not 
fully understood. This highlights the complexity of signal transductions and 
shows that one protein can trigger different signalling pathways. Even though 
the members of R3 RPTP subgroup show the specificity towards the same 
substrate, the biological downstream activities could be diverse. In addition, it 
is still not entirely understood how their involvement in certain signalling 


















Figure 5. Regulation of signal transduction required for endothelial cell 
survival and proliferation by DEP-1. DEP-1 dephosphorylates VEGFR2 on 
tyrosine residues in the activation loop (Y1054 and Y1059), attenuating 
VEGFR2 kinase activity and resulting in the inhibition of the proliferative 
ERK1/2 pathway. At the same time DEP-1 positively regulates VEGF-
induced Src and Akt activation. DEP-1 dephosphorylates the Src-inhibitory 
Y529, activating it. Upon VEGFR2 stimulation an adaptor protein Gab1 is 
rapidly phosphorylated by the activated Src and relocated to membrane, 
where it is recruited to the VEGFR2/VE-cadherin complex. This results in the 
induced association of PI3K to PH domain of Gab1 and the optimal activation 























1.2.2 VE-PTP (PTPRB) 
VE-PTP is expressed in vascular endothelial cells, especially in brain, lung 
and heart and more strongly in arterial endothelium (Fachinger et al, 1999). 
VE-PTP was shown to interact with the tyrosine kinase Tie-2 receptor (a 
receptor for angiopoietin that plays an important role in angiogenesis) via the 
intracellular parts of the proteins, causing dephosphorylation of Tie-2, which 
in turn results in inhibition of the proliferation of endothelial cells (cited in 
Matozaki et al, 2010; Baumer et al, 2006; Fachinger et al, 1999). 
Furthermore, co-precipitation experiments using COS-7 cells showed that 
VE-PTP also associates with the adhesion molecule of endothelial adherens 
junctions VE-cadherin and enhances cell-cell adhesion mediated by this 
molecule. But the interesting point is that this association takes place 
independently of their cytoplasmic tails and occurs via extracellular domains 
(Nawroth et al, 2002).  Experiments using a series of truncation mutants led 
to the conclusion that the 5th cadherin domain of VE-cadherin interacts with 
the 17th FNIII repeat of VE-PTP.  This finding raises a question as to the role 
of the other 16 FNIII domains in VE-PTP and other 4 domains in VE-
cadherin. Taking into account that VE-PTP interacts with Tie-2 and VE-
cadherin, it might play an important role in the regulation of functions of 
vascular adhesion molecules required for efficient angiogenesis (Matozaki et 
al, 2010). Some results showed the up-regulation of VE-PTP expression in 
new tumour vessels, suggesting the involvement of VE-PTP in tumour 













1.2.3 GLEPP-1 (PTPRO) 
 
Alternative splicing of GLEPP1 mRNA generates either a cytoplasmic or 
transmembrane form of the enzyme (Pixley et al, 1995). Five spliced 
isoforms are known: two transmembrane-type isoforms are highly expressed 
in the developing nervous system, where they are involved in the regulation 
of axon guidance. Three truncated isoforms of GLEPP1 lacking the 
extracellular domain are expressed in macrophages, B cells and osteoclasts 
(cited in Matozaki et al, 2010). GLEPP1 is also expressed in the renal 
visceral glomerular epithelial cell (podocytes), where it may play an important 
role in signalling pathways required for the regulation of structure and 
function of the slit diaphragm of podocytes, necessary for the size-selective 
filtration barrier of the kidney (Thomas et al, 1994; Matozaki et al, 2010; 
Beltran et al, 2003). This regulation is achieved through 
phosphorylation/dephosphorylation of serine, threonine or tyrosine residues 
of the adhesion proteins nephrin and neph1, creating binding sites for SH2 
domain-containing molecules and forming multiprotein complexes (Benzing, 
2004). The GLEPP1 (PTPRO gene)-deficient mice showed reduced 
glomerular filtration and a tendency to hypertension (Wharram et al, 2000). 
Some evidence showed that the likely relevant substrate for GLEPP1 is the 
high-affinity receptor for neurotrophin-3 (NT-3) tropomyosin-related kinase C 
(TrkC) (Hower et al, 2009). GLEPP1 is co-expressed with TrkC in neurons in 
several locations, including sensory ganglia, cranial ganglia, spinal cord and 
cortex (cited in Hower et al, 2009). Studies on PTPRO-/- mice demonstrated 
that lack of GLEPP1 resulted in a disturbed axon guidance in TrkC-
expressing sensory neurons, suggesting that GLEPP1 may play a role in 
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1.2.4 SAP-1 (PTPRH) 
SAP-1 is expressed in the gastrointestinal tract, particularly in the small 
intestine and colon as well as stomach, and specifically localised at the 
microvilli of the brush border in gastrointestinal epithelial cells (Sadakata et 
al, 2009). It has been suggested that SAP-1 regulates intestinal 
tumorigenesis, though the exact mechanism of this regulation remains 
unclear (Sadakata et al, 2009). Using a substrate-trapping strategy it was 
possible to identify likely physiological substrates that are dephosphorylated 
by SAP-1 – prominent focal adhesion-associated proteins p130Cas and, to a 
lesser extent, paxillin. Since p130Cas plays an important role in the 
maintenance of actin stress fibres and focal adhesions through the 
association with the SH2 domain-containing adapter protein Crk as well as 
contributing to cell spreading on the extracellular matrix (ECM), SAP-1 is 
probably involved in regulation of the rearrangement of the actin-based 
cytoskeleton and cell spreading on fibronectin (Noguchi et al, 2001). The 
cytoplasmic region of SAP-1 was shown to bind to protein kinase Lck, 
resulting in the inhibition of the Lck kinase activity and consequent inhibition 
of T cell receptor-mediated T cell function (Sadakata et al, 2009). However, 
the exact mechanism of SAP-1 regulation of Lck-mediated T cell function 
remains unclear. SAP-1 has been shown to regulate negatively the 
progression of human hepatocellular carcinoma (HCC) by suppressing 
mitogenic and survival signalling and the expression of this protein seems to 
be down-regulated at the later stages of human HCC (Nagano et al, 2003). 
Similar results were obtained by studying colorectal cancer tissues, showing 
a decrease in SAP-1 expression with the progression of this cancer (Seo et 










1.2.5 DEP-1 (PTPRJ) 
 
DEP-1 (also known as PTPRJ and CD148) is expressed by all resting 
leukocytes, with the highest level of expression on monocytes, intermediate 
level on NK cells, B cells and CD8+ T cells and the lowest level on CD4+ T 
cells. The expression of DEP-1 on peripheral T cells is up-regulated in the 
presence of IL-2 and IL-15, suggesting that DEP-1 is involved in the 
functional regulation of activated T cells, particularly CD8+ T cells. The fact 
that DEP-1 is also expressed on monocytes, B cells and NK cells suggests 
that CD148 may have a role in the biological responses of different 
populations of mononuclear cells and that its primary function is not 
restricted to T cells (Tangye et al, 1998). In addition, a study by Borges et al 
(1996) showed that the high expression levels of DEP-1 are also present in 
distal tubule epithelia and endothelial cells at sites of cell-cell interactions as 
well as megakaryocytes (Borges et al, 1996). The expression of this PTP 
displayed a direct relation to cell density, suggesting that it may play a role in 
regulation of cell contact-mediated growth inhibition (Borges et al, 1996; 
Matozaki et al, 2010). DEP-1 has been found to function as a tumour 
suppressor and deletion or mutation of a gene PTPRJ that encodes for this 
protein can be observed in colon cancer (Ostman et al, 2006; Barr, 2010). A 
study by Whiteford et al (2011) showed that heparin sulphate proteoglycan 
Syndecan-2 acts as a ligand for the DEP-1 and through the interaction of the 
extracellular domains of these two proteins (which requires PI3K activity 
downstream of Src kinase) the extracellular core protein of Syndecan-2 
promotes β1 integrin-mediated fibroblast attachment and spreading. Another 
ligand for DEP-1 is Thrombospondin-1 (TSP1) – a glycoprotein that mediates 
cell-cell and cell-matrix interactions. TSP1 increases DEP-1 activity, 









1.3 Function of R3 RPTP extracellular domain 
Even though these PTPs show functional importance in the regulation, both 
positive and negative, of signal transduction, the exact functions and 
mechanisms remain uncharacterised and require further investigation.  
Although the function of the intracellular catalytic domain of RPTPs has been 
extensively studied the function of the extracellular domain for RPTPs is less 
clearly defined but probably plays an important role in regulating activity. For 
example, the extracellular domain (ECD) of a type IIB receptor protein 
tyrosine phosphatase RPTPµ was shown to play a key regulatory role in 
modulating the stability of adherens junctions. The extracellular region of this 
protein is highly N-glycosylated and consists of one MAM (meprin/A5/µ) 
domain, one immunoglobulin (Ig)-like domain and four fibronectin (FN) type 
III repeats, forming rigid rod-like architecture. RPTPµ is a cell adhesion 
molecule that forms high affinity trans-dimers, the dimensions of which match 
cadherin-mediated cell junctions and, thus, has a potential to act as a spacer 
clamp, locking the phosphatase activity at the adherens junction (Aricescu et 
al, 2007). 
Recent findings demonstrate that the extracellular domains of DEP-1 (also 
named PTPRJ and CD148) and CD45 are involved in regulation of T-cell 
receptor (TCR) triggering through mediating their passive (i.e. signalling 
independent) segregation from areas of close cell-cell contact (Cordoba et al, 
2013). It was suggested that the segregation from the engaged TCR is 
enhanced by the large extracellular domains of CD148 and CD45. The 
results also showed that it is the large size of the CD148 extracellular domain 
that prevents it from inhibiting TCR signalling, whereas truncated CD148 has 
a strong inhibitory effect (Cordoba et al, 2013). Another member of R3 RPTP 
subgroup VE-PTP was suggested to exert its role in the regulation of the 
endothelial barrier via its extracellular domain. The association of VE-PTP 
and VE-cadherin appears to stabilise VE-cadherin-plakoglobin complex and 
to enhance the adhesive function of VE-cadherin. The inhibition of VE-PTP 
expression resulted in increased permeability of endothelial cells and 
leukocyte extravasation, suggesting that VE-PTP could play an important 
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role in regulation of immune responses and that its extracellular domain 
plays an active part (Nottebaum et al, 2008). However, the molecular basis 
of the association between VE-PTP and VE-cadherin in live cells has not yet 
been defined. 
 
1.4 Fibronectin and FN type III-like domain 
 
To date the role of the extracellular domain of the R3 PTPs remains unclear. 
However, perhaps some light can be shed from a study on a key adhesion 
protein fibronectin (FN) found in the blood, interstitial extracellular matrix 
(ECM) and pericellular matrix. Fibronectin is a high molecular weight tandem 
modular glycoprotein consisting of individually folded functional domains 
termed type I, II and III repeats (Figure 6). Fibronectin provides a substrate 
for cell anchorage and serves as a regulatory protein in processes such as 
cell adhesion, motility, differentiation and proliferation (Gao et al, 2003). The 
modular fibronectin (FN) domains function by binding to other molecules and 
by acting as spacers separating and orienting other domains of the protein 
(Carr et al, 1997). Two intramolecular disulfide bonds form within each type I 
and type II module to stabilise the folded structure (Singh et al, 2010). 
Individual FNIII modules have been proposed to unfold on mechanical 
stretching of fibronectin protein, providing for the elasticity of FN fibrils, which 
is believed to expose buried binding sites (also known as cryptic sites) that, 
for example, serve as nucleation sites for the assembly of FN into its fibrillar 
form (Gao et al, 2003). Fibronectin III motifs comprise 90-100 amino acids 
characterised by highly conserved hydrophobic residues (Brady-Kalnay and 
Tonks, 1995). These domains are composed of seven antiparallel β strands 
denoted A, B, C, C′, E, F, G, arranged into two sheets (Figure 6) (Carr et al, 
1997). As a study by Martino et al (2010) showed, FN bind a wide range of 
growth factors (GFs) from different families, e.g. platelet-derived growth 
factor (PDGF) family, fibroblast growth factor (FGF) family and insulin-like 
growth factor (IGF) family. Some of these molecules bind to a heparin-
binding domain II of the FN consisting of the 12th to 14th type III repeats 
(FNIII12-14) and others bind to the full-length FN with the exact binding 
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location yet to be identified. In addition there was some evidence that the 
neurotrophins NT-3 and BDNF, hepatocyte growth factor (HGF) and 
connective tissue growth factor (CTGF) also bind to FNIII12-14 with a high 
affinity (Martino et al, 2010). The physiological role of these interactions still 
needs to be investigated in the context of each GF and potentially they could 
play a role during development and tissue repair (Martino et al, 2010). In 
addition it was shown that the tenth FN-III domain of fibronectin contains the 
cell-adhesive triplet Arg-Gly-Asp (RGD loop) sequence, which is known to 
interact with integrins, and the residues outside this loop provide specificity 
and high affinity for each integrin-ligand pair (Carr et al, 1997; Takagi, 2003). 
A member of the integrin family α5β1 interacts with FNIII through RGD motif, 
mediating FN fibril formation and governing extracellular matrix assembly 
(Figure 6). This interaction was shown to be essential for vertebrate 
development (Takagi, 2004). However, none of the FN type III-like domains 
of R3 RPTP members has an RGD sequence but instead an XGD (where X 
represents any amino acid; G – glycine and D – aspartic acid) sequence was 
found on the expected loop in five FN type III-like domains of DEP-1, through 































Figure 6. A structural representation of fibronectin glycoprotein. The 
top part of the image shows the schematic presentation of the modular 
structure of human fibronectin monomer, emphasising folding motifs FNI, 
FNII and FNIII, as well as a secondary structure of a FNIII module with 
accurate representation of relative β-strand lengths with respect to each 
other. The bottom part of the image represents a structure of the disulphide 
cross-linked fibronectin (FN) dimer and location of key binding sites. 
Fibronectin exists as a dimer of nearly identical monomers linked by a pair of 
disulphide bonds. It is made up of multiple FNI, FNII and FNIII domains 
arranged into various functional domains. The RGD sequence (Arg–Gly–
Asp) is located on the 10th type III module and is the site of cell attachment 
via α5β1 and αVβ3 integrins on the cell surface. The "synergy site" is on the 
ninth type III module and has a role in modulating fibronectin's association 






1.5 Regulation of R3 RPTPs 
A family of enzymes that play a crucial role in the regulation of cell signalling 
and the fundamental cellular processes, such as cell migration, proliferation 
and differentiation, must be tightly controlled in vivo by some regulatory 
mechanisms. It is essential that tyrosine phosphorylation mediated by PTKs 
and dephosphorylation mediated by PTPs are fine-tuned since these two 
families of enzymes have important roles in diseases like cancer and 
diabetes.  
1.5.1 Regulation by reversible oxidation 
Recently it became apparent that reversible oxidation is one of the important 
regulators of RPTPs. Most RPTPs contain two conserved cytoplasmic PTP 
domains: D1, which contains most, if not all, catalytic activity, and D2, which 
has a regulatory role. Due to their microenvironment, the catalytic cysteines 
have a low pKa. Under normal conditions the active site cysteines are in the 
thiolate anion form and thus are highly susceptible to oxidation. Some 
studies show that reactive oxygen species (ROS), the production of which is 
induced by stimuli such as ultraviolet (UV) light and cytokines, oxidise the 
essential active site nucleophilic cysteine residue, located in the HC(X)5 
signature motif, in PTPs, inactivating them (Tonks, 2006). For example, 
hydrogen peroxide (H2O2) produced in response to epidermal growth factor 
(EGF) has been shown to oxidise PTP1B’s catalytic site cysteine to sulfenic 
acid, causing reversible inactivation (Lee et al, 1998; Mahadev et al, 2001). 
This process shifts the equilibrium between the actions of protein tyrosine 
kinases and protein tyrosine phosphatases towards phosphorylation, 
activating signal transduction pathways (Lee et al, 1998). A study by Krejsa 
et al (1997) showed that CD45 RPTP is also inactivated by intracellular 
oxidation induced by vanadium PTP inhibitors and this inactivation led to the 
activation of kinase signalling cascades. However, it was also shown that not 
all the PTPs are equally sensitive to oxidation. Based on studies of RPTPα, 
the D2 domain displays greater sensitivity to oxidation than the D1 domain, 
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suggesting that PTPs containing only the D1 domain might be less sensitive 
to oxidation (den Hertog et al, 2008). 
 
1.5.2 Regulation by ligand-binding 
RPTPs could be regulated by various mechanisms and perhaps there is 
more than one way to regulate the same RPTP. The extracellular domains of 
PTPs are typically large, highly glycosylated, structurally diverse and 
evolutionarily conserved, suggesting their roles in the regulation of PTP 
function. Recent studies have defined some RPTPs through which signal 
transduction may be regulated by ligand-controlled dephosphorylation of 
tyrosyl residues in proteins. One such RPTP is a cell-adhesion-molecule-like 
RPTP leukocyte common antigen related (LAR). The activity of this protein 
was shown to be controlled by ligand binding. A high-affinity interaction 
between LAR and its ligand transmembrane protein syndecan (Sdc) results 
in promotion of LAR’s function, whereas the binding of the 
glycosylphosphatidylinositol-anchored protein Dallylike (Dlp) to LAR 
suppresses its activity (Tonks, 2006). The activity of RPTPζ was also shown 
to be regulated by ligand-binding. It has been demonstrated that a secreted 
growth factor pleiotrophin (PTN) directly binds to and inactivates the catalytic 
activity of RPTPζ, resulting in inability to dephosphorylate β-catenin and, 
thus, an increased phosphorylation of  β-catenin and the subsequent loss of 
contact inhibition, cell adhesion and the destruction of cytoskeletal 
architecture (Meng et al, 2000). Despite different regulatory mechanisms 
being identified, the mechanisms regulating R3 RPTPs activity remain 
undefined.  Although the extracellular ligand interactions were proposed to 
be one of the regulatory mechanisms the strong evidence for such regulation 
for R3 RPTPs has not yet been provided. Potential ligand proteins have been 





1.5.3 Regulation by dimerisation 
The catalytic activity of some PTPs has been shown to be affected by 
dimerisation. Unlike with PTKs PTPs are believed to be inactivated by 
dimerisation. The artificial induction of dimerisation for CD45, RPTPα and 
DEP-1 clearly affected their enzymatic activity (Noordman et al, 2008). Some 
evidence suggests that the ligand-induced oligomerisation of CD148 (DEP-1; 
PTPRJ) could be a potential mechanism to regulate this protein and that the 
extracellular domain plays a crucial role. The observations by Takahashi et al 
(2006) showed that the role of CD148 in endothelial vessel formation and in 
cell-growth control was inhibited in the presence of a bivalent monoclonal 
antibody (Ab1), generated against the extracellular domain sequence of 
CD148. It was demonstrated that bivalent but not monovalent Ab1 inhibits 
endothelial cell-growth and angiogenesis. Therefore these findings 
demonstrate that the activity of CD148 can be potentially regulated by 
extracellular domain oligomerisation (Takahashi et al, 2006). This is an 
important discovery implying that CD148 could serve as a molecular target 
for antiangiogenesis therapy, which could be forced to oligomerise and, thus, 
be activated by a synthetically generated agonist.  
However, whether dimerisation is a general regulatory mechanism of RPTPs 
is still a subject to debate. The dimerisation of R3 RPTPS is poorly 
understood and whether this dimerisation is related to the binding of 
extracellular ligands remains unclear. It has been shown that the activity of 
RPTPs is inhibited by ligand-induced dimerisation (Tonks, 2006). Although a 
study by Barr et al (2009) demonstrated that the members of R3 PTPs exist 
as monomers in solution, the dimerisation may still occur in vivo as a result 
of ligand binding to the extracellular domain. A contradictory study by Walchli 
et al (2005) showed that SAP-1 enzymes form homodimers and this 
dimerisation is mediated by the extracellular domains. It was also 
demonstrated that the monomeric form of SAP-1 is significantly more active 
than the dimeric one (Walchli et al, 2005). On the other hand, the same study 
by Walchli et al (2005) showed no dimerisation of VE-PTP and DEP1 when 
tested in parallel with SAP-1. The mechanism of ligand-induced dimerisation 
was obtained only for RPTPα and CD48, where N-terminal helix-turn-helix 
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wedge motif occludes the active site of the partner domain (Barr et al, 2009; 
Tonks, 2006). However, such a model of dimerisation-induced RPTP 
inhibition prompted by these findings cannot be extrapolated to other 
members of the RPTP family because the residues that occlude the active 
site of RPTPα and CD48 are poorly conserved among other RPTPs 
(Takahashi et al, 2006; Barr et al, 2009). It has been now shown that 
GLEPP1 could exist as a dimer in living cells and this dimerisation is partly 
regulated by disulphide linkages (Hower et al, 2009). Interestingly the 
presence of nerve growth factor (NGF) increases dimerisation of GLEPP1 by 
nearly twofold. In addition the catalytic domain of this enzyme is not involved 
in dimerisation whereas the extracellular domain and probably the 
transmembrane domain may play a role in the dimerisation. The dimerisation 
of GLEPP1 appeared to result in a strong decrease in its intrinsic activity 
(Hower et al, 2009).  
Deregulation of R3 RPTPs’ activity that results in either loss or gain of 
function contributes to the pathogenesis of human disease. For example, as 
already mentioned above, VE-PTP was shown to be an important 
component of the VE-cadherin-plakoglobin complex, required for the 
maintenance of the endothelial barrier function. VE-PTP seems to enhance 
plakoglobin/VE-cadherin association, suggesting that plakoglobin could be a 
substrate for the VE-PTP. Knocking down VE-PTP expression by RNA 
interference resulted in increased diepedesis of leukocytes, which 
demonstrates that the deregulation of VE-PTP leads to an increased 
inflammatory response. During inflammatory stimuli, leukocytes cause a 
disruption of VE-PTP/VE-cadherin association, destabilising endothelial 
contacts (Nottebaum et al, 2008). Therefore VE-PTP represents a novel 
therapeutic target for the treatment of inflammatory diseases. Because the 
selective suppression of the activity of R3 RPTPs can be essential in cells, it 
is important to understand how the inhibition of activity of these enzymes is 
regulated by dimerisation and whether this dimerisation is induced by 
ligands. This knowledge will shed more light on mechanisms of function and 
regulation of these enzymes and will help to develop novel molecular targets 
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for the development of medicinal reagents that possess distinct modes of 
action. 
1.6 Membrane protein interaction technologies 
Different methods have been developed to investigate membrane protein-
protein interactions, such as bioluminescence resonance energy transfer 
(BRET) and fluorescence resonance energy transfer (FRET), which 
represent valuable tools but are technically challenging. BRET and FRET 
rely on the ability to capture fluorescent signals from the interactions of 
labelled molecules and have been widely used to determine the 
compartmentalisation and functional organisation of living cells as well as 
protein-protein interactions and their movement inside cells (Sekar and 
Periasamy, 2003). The mammalian-membrane two-hybrid (MaMTH) assay is 
based on split-ubiquitin technique that can be used to detect dynamic and 
stimulus-dependent protein-protein interactions in mammalian cells. One 
protein of interest is fused to the C-terminal half of ubiquitin and a chimeric 
transcription factor (TF) and the other is fused to the N-terminal half of 
ubiquitin. If the two proteins of interest interact together the split halves 
reconstitute functional ubiquitin protein, which is recognised by cytosolic 
deubiquitinating enzymes, resulting in cleavage of the TF and expression of 
a reporter gene, such as luciferase (Petschnigg et al, 2014). MaMTH assay 
has been successfully applied to investigate stimulus-dependent interactions 
of the wild-type as well as oncogenic variant of epidermal growth factor 
receptor (Petschnigg et al, 2014). However, this assay has some limitations. 
The activation of a reporter gene could be caused by an interaction of 
proteins that are not being investigated, leading to false positive results. 
Over-expression of proteins is common in transient transfections and it can 
lead to non-relevant forced protein-protein interactions and self-activation of 
the reporter gene by the bait protein, resulting in false positive results (Suter 
et al, 2008). Receptor alkaline phosphatase (RAP) assay is another method 
that can be used to identify potential extracellular binding ligands. This assay 
can be carried out on endogenously expressed proteins without the risk of 
over-expressing the proteins that could lead to false-positive results. This 
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method provides a direct indicator of extracellular domain binding and it is 
heat stable and thus can be differentiated from the heat labile alkaline 
phosphatases of most tissues. It is also useful when a reliable monoclonal 
antibody is not available for the protein of interest (Stoker, 2005).  
In this study the bimolecular fluorescence complementation (BiFC) assay 
was chosen for the simple and direct visualisation of protein-protein 
interactions in live cells with minimal perturbation of their normal 
environment. The schematic representation of the BiFC assay is shown in 
Figure 7. BiFC assay can provide information about the localisation of 
protein-protein interactions and it has been used previously to investigate 
membrane protein interactions. De Virgilio et al (2004) used this assay to 
define successfully the interaction between integrin αIIbβ3 and protein 
tyrosine kinases C-Src and Syk in live cells. Some techniques are used for 
an initial screen for novel binding partners. The initial experiments on VE-
PTP and VE-cadherin interaction, as well as on R3 RPTP dimerisation 
studies, have been carried out using affinity chromatography and co-
immunoprecipitation assays (Nawroth et al, 2002; Hower et al, 2009; 
Takahashi et al, 2006). Co-immunoprecipitation provides an excellent 
method to purify and identify multiprotein complexes. However, during cell 
lysis the expressed tagged proteins could be present in a mixture of both 
physiological and non-physiological targets and the latter could be 
incorporated in the complex without any biological significance, especially if 
they interact with high affinity and/or slow kinetics of dissociation and thus 
more easily replacing the physiological targets (Berggård et al, 2007). In 
contrast to co-immunoprecipitation assays BiFC can be used to detect 

















Figure 7. Schematic representation of the principle of the BiFC assay. 
This is based on the complementation of two non-fluorescent N- and C-
terminal fragments from a Venus yellow fluorescent protein. When the two 
fragments are brought into proximity by an interaction between two proteins 
fused to the fragments the reconstituted fluorescence can be easily observed 
by any fluorescence microscopy. 
 
This method is based on the formation of a fluorescent complex when two 
fragments of a fluorescent protein are brought together by an interaction 
between proteins fused to the fragments (as shown in Figure 7) and can be 
used for visualisation of interactions between many different proteins 
expressed at low concentrations (i.e. at levels comparable to endogenous 
counterparts) in many cell types and organisms (Kerppola, 2006). However, 
BiFC assay has some limitations. One common limitation of the BiFC assay 
is the self-assembly between the two non-fluorescent fragments, contributing 
to false-positive fluorescence and making data interpretation difficult 
(Kerppola, 2006; Kodama and Hu, 2010). This problem would be addressed 
in further chapters by using negative controls and by carrying out quantitative 





1.7 Aims of the thesis 
The identification of ligands for R3 PTPs and the mapping of their binding 
sites on the extracellular domains of these enzymes will provide additional 
information on their functions, mechanisms of function and, perhaps, may 
provide tools to fine-tune the signalling pathways, mediated by these PTPs. 
For that reason investigation of the functional role of the extracellular 
domains of these proteins and identification of cognate ligands will be the 
main focus of this research. 
The initial aim of this project was to confirm the interaction between VE-PTP 
and VE-cadherin via their extracellular domains in live cells as well as to 
investigate the molecular basis of their interaction. The second aim was to 
gain a better understanding of the role of R3 RPTP extracellular domains in 
ligand-binding specificity. This was addressed by examining whether all the 
members of R3 RPTP have the potential to interact with VE-cadherin via 
their extracellular domains in live cells. Additionally the potential dimerisation 
of the R3 RPTPs via their extracellular domains was investigated in live cells.  
To address the aims of this thesis the bimolecular fluorescence 
complementation (BiFC) assay was used, which was first developed and 
validated with fusion proteins bJun and bFos that are known to interact. The 
quantitative analyses were adapted and validated from previous studies to 

































2.1 Bacterial strains 
Table 1. E. coli strains for cloning and associated genotypes 
Strain Genotype Source 
XL1-Blue recA1 endA1 gyrA96 thi-1 
hsdR17 supE44 relA1 lac [F´ 
proAB lacIq Z∆M15 Tn10 (Tetr )] 
Agilent 
SCS110 rpsL (Strr) thr leu endA thi-1 lacY 
galK galT ara tonA tsx dam dcm 
supE44 ∆(lac-proAB) [F´ traD36 
proAB lacIq Z∆M15] 
Agilent 
 
Table 2. Antibiotics for bacterial cell cultures 
Name Stock Concentration 
Working 
Concentration Source 
Ampicillin 100 mg/ml 100 µg/ml Sigma 
Chloramphenicol 
Kanamycin   







2.2 Preparation of competent E. coli  
Competent E.coli XL1-Blue and SCS110 bacterial strains were a kind gift 
from Dr. Markiv and were used to prepare stocks of competent cells. XL1-
Blue and SCS110 cells were streaked on to LB plates and grown overnight in 
37°C incubator. Single colonies from each of the plates for XL1-Blue and 
SCS110 cells were picked and grown in 10 ml Luria-Bertani (LB) Broth in the 
absence of antibiotics for 12 hours at 37°C with shaking at 180 rpm. After the 
incubation 10 ml of each bacterial culture was inoculated into 200 ml of fresh 
LB Broth and incubated at 37°C with shaking at 250 rpm until the optical 
density at 595 nm (OD595) reached 0.4. The flasks were then chilled on ice 
for 30 minutes and 50 ml of each chilled bacterial culture was aliquoted into 
sterile chilled falcon tubes. Cells were harvested by centrifugation for seven 
minutes at 3500 rpm at 4°C and the supernatants were discarded. Each 
pellet then was resuspended in 12.5 ml 0.1 M MgCl2 and centrifuged as 
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previously. Supernatants were discarded and each pellet was resuspended 
in 25 ml 0.1 M CaCl2. Resuspended cells were incubated on ice for 30 
minutes, centrifuged as previously and the supernatants were discarded. 
Each pellet was resuspended in 700 µl 0.1 M CaCl2 and 300 µl 50% (v/v) 
glycerol and the 50 µl aliquots were stored at -80°C. 
SCS110 competent cells were used when the DNA had to be digested with 
methylation-sensitive restriction enzymes (e.g. ApaI and EcoRI) since these 
cells lack DNA adenine methylation (dam) and DNA cytosine methylation 






















2.3 Media, buffers and solutions   
Table 3. Media and buffers 
Name  Composition 
SOC 2% (w/v) tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose 
LB Broth 1% (w/v) Bacto tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl 
0.1 M MgCl2 2.03 g MgCl2.6H2O, 100 ml ddH2O 
0.1 M CaCl2 11 g CaCl2.6H2O, 500 ml ddH2O 
50% (w/v) Glycerol 5 ml glycerol, 5 ml ddH2O 
50x Tris-acetate EDTA 
(TAE) 
2.0 M TrisBase, 50 mM EDTA(pH8.0), 1.0 M Glacial Acetic Acid, dH2O 
6x DNA Loading Buffer 0.4% (w/v) Orange G, 0.03% (w/v) Bromophenol blue, 0.03% (w/v) 
xylene cyanol FF, 15% (w/v) Ficoll 400 in TAE buffer 
TE Buffer 10 mM Tris-HCl, 1 mM EDTA, pH 7.5 
1 M DTT 1.54 g DTT in 10 ml MilliQ water. Store 1 ml aliquots at -20°C. 
3% Paraformaldehyde 2.4 ml 37% paraformaldehyde, 27.6 ml PBS (Mg2+/Ca2+ ) 
0.5% Triton X-100 100 µl TritonX-100, 20 ml PBS (Mg2+/Ca2+ ) 
5% Bovine Serum 
Albumin (BSA)  
1 g BSA, 20 ml PBS (Mg2+/Ca2+ ) 
10% SDS 10 g SDS in 100 ml of MilliQ water. Store at room temperature 
1 M Tris-HCl (pH 8.0) 12.114 g Tris-base in 80 ml MilliQ water. Adjust pH to 8.1 and add water to 100 ml. Store at 4°C. 
Trypsin 25 mg/ml 1 g trypsin in 40 ml 25 mM NH4HCO3 (pH 8.1) (100x solution). Store 1 ml aliquots at -20°C. 
1 M NH4HCO3 (pH 8.1) 7.9 g NH4HCO3 in 80 ml MilliQ water. Adjust pH to 8.1 and add water to 100 ml. Store at 4°C. 
Lysis Buffer 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, Milli Q water 
2x SDS-gel loading 
buffer 
50 mM Tris-base, 4% SDS, 100 mM DTT, 0.01% Bromophenol blue, 
23% Sucrose, pH6.8. 
4x Sample Buffer 240 mM Tris-HCl, pH 6.8, 8% SDS, 5% β-Mercaptoethanol, 0.04% Bromophenol blue, 40% Glycerol 
10 x SDS Running 
Buffer (sodium dodecyl 
sulfate) 
25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3  
1 x SDS Running 
Buffer 100 ml 10x SDS Running Buffer, 900 ml dH2O 
1x Transfer Buffer  25 mM Tris, 192 mM Glycine, 20% (v/v) methanol and ddH2O up to 1.25 L 
10x TBS (Tris Buffered 
Saline) 200 mM Tris-Base, 1.5 M NaCl, Milli Q water up to 1L, pH 7.6 
1x TBS 100 ml 10x TBS, 900 ml Milli Q water 
1x TBST 100 ml 1x TBS, 0.5 ml Tween 20 
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2.4 Standard molecular biology methods 
2.4.1 Primer design 
Primer design specific for each PCR template was performed using 
VectorNTI Advance® 11.5 software (ThermoFisher Scientific). First, the 
desired fusion protein sequence was generated by assembling 
corresponding nucleotide sequences for the chosen domains (e.g. signal 
peptide, extracellular and transmembrane domains) that were obtained from 
GenBank database (NCBI). The sequence has then been modified to include 
an in-frame, upstream sequence for either myc or HA epitope tags between 
Apal and either XhoI or EcoRI restriction enzyme sequences. Primers were 
designed to amplify a created target sequence by choosing auto primer 
design in VectorNTI software and selecting the regions of analysis. The 
software then automatically generated a pair of primers with calculated 
length of primers, GC content and melting temperature. In addition the 
required restriction enzymes for subcloning were selected and the 
corresponding sequences were added to each primer. Additional bases were 
added where necessary to keep the polymerase reading frame between the 
restriction enzyme cutting sequence and the rest of the primer. Also, few 
more bases (e.g. GATC) were added at 5’ ends of the primers to facilitate the 
digest close to the end of DNA regions. 
 
2.4.2 Miniprep of DNA 
Plasmid DNA was extracted and purified from bacterial cultures using a 
QIAprep Spin Miniprep Kit (QIAGEN) according to manufacturer’s 
instructions. A single colony from a freshly streaked selective plate was 
picked and inoculated into 10 ml LB Broth supplemented with an appropriate 
antibiotic and incubated overnight at 37°C with 200 rpm. The bacterial 
cultures were then pelleted by centrifugation at 4500 rpm on a bench-top 
centrifuge for 10 minutes at 25°C at 8000 rpm. The supernatant was 
discarded and the bacterial cell pellet was resuspended in 250 µl Buffer P1 
(50 mM Tris-HCl, 10 mM EDTA, 50 µg/ml RNaseA, 0.0025% (w/v) 
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thymolphtalein, pH 8.0) and transferred to a sterile 1.5 ml microcentrifuge 
tube. To lyse the cells 250 µl Buffer P2 (0.2 M NaOH, 1% (w/v) SDS) was 
added, mixed thoroughly by inverting the tube 4-6 times until the solution 
became clear (or blue if using thymolphtalein) and incubated at room 
temperature for up to 5 minutes. To neutralise the lysis buffer 350 µl Buffer 
N3 was added and mixed immediately and thoroughly by inverting the tube 
4-6 times. The solution of lysed cells was then centrifuged for 10 minutes at 
13000 rpm in a table-top microcentrifuge to precipitate the cell membrane, 
proteins and genomic DNA. The supernatant containing soluble plasmid 
DNA was applied to the QIAprep spin column by pipetting and centrifuged for 
1 minute at 13000 rpm, discarding the flow-through. The QIAprep spin 
column was then washed by adding 0.5 ml Buffer PB (5 M guanidine 
hydrochloride, 20 mM Tris-HCl, 38% (v/v) ethanol, pH 6.6) and centrifuged 
for 1 minute at 13000 rpm, discarding the flow-through. The QIAprep spin 
column was washed again by adding 0.75 ml Buffer PE (20 mM NaCl, 2 mM 
Tris-HCl, 80% (v/v) ethanol, pH 7.5) and centrifuged for 1 minute at 13000 
rpm, discarding the flow-through. To remove residual wash buffer the 
QIAprep spin column was centrifuged for additional 2 minutes at 13000 rpm. 
To elute DNA the QIAprep column was placed in a clean 1.5 ml 
microcentrifuge tube, 50 µl Buffer EB (10 mM Tris-Cl, pH 8.5) was added to 
the centre of the QIAprep spin column and allowed to stand for 1-2 minutes 
before centrifuging for 1 minute at 13000 rpm. The concentration and purity 
of the extracted DNA were assessed using a Nanodrop 1000 (Thermo 
Scientific) at 260 nm and 280 nm.  
2.4.3 PCR of constructs and reaction conditions 
The polymerase chain reaction (PCR) was used to amplify the coding 
sequences for extracellular and transmembrane domains (ECD+TM) for the 
R3 RPTPs, VE-cadherin and sialophorin (SPN). The details of constructs, 
their amplified regions and the PCR conditions are provided in Table 4. The 
primers used to amplify the desired regions are listed in Table 6. PCR 
amplification was performed using Platinum Pfx DNA Polymerase 
(Invitrogen) according to manufacturer’s instructions. Reactions were carried 
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out using BioRad MJ Mini thermal cycler. The thermocycler programs were 
customised for each target sequence based on gene length and primer 
optimal melting temperature (refer to Table 10). The dNTP mixture (10 µl of 
each NTP) was obtained by mixing 1 M stock solutions for each nucleotide 
(New England Biolabs) in the appropriate dilution. Master mix for each PCR 
reaction was prepared, using 5 µM of each primer, 10 mM dNTP mixture and 
2.5 ng/µl DNA template in a final volume of 20 µl in a thin-walled PCR tubes 
(ThermoFisher Scientific). PCR products were resolved on an agarose gel 
the DNA fragments were detected using a UV Transilluminator (Ultra-Violet 










Table 4. PCR conditions for ECD+TM amplification with Pfx platinum. The PCR conditions below were used to generate 
extracellular and transmembrane domains of the indicated proteins. For the template and primer details refer to Tables 8 and 10 
respectively.




PCR steps/Thermocycle conditions  
Enzyme Initialisation 25 cycles Final Elongation Enhancer Denaturation Annealing Extension 
PTPRB VE-PTP ECD+TM 
(A.A.23-1642) 
94°C,5min 94°C,30sec 55°C,30sec 72°C,30sec 72°C,5min - Pfx 
PTPRJ DEP-1  ECD+TM 
(A.A.36-996) 
94°C,5min 94°C,30sec 52°C,30sec 68°C,3min 72°C,10min 1x Pfx 
PTPRO GLEPP-1  ECD+TM 
(A.A.30-843) 
94°C,5min 94°C,30sec 55°C,30sec 68°C,3min 72°C,10min - Pfx 
PTPRH SAP-1  ECD+TM 
(A.A.28-755) 





94°C,5min 94°C,30sec 58°C,30sec 68°C,2min 72°C,10min - Pfx 
SPN SPN ECD+TM 
(A.A.20-276) 
94°C,5min 94°C,30sec 62°C,30sec 68°C,1min 72°C,5min 2x Pfx 
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2.4.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used for visualisation and purification of 
DNA. Agarose gels were commonly used in concentrations of 0.7% to 1.0% 
w/v depending on the size of bands needed to be separated. The appropriate 
amount of agarose powder was measured out and placed into a 
microwavable flask with 100 ml of 1x TAE (Tris-acetate-EDTA) Buffer. The 
resulting solution was then microwaved for 1-2 minutes or until the agarose 
was completely dissolved. The dissolved agarose was allowed to cool down 
for 5 minutes at room temperature until it was comfortable to handle the flask 
and 1 µl SYBR® Safe DNA gel stain (Thermo Fisher Scientific) was then 
added that binds to DNA and allows visualisation under UV light.  The 
agarose was poured into a gel tray with the well comb in place and was left 
to set at room temperature for 15-20 minutes until it had completely 
solidified. The well comb was removed and solidified agarose was placed 
into the electrophoresis unit, which was then filled with 1x TAE Buffer.  
A molecular weight 1 Kb Plus DNA ladder (Thermo Fisher Scientific) and 
DNA samples were mixed with 6x Gel Loading Dye Purple (New England 
Biolabs) at a volume ratio of 5:1 and carefully loaded into the wells of the gel. 
Electrophoresis was set to run at 110 V constant for 30-45 minutes until the 
dye line was approximately 75-80% of the way down the gel.  
The DNA fragments were detected using a UV Transilluminator (Ultra-Violet 
Ltd.) with short wavelength UV light of 200-280 nm. Long wavelength UV 
light of 315-400 nm was used to analyse the gel of the DNA that was used 







2.4.5 Purification of DNA from agarose gels 
To purify the DNA from the agarose gel the QIAquick gel extraction kit 
(Qiagen Ltd.) was used according to the manufacturer’s recommendations. 
The DNA bands of the desired size were excised with a clean scalpel, 
weighed and solubilised at 50°C for 10 minutes with three volumes of Buffer 
QG (5.5 M Guanidine thiocyanate, 20 mM Tris-HCl, 0.0025% (w/v) Cresol 
Red, pH 6.6) to one volume of excised gel. One gel volume of isopropanol 
was added to the sample and mixed thoroughly to increase the yield of DNA 
fragments. To bind the DNA the sample was applied to the QIAquick column 
and centrifuged for one minute at 14000 rpm. To remove all traces of 
agarose, the flow-through was discarded and the QIAquick column was put 
back in the same collection tube, adding 0.5 ml of Buffer QG and centrifuging 
for one minute at 14000 rpm. To wash the column 0.75 ml of Buffer PE was 
added to QIAquick column and centrifuged for one minute at same speed, 
discarding the flow-through and centrifuging for further one minute at 10,000 
rpm to remove all the traces of ethanol. To elute the DNA the QIAquick 
column was placed into a clean 1.5 ml microcentrifuge tube, adding 30 µl of 
Buffer EB (10 mM Tris·HCl, pH 8.5) and incubating for 2 minutes at room 
temperature, following by centrifugation for one minute at 14000 rpm. The 
concentration and purity of the extracted DNA were assessed using a 
Nanodrop 1000 (Thermo Scientific) at 260 nm and 280 nm. The purified DNA 
was stored at -20°C until further use. 
 
2.4.6 Purification of DNA from PCR 
DNA from the PCR reaction mixture was purified using the QIAquick DNA 
purification kit (Qiagen Ltd.) according to the manufacturer’s 
recommendations. In short, five volumes of Buffer PB were added to one 
volume of the PCR reaction, mixed thoroughly and the pH was adjusted by 
adding 10 μl 3 M sodium acetate (or until the colour of the mixture turned 
yellow). To bind the DNA the resulting mixture was applied to the QIAquick 
column inserted into a collection tube that was spun for one minute at 14000 
41 
 
rpm. The flow-through was discarded and the QIAquick column was placed 
back in the same collection tube. To wash the column, 0.75 ml of Buffer PE 
was added to the QIAquick column and spun for one minute at 14000 rpm. 
The flow-through was discarded and the column was spun again for one 
minute to remove residual wash buffer. The QIAquick column with bound 
DNA was then placed in a sterile 1.5 ml microcentrifuge tube. To elute DNA, 
30 µl Buffer EB (10 mM Tris·HCl, pH 8.5) was added to the centre of the 
QIAquick column and was allowed to stand for two minutes at room 
temperature in order to increase DNA concentration and then spun for one 
minute at 14,000 rpm. The concentration and A260/A280 purity ratio were 
assessed using a NanoDrop Lite (Thermo Scientific). The purified DNA was 
stored at -20°C until further use. 
 
2.4.7 Restriction enzyme digest 
Restriction enzyme digestion was used as part of the molecular cloning 
procedure to generate BiFC constructs. All restriction enzymes used in this 
project were purchased from New England Biolab (NEB) and used according 
to manufacturer’s instructions. Information of restriction enzymes and 
experimental conditions used for the generation of each BiFC construct is 
provided in Table 5. The DNA samples and vectors were digested with 1.0 µl 
of the appropriate restriction enzyme in a final volume of 50 µl to create 
complementary sticky-ends for ligation. Double digest was done sequentially 
if the buffer and/or incubation temperature for restriction enzymes were not 







Table 5. Restriction digest. Conditions for the restriction enzyme digests of the transmembrane and extracellular domains of the 










Construct TM +ECD Cloning Site Buffer T°C Digest Duration Heat Inactivation 
VE-PTP A.A. 23-1642 XhoI CutSmart 37°C 2 hours 65°C; 20 min 
DEP-1 A.A. 36-996 XhoI CutSmart 37°C 2 hours 65°C; 20 min 
SAP-1 A.A. 28-755 XhoI CutSmart 37°C 2 hours 65°C; 20 min 
GLEPP-1 A.A. 30-843 XhoI CutSmart 37°C 2 hours 65°C; 20 min 













65°C; 20 min 
 
NO 




Digested PCR fragments were ligated into vectors, following insertion of the 
synthetic signal peptide and epitope tag sequence, (as shown in Figure 8) 
using T4 DNA Ligase (Roche) at vector-to-insert molar ratio of 1:3 (see 
calculation below) for 2 hours at room temperature to produce constructs 
encoding for fusion proteins with either the N- or C-terminal fragment of the 
Venus protein.  
Since vector ends were compatible after the digest the vector DNA was first 
dephosphorylated with alkaline phosphatase (part of the Rapid Ligation Kit; 
Roche) to prevent self-ligation. The dephosphorylation of the linearised 
vectors was carried out according to manufacturer’s instructions in a final 
volume of 20 µl. One microgram of each vector DNA was mixed with 2 µl 10x 
rApid alkaline phosphatase Buffer, 1 µl rApid alkaline phosphatase and 
sterile deionised water was added to make up 20 µl. The dephosphorylation 
reaction mixture was mixed thoroughly and incubated at 37°C for 30 minutes, 
followed by inactivation of the rApid Alkaline Phosphatase at 75°C for two 
minutes. The dephosphorylation reaction mixture was then directly used in 
the ligation reaction. Minimum 12 ng of each vector was used for the ligation. 
To calculate the amount of each insert DNA to be used for ligation the 




The ligation was performed at 3:1 insert:vector ratio, thus, the resulting value 
for the insert was then multiplied by three.  
The appropriate amounts of vector DNA and the PCR product (insert DNA) 
were mixed together with 4 µl 5x Rapid Ligation Buffer, 1 µl T4 DNA Ligase 
(Weiss units) and nuclease-free water to final volume of 20 µl. The ligation 
mixture was spun briefly to collect drops and incubated for 30 minutes at 
Kb of insert 
Kb of vector 
X ng of vector = 
ng of insert needed 
for a 1:1 molar ratio 
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25°C. Fifteen microliters of the ligation mixture was used for transformation 
(as described in section 2.4.9 below).   
 
 
2.4.9 Transformation of competent cells 
 
E.coli competent cells, strain XL1-Blue, were transformed with the resulting 
ligation mixtures of expression vectors, using heat-shock methodology. In 
short, 50 µl aliquots of bacterial suspensions were thawed out on ice for 5 
minutes. One microliter of ligation mixture was added to the 16 µl of 
competent cells and incubated on ice for 5 minutes. The cells were heat-
shocked for 1 minute in a water bath at 42°C and then allowed to recuperate 
on ice for 5 minutes. 250 µl of SOC medium was added and cells were 
incubated at 37°C for one hour with shaking at 250 rpm. The transformed 
cells were then aseptically plated on agar plates with 50 µg/ml of ampicillin 
and allowed to grow at 37°C for 14-16 hours. Colonies were then screened 
by colony PCR (section 2.4.10) to identify clones containing the insert in the 
correct orientation. 
 
2.4.10 Colony PCR 
Colony PCR, performed with MyTaqRed DNA Polymerase (Bioline), was 
used for screening for successful insertion of insert to vector in correct 
orientation. Colony PCR was performed with a combination of gene-specific 
and vector-specific primers. For primer sequences refer to Table 11. Single 
colonies were picked with sterile 10 µl pipette tips and suspended in 10 µl 
Milli-Q water in a clean 1.5 ml Eppendorf tube. Working on ice, 5 µl of 
bacterial suspension was mixed with 10 µl 5x MyTaq Red Reaction Buffer 
(5mM dNTPs, 15mM MgCl2, stabilisers and enhancers), 1 µl of 20 µM 
forward primer (refer to Table 11), 1 µl of 20 µM reverse primer (refer to 
Table 11), 0.4 µl MyTaq Red DNA Polymerase and Milli-Q water to make up 
the final volume of 50 µl. The PCR parameters are shown in the Table 6. 
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Table 6. The PCR parameters for colony PCR. The PCR parameters used 














Colonies that produced positive results were then used to inoculate 10 ml LB 
Broth supplemented with 100 µg/ml of ampicillin and incubated overnight at 
37°C with shaking at 200 rpm. Putative positive colonies were then pelleted 
by centrifugation at 4500 rpm in a bench-top centrifuge for 10 minutes at 
25°C. Plasmid DNA was subsequently purified from the harvested pellet as 
described above in section 2.4.2 and then sequenced by GATC Biotech. The 
sequenced DNA was aligned with the template sequence in VectorNTI 
software by ContigExpress assembly. 
 
2.4.11 Purification of high yields of plasmid DNA for transfection 
The correct sequenced constructs were used to generate a high yield of 
plasmid DNA with high purity suitable for mammalian cell transfections. The 
required miniprepped plasmid DNA was used to transform competent XL1-
Blue bacterial cells, using the same experimental procedure as described in 
section 2.4.9. After the incubation a single colony was picked and suspended 
Step Temperature Time Cycles 
Initial denaturation 95°C 1 min 1 
Denaturation 95°C 15 s 
25 Annealing 55°C 15 s 
Extension 72°C 30 s 
Final extension 72°C 5 min 1 
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in 10 ml sterile LB Broth supplemented with 100 µg/ml ampicillin and 
incubated for 8 hours at 37°C at 200 rpm. After the incubation period 1 ml of 
the bacterial culture was added to 100 ml sterile LB Broth supplemented with 
100 µg/ml ampicillin and incubated for 12 hours at 37°C at 200 rpm. Plasmid 
DNA was extracted and purified using QIAprep Spin Midiprep Kit (QIAGEN) 
as described in section 2.5.1. The overnight bacterial culture was harvested 
by centrifuging at 6000 g for 15 minutes at 4°C. The bacterial pellet was 
resuspended in 4 ml Buffer P1. To lyse the bacterial cells 4 ml Buffer P2 was 
added, mixed thoroughly by inverting vigorously 4-6 times and incubated for 
5 minutes at room temperature. To neutralise the lysis buffer 4 ml prechilled 
Buffer P3 was added, mixed thoroughly by inverting vigorously 4-6 times and 
incubated on ice for 15 minutes. A QIAGEN-tip 100 was equilibrated by 
applying 4 ml Buffer QBT and allowing column to empty by gravity flow. The 
bacterial lysate was centrifuged for 30 minutes at 20000 g at 4°C. The 
supernatant was then applied to the equilibrated QIAGEN-tip and allowed to 
enter the resin by gravity flow. The QIAGEN-tip was washed with 2 x 10 ml 
Buffer QC, each time allowing the column to empty by gravity flow. The DNA 
was eluted into a clean 15 ml vessel by adding 5 ml Buffer QF. To precipitate 
DNA 3.5 ml room-temperature isopropanol was added, mixed well and 
centrifuged at 15000 g for 30 minutes at 4°C, carefully removing supernatant. 
Marking the outside of the vessel helps to see what side the DNA 
precipitates on. The DNA pellet was washed with 2 ml room-temperature 
70% (v/v) ethanol and centrifuged for 10 minutes at 15000 g, carefully 
removing supernatant as in the previous step. The DNA pellet was allowed to 
air-dry at room temperature for 10 minutes and then resuspended in 500 µl 
Buffer TE. The concentration and purity of the eluted DNA was assessed and 








2.5 Molecular cloning for generation of BiFC constructs 
2.5.1 Plasmids and primers 
 
Table 7. Addgene plasmids. Plasmids purchased from Addgene encoding 
for bJun-VN (fused to the NH2-terminal fragment of the Venus yellow 
fluorescent protein (vYFP)), bFos-VC and bFosΔZIP (both fused to the 
COOH-terminal fragment of the vYFP). These plasmids were used for 








bJun-VN pBiFC-VN155(I152L) pMyc-CNV myc Ampicillin 
bFos-VC pBiFC-VC155 pCMV-HA HA Ampicillin 















Source Plasmids Antibiotic 
resistance 
PTPRB  Protein tyrosine 
phosphatase, 
receptor type, B 
H.Sapiens VE-PTP, 
RPTPB 
BC113463.1 SourceBioScience pCR4-TOPO Ampicillin 
(50µg/ml) 
PTPRJ  Protein tyrosine 
phosphatase, 




BC063417.1 Art Weiss (UCSF) pCR4-TOPO Ampicillin 
(50µg/ml) 
PTPRO  Protein tyrosine 
phosphatase, 
receptor type, O 
H.Sapiens GLEPP1,   
RPTPO 
BC126203.1 SourceBioScience pCR-XL-TOPO Kanamycin 
(30µg/ml) 
PTPRH  Protein tyrosine 
phosphatase, 





































































Cont. Table 9. Synthetic DNA sequences and oligonucleotides used to generate signal peptides and epitope tags in expression 
constructs. 
 





































Table 10. Cloning primers for extracellular and transmembrane domains of the BiFC constructs. Underlined sequences are 
















































Table 11. Colony PCR primers. The provided primers were used to check the insert and its orientation in the expression vector 
after ligation and transformation. 
Construct Insert Forward 
Primer 
Forward primer sequence (5’→3’) Reverse 
Primer 
Primer sequence (5’→3’) 
Cadherin ECD+TM CMV-F CGCAAATGGGCGGTAGGCGTG  CADH5-B GATCGGTACCCCGGAGCCG
CCGCCGCAGGAAG 
VE-PTP ECD+TM CMV-F CGCAAATGGGCGGTAGGCGTG  EBV-R GTGGTTTGTCCAAACTCATC 
GLEPP1 ECD+TM CMV-F CGCAAATGGGCGGTAGGCGTG  RO-D  
VE-PTP SP+HA RB-APF GATCCCCGGGATGCTGAGCCAT
GGAGCC 
EBV-R GTGGTTTGTCCAAACTCATC  
DEP-1 SP+HA/SP+Myc RJ-APF GATCAAGCTTATGAAGCCGGCG
GCGCGG 
EBV-R GTGGTTTGTCCAAACTCATC  
DEP-1 ECD+TM RJ-s GATCTCTCGAGGTACCCCTAGTC
CAATTCCTGA 
EBV-R GTGGTTTGTCCAAACTCATC 
SAP-1 SP+HA/SP+myc RH-APF GATCAAGCTTATGGCTGGGGCTG
GCGGG 
EBV-R GTGGTTTGTCCAAACTCATC 
SAP-1 ECD+TM CMV-F CGCAAATGGGCGGTAGGCGTG  EBV-R GTGGTTTGTCCAAACTCATC 
GLEPP1 SP+HA/SP+myc RO-APF GATCATCGATATGGGGCACCTGC
CCACG 
EBV-R GTGGTTTGTCCAAACTCATC 
SPN SP+HA/SP+myc SPN-sp ATGGCCACGCTTCTCCTTCT EBV-R GTGGTTTGTCCAAACTCATC 
SPN ECD+TM SPN-sp ATGGCCACGCTTCTCCTTCT EBV-R GTGGTTTGTCCAAACTCATC 
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Table 12. Sequencing primers. These primers were used for sequencing by GATC Biotech to confirm the right insert and its 
orientation and absence of mutations.   
Name of 
Construct 
Insert Vector Forward 
primer 
Sequence (5’→3’) Reverse 
primer 
Sequence (5’→3’) 
VE-PTP SP+HA pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
VE-PTP ECD+TM pBiFC-VN155 RBseq8 ACAATATTGCCATCACAGCTGT RBseq9 GGTTGCCCAGAGATGCACTT  
VE-PTP ECD+TM pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
DEP-1 SP+HA pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
DEP-1 SP+myc pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
DEP-1 ECD+TM pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
DEP-1 ECD+TM pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
SAP-1 SP+HA pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
SAP-1 SP+myc pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
SAP-1 ECD+TM pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
SAP-1 ECD+TM pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
GLEPP1 SP+HA pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
GLEPP1 SP+myc pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
GLEPP1 ECD+TM pBiFC-VC155 RO-FC-1F GATCGCTAGCATGGGGCACCTGCCCA RO-F340 AGATGAATTTGTCAGCGTAC 
GLEPP1 ECD+TM pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
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SPN SP+HA pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
SPN SP+myc pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG - - 
SPN ECD+TM pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
SPN ECD+TM pBiFC-VC155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
VE-PTP-
17FN 
ECD+TM pBiFC-VN155 CMV-F CGCAAATGGGCGGTAGGCGTG EBV-R GTGGTTTGTCCAAACTCATC 
Cont. Table 12. Sequencing primers. These primers were used for sequencing by GATC Biotech to confirm the right insert and 





2.5.2 Generation of BiFC constructs 
Constructs for BiFC studies were generated by PCR and by standard 
molecular cloning procedures described in section 2.4 using the plasmids 
pBiFC-VN155(I152L) and pBiFC-VC155. A diagram of the strategy is shown 











Figure 8. Schematic diagram of BiFC constructs generation. Signal 
peptide sequences followed by an epitope tag sequence (either HA or myc) 
were designed and provided by Genscript. “             ” indicates forward and 
reverse primer pair used for generating the extracellular and transmembrane 
domains gene sequence (ECD+TM). Details of primers are provided in Table 
10. The generation of BiFC constructs was done in two steps. First, signal 
peptide and an epitope tag were inserted into vectors, followed by the 
ligation of extracellular and transmembrane domains into the corresponding 
vector containing the N- or C-terminal sequence of Venus Yellow fluorescent 
protein (N-YFP, C-YFP).   
 
Signal peptides of PTPRJ, PTPRO, PTPRH and SPN with either HA or myc 
tags, flanked by ApaI/XhoI restriction sites, were designed and purchased 
from Genscript in a pUC57 vector (refer to Table 9). DNA vectors were 














transformed with each of the pUC57 vector as described in section 2.4.9. 
DNA plasmids were then extracted and purified from bacterial culture as 
described in section 2.4.2. The synthetically generated signal peptide and 
myc/HA tag sequences were digested with appropriate restriction enzymes 
(refer to Table 9) and cloned into the BiFC expression vectors (Figure 8) as 
described in sections 2.4.8 and 2.4.9. Successful ligation was checked by 
Colony PCR as described in section 2.4.10 using vector and gene specific 
primers (refer to Table 11), followed by gel electrophoresis (section 2.4.4). 
DNA plasmids containing the correct signal peptide and an epitope tag insert 
were purified as described in section 2.4.2 and sequenced by GATC Biotech.  
 
Polymerase chain reaction was used to amplify the coding sequences for 
extracellular and transmembrane domains for all R3 RPTPs, VE-cadherin 
and SPN as described in section 2.4.3. Details and sources of clones used 
are listed in Table 8. Cloning primers are provided in Table 10. The 
thermocycler programs were customised for each target sequence based on 
gene length and primers’ melting temperature (refer to Table 4). PCR 
products were analysed on agarose gel and purified as described in sections 
2.4.4 and 2.4.6 respectively.   
 
Three micrograms of each of the purified PCR products and pBiFC-VN155 
(27097) and pBiFC-VC155 (22011) vectors containing corresponding DNA 
sequences for signal peptides were digested with one unit of the appropriate 
restriction enzymes as described in section 2.4.7.  Information on restriction 
enzymes used for each construct and on conditions is provided in Table 5. 
The digested fragments were analysed by agarose gel electrophoresis 
(section 2.4.4), purified (section 2.4.5) and ligated together (section 2.4.8). 
The resulting ligation mixture of expression vectors containing the final 
products was used to transform XL1-Blue strain of E.coli competent cells as 
described in section 2.4.9. Colony PCR was then performed to screen for 
successful ligations (section 2.4.10), which was analysed by gel 
electrophoresis (section 2.4.4). DNA plasmids containing the correct insert 




The miniprepped plasmid DNA that corresponded to the predicted sequence 
was used to generate high yield of plasmid DNA with greater purity suitable 
for mammalian cell transfections as described in section 2.4.11.   
 
2.5.3 Generation of VE-PTPΔ17FN mutant using a polymerase chain 
reaction based approach 
In order to generate the VE-PTP∆17FN construct (as illustrated in Figure 23) 
in which 17th fibronectin III-like domain has been removed the pBiFC-VN155 
vector containing sequences for signal peptide, myc-tag, full-length 
extracellular and transmembrane domains followed by the N-terminal part of 
the YFP was used as a template. First, the sequence for the above vector 
was checked for all the restriction sites using VectorNTI software. The cutting 
sequence for the restriction enzyme XmaI was chosen to be included with 
primer sequence as there were no restriction sites for this enzyme in the 
above vector. Primers were designed, corresponding to the sequence on 
either side of the 17th FNIII domain, using VectorNTI software with an XmaI 
sequence at the start (Figure 9). The 5’ ends of the primers were designed 
so that they would complement each other, and could be ligated together, 
and 3’ ends oriented so that the extension would amplify the entire plasmid 





















Figure 9. Schematic diagram of VE-PTPΔ17FN-VN mutant generation. 
This diagram illustrates the basis on which the primers were designed 
containing the sequence of the restriction enzyme at the 5’ end and with the 
3’ end oriented so that polymerase would amplify the entire vector but 
excluding the region to be deleted. 
 
The 5’ ends of the primers contained the cutting sequence of the XmaI 
restriction enzyme (highlighted in bold in Table 13). As this cutting sequence 
contains six bases it was not necessary to include any additional bases to 
keep the polymerase reading frame between the restriction enzyme cutting 
sequence and the rest of the primer. Additional bases (GATC) were added at 
5’ ends of the primers to facilitate the restriction digest close to the end of 






 FNIII-like domain 
(1458 – 1554 AA) 
Vector 






Table 13. Primers for the generation of the VE-PTP mutant. Primers 
designed for the deletion of the 17th FN-III like domain from the previously 
generated VE-PTP BiFC construct. The restriction site for the XmaI enzyme 
is shown in bold. 
 
Primer Sequence Length TM GC 
VE-PTP-17FN-sp GATCCCCGGGCTAGG 
TGGAAAATGCGATCC 
26 69.7°C 61.5% 
VE-PTP-17FN-ap GATCCCCGGGCACAC 
GAATGTGTGGGGGTG 




PCR was then performed as described in section 2.4.3 in a reaction 
containing 100 ng template plasmid from which the 17th FNIII-like domain 
was to be removed. For the PCR conditions refer to Table 14. 
The PCR product was analysed on agarose gel electrophoresis as described 
in section 2.4.4. The DNA bands of the desired size were purified from the 
agarose gel as described in section 2.4.5. 
The gel extracted PCR product was digested with 1 U DpnI (to digest 
template DNA) and 1 U XmaI restriction enzymes simultaneously in a 
Cutsmart Buffer at 37°C for 2 hours, followed by heat deactivation at 64°C for 
20 minutes. Digested DNA was again analysed on agarose gel, extracted 
and purified as described above.  
The ligation of DpnI-XmaI digested DNA was performed using 110 ng of 
purified DNA as described in section 2.4.8. The ligation mixture was 
incubated at room temperature for 10 minutes, followed by heat deactivation 
at 65°C for 10 minutes. The resulting ligated DNA was chilled on ice for 5 
minutes, followed by transformation into E.coli competent cells, strain XL-1 
Blue, as described in section 2.4.9. Plasmids were then purified using 
QIAprep Spin Miniprep Kit (QIAGEN) according to manufacturer’s 
instructions as described in section 2.4.2. The concentration and purity of the 
purified DNA was assessed using Nanodrop 1000 (Thermo Scientific) at 260 
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nm and 280 nm and then sequenced by GATC Biotech. The miniprepped 
plasmid DNA that corresponded to the predicted sequence, containing the 
deletion of the 17th FNIII-like domain, was then used to generate high yield of 
plasmid DNA with greater purity suitable for mammalian cell transfections as 






















Table 14. PCR parameters used for generation of VE-PTP∆17FN mutant. 
(A) Master Mix for one reaction to generate VE-PTP mutant was prepared 
according to manufacturer’s recommendations. (B) Optimal PCR conditions 























Master Mix (one reaction) 
10x Pfx Buffer 10 µl 
10 mM dNTPs 3 µl 
50 mM MgSO4 1 µl 
VE-PTP-17FN-sp 3 µl 
VE-PTP-17FN-ap 3 µl 
VE-PTP-VN template 1 µl (100 ng) 
Plat.Pfx DNA Polymerase 0.5 µl 
HPLC dH2O 28.5 µl 
PCR Conditions 
Step Temp. Time Cycles 
Initial 
Denaturation 94°C 5 min 1 
Denaturation 94°C 15 sec 
30 Annealing 59.6°C 30 sec 
Extension 68°C 9 min 
Final 





2.5.4 Generation of membrane anchored N- and C-terminal Venus-YFP 
fragments using the annealed Oligo Cloning technique 
Three micrograms of each of pBiFC-VN155 (27097) and pBiFC-VC155 
(22011) vectors that contain sequence for the N- and C-terminal Venus-YFP 
respectively were digested with 1 U ApaI restriction enzyme in 6 µl CutSmart 
Buffer and HPLC dH2O up to the final volume of 60 µl at 25°C for 2 hours. 
One unit of EcoRI-HF was then added to the same mixture and further 
incubated for 2 hours at 37°C. The digested vectors were then analysed on 
an agarose gel as described in section 2.4.4.  
Overlapping primers were designed using a trial version of VectorNTI 
software to contain ApaI and EcoRI restriction sites at 5’ and 3’ ends 
respectively, the membrane association sequence from the protein tyrosine 
kinase Lck (ATGGGCTGTGGCTGCAGCTCACACCCGGAAGATGACTG) 
and a myc tag (GGAGCAGAAGCTGATCTCAGAGGAGGACCT) sequence.  
The oligos were re-suspended in the appropriate amount of HPLC dH2O and 
2 µg of each primer was mixed together with annealing buffer (10 mM Tris, 
pH7.5-8.0, 50 mM NaCl, 1 mM EDTA) up to the final volume of 50 µl. Mixed 
oligos were then placed in a sterile PCR tube and heated to 95°C for 2 
minutes in the thermocycler and allowed to cool down gradually to 25°C at 
room temperature. 
Five microlitres of annealed oligos was diluted with 45 µl HPLC dH2O and 
the concentration and purity was assessed using Nanodrop 1000 at 260 nm 
and 280 nm. The annealed primers were then directly cloned into the 
ApaI/EcoRI sites of the previously digested and purified vectors using 5 U T4 
DNA Ligase, 10 µl of 2x T4 DNA Ligation Buffer (Roche) and HPLC dH2O up 





Table 15. Generation of membrane anchored N- and C-terminal Venus-
YFP fragments. (A) Primers designed using VectorNTI software to generate 
YFP-VN155/YFP-VC155 negative control. Overlapping primers, when 
annealed, would create restriction sites for ApaI and EcoRI shown in bold. 
The protein tyrosine kinase Lck sequence and a myc tag sequence are 




































   M  G  C  G  C  S  S  H  P  E  D  D  W  E  Q  K  L  
atctcagaggaggacctgcgaattcggtcgaccgagatctctcgaggtaccggaggtggc 
 I  S  E  E  D  L  R  I  R  S  T  E  I  S  R  G  T  G  G  G  
gggagcggaggtggcgggagtatggtgagcaagggcgaggagctgttcaccggggtggtg 
 G  S  G  G  G  G  S  M  V  S  K  G  E  E  L  F  T  G  V  V  
cccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgag 
 P  I  L  V  E  L  D  G  D  V  N  G  H  K  F  S  V  S  G  E  
ggcgagggcgatgccacctacggcaagctgaccctgaagctgatctgcaccaccggcaag 
 G  E  G  D  A  T  Y  G  K  L  T  L  K  L  I  C  T  T  G  K  
ctgcccgtgccctggcccaccctcgtgaccaccctgggctacggcctgcagtgcttcgcc 
 L  P  V  P  W  P  T  L  V  T  T  L  G  Y  G  L  Q  C  F  A  
cgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctac 
 R  Y  P  D  H  M  K  Q  H  D  F  F  K  S  A  M  P  E  G  Y  
gtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtg 
 V  Q  E  R  T  I  F  F  K  D  D  G  N  Y  K  T  R  A  E  V  
aagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggag 
 K  F  E  G  D  T  L  V  N  R  I  E  L  K  G  I  D  F  K  E  
gacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatctc 
 D  G  N  I  L  G  H  K  L  E  Y  N  Y  N  S  H  N  V  Y  L  
accgcctgagcggccgc 















Lck membrane association sequence myc tag 
gggccc = ApaI site 




E.coli competent cells, strain XL1-Blue, were then transformed with the 
resulting ligation mixtures as described in section 2.4.9. The transformed 
cells were then aseptically plated on agar plates with 50 µg/ml of Ampicillin 
and allowed to grow at 37°C for 14-16 hours, followed by the colony PCR as 
described above in section 2.4.10. Putative positive colonies were used to 
start an overnight bacterial culture (refer to section 2.4.10). Plasmid DNA 
was extracted and purified from the harvested pellet using QIAprep Spin 
Miniprep Kit (QIAGEN) as described in section 2.4.2. The concentration and 
purity of the eluted DNA was assessed using Nanodrop 1000 (Thermo 
Scientific) and then sequenced by GATC Biotech. The miniprepped plasmid 
DNA that corresponded to the predicted sequence was then used to 
generate high yield of plasmid DNA with high purity suitable for mammalian 
cell transfections as described in section 2.4.11. 
 
 
2.5.5 Cell Culture 
Human Embryonic Kidney 293 (HEK293) and 293T cells (ATCC code CRL-
1573 and CRL-11268) were purchased from ATCC. Both HEK293 and 
HEK293T cell lines were used initially to compare the transfection and 
expression efficiency. The HEK293T cells are derived from 293 cells but 
stably express the simian virus 40 (SV40) large T antigen, which can bind to 
SV40 enhancer of expression vectors to increase protein production. 
HEK293 and HEK293T cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM, with GlutaMAX, 4500 mg/L glucose; Gibco) supplemented 
with 10% (v/v) foetal bovine serum at 37°C in 5% CO2 in a humidified 
incubator. Cells were trypsinised at 80% confluence and seeded 24 hours 







2.5.6 Transfection and confocal visualisation 
Transient transfections were performed using Lipofectamine® LTX Plus 
(Invitrogen) according to the manufacturer’s instructions. Briefly, 500 µl Opti-
MEM® Reduced Serum Medium, 0.5 µg of each DNA construct and PLUS™ 
Reagent (at the 1:1 ratio of DNA (μg) to PLUS™ Reagent (μl)) were mixed 
together in a sterile Eppendorf tube and allowed to incubate at room 
temperature for 5 minutes. Lipofectamine® LTX was mixed gently and added 
to the diluted DNA (2 µl per µg of DNA) and incubated at room temperature 
for 30 minutes. DNA-lipid complexes were then added directly to the cells in 
a drop-wise manner and incubated at 37°C in a CO2 incubator. After 24 
hours cells were stained with CellMask™ DeepRed plasma membrane stain 
(ThermoFisher Scientific) for 1 hour at 37°C by directly adding 1 µl/well of the 
stain to live cells. The media were then removed, cells were rinsed with 
warm HBSS (Gibco) and images were acquired by sequential scanning using 
a Leica TCS SP2 confocal microscope system (Leica Microsystems) with a 
63× ceramic dipping objective, using a dichroic beamsplitter DD458/514. A 
514 nm argon ion laser was used to excite Venus YFP (Ex/Em 514/527 nm) 
with detection at 525-560 nm; and a 633 nm helium neon laser, intensity 
35%, was used for the red stain (Ex/Em 649/666 nm) with detection at 660-
685 nm.  
2.5.7 Immunoblotting 
Transfected HEK293T cells were rinsed with 2 ml/well ice-cold PBS 
containing Ca2+ and Mg2+ and lysed by adding 300 µl 4x Sample Buffer (240 
mM Tris-HCl, pH 6.8, 8% SDS, 5% β-mercaptoethanol, 0.04% (v/v) 
bromophenol blue, 40% (v/v) glycerol) into each well. In some experiments 
some cells were lysed using 250 µl/well ice-cold lysis buffer containing 
complete protease inhibitor tablet (Roche). To prepare samples for loading 
30 µl of cell lysates were mixed with 10 µl 4x sample buffer. The total cell 
lysate (20 µl) was loaded on to a 4–20% Mini-Protean TGX precast gel (Bio-
Rad) and subjected to electrophoresis at 110 V for 60 minutes in 1 x SDS 
running buffer (for buffer composition refer to Table 3). For accurate 
molecular weight estimation on SDS-polyacrylamide gel and on immunoblots 
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pre-stained ColorBurstTM electrophoresis marker (Sigma-Aldrich) was also 
used. Proteins were transferred onto PVDF membranes (GE Healthcare) by 
tank electroblotting in 1x Transfer Buffer (25 mM Tris, 192 mM glycine, 20% 
(v/v) methanol and ddH2O) for 2 hours at room temperature with an ice block 
and stirring to allow heat dissipation.  
Each membrane was blocked with blocking buffer (3% (w/v) non-fat dry milk 
dissolved in 1x TBS) for one hour at room temperature with gentle shaking. 
An appropriate primary antibody was added directly to the blocking solution 
at 1 in 2000 dilution and incubated for one hour. A list of primary antibodies 
used in Western blotting is provided in Table 16. Membranes were then 
washed 3x for 5 minutes with 1x TBST and incubated with secondary anti-
mouse IgG (whole molecule)-HRP linked secondary antibodies (A4416; 
Sigma-Aldrich) at 1 in 5000 dilution in fresh blocking buffer for 1 hour at room 
temperature with shaking. Membranes were washed 6x for 5 minutes with 1x 
TBST and developed with SuperSignal West Femto Maximum Sensitivity 
Substrate (ThermoScientific) according to the manufacturer’s instructions 
and the chemiluminescence was visualised using Labworks 4.1 software. 
 
Table 16. List of primary antibodies used in Western blotting.  
Antibody Clone Description Source Dilution 
Anti-myc 4A6 Mouse monoclonal to myc tag 
Millipore 1:2000 






Mouse monoclonal to 
VE-cadherin Abcam 1:2000 
Anti-β-Actin ab8226 Mouse monoclonal to β-




2.5.8 Membrane localisation study by immunoprecipitation 
 
To test that the epitope tags do not interfere with protein localisation and that 
the BiFC epitope-tagged proteins lacking a cytosolic domain still reach the 
plasma membrane the proteins were immunoprecipitated with antibodies 
specific to their tags, followed by detection by immunoblotting. The antibody 
was added directly to the cells that express the protein of interest so that only 
the proteins on the plasma membrane would be detected. The plasma 
membrane expression level could then be compared with the expression of 
the corresponding full-length protein as well as the expression in whole cell 
lysates.   
HEK293T cells were transiently transfected with 2.5 µg of each DNA 
construct using Lipofectamine® LTX Plus as described in section 2.10. After 
the 24 hours of incubation at 37°C in the humidified incubator anti-myc 
(mouse monoclonal 4A6; Millipore) primary antibody was added to each well 
at 1 in 1000 dilution and incubated at room temperature for 10 minutes with 
gentle rocking. The media was then removed and cells were rinsed once with 
1 ml/well ice-cold HBSS. The cells were lysed by adding 250 µl of ice-cold 
lysis buffer (refer to Table 3 for the composition) containing complete 
Protease Inhibitor Tablet (Roche) to each well and gently aspirating. The 
lysates were transferred to clean Eppendorf tubes and centrifuged at 4°C for 
15 minutes at 14000 g. The supernatant was then transferred to clean 
Eppendorf tubes and 50 µl of the protein A-sepharose beads (GE Healthcare 
Life Sciences) was added to each tube. The lysate-beads mixture was 
agitated at 4°C for 2 hours and centrifuged for 2 minutes at 4°C, discarding 
the supernatant.  The beads were washed 3x with 100 µl lysis buffer, 
centrifuging each time for 1 minute at 4°C and discarding the supernatant.  
After the last supernatant was removed 25 µl of 4x sample buffer was added 
to each tube and boiled for 5 minutes at 95°C. The tubes were centrifuged at 
4°C for 2 minutes and the supernatant containing proteins was transferred to 
clean Eppendorf tubes.  
Samples were then subjected to SDS-PAGE, followed by Western blot and 
visualisation as described above in section 2.5.7. 
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2.5.9 Generation of quantitative data and statistical analysis 
ImageJ software (https://imagej.nih.gov/ij/) was used to carry out quantitative 
analysis of results. HEK293T cells were transiently co-transfected with an 
interacting fusion pair of interest, stained with CellMask™ DeepRed 
Plasma Membrane Stain and analysed using confocal microscope. The 
confocal images were then used to measure the fluorescence intensity. For 
BiFC quantification multiple images were taken in random distribution.  
Confocal images, one from yellow channel (YFP fluorescence signal) and 
one from red channel (plasma membrane stain) were opened in ImageJ 
software. Images were then merged by selecting from Menu Bar: Image → 
Colour → Merge channels and then selecting the image for the red channel 
(C1) and for the yellow channel (C7), thus creating a composite image and 
keeping the source images too. The composite image was then used to 
select the border of each cell using a polygon selection tool and adding the 
selection, one at a time, in region of interest (ROI) manager 
(Analyse→Tools→ROI Manager). In addition, a region containing no cell was 
selected as a background in each confocal image analysed. The selected 
cells were analysed, each channel at a time, by selecting from Menu Bar 
option Analyse→Set Measurements→select Area, min and max grey value, 
integrated density and mean grey value→redirected to (a channel to be 
analysed)→OK. To get the values for the selected channel the Measure 
option in ROI Manager was chosen and the results were saved as an Excel 
file. 
To calculate the corrected total cell fluorescence (CTCF) the following 
formula was used: integrated density minus (area of selected cell x mean 
fluorescence of background readings). This was done for all the selected 
cells from the yellow channel as well as the red channel. The values were 
then used to calculate yellow/red ratio in individual cells by dividing the 
corrected fluorescent intensity derived from bimolecular fluorescence 
complementation (e.g. YFP-VN+YFP-VC) by the corrected fluorescence 
signal derived from the plasma membrane stain. On average about 700 cells 
for each fusion protein combination were analysed from several fields in at 
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least three independent experiments. To determine the distribution of ratios 
Bin Limits were first created ranging from 0.01 to 4.01 in the interval of 0.1. 
Then, the frequency was determined using the Frequency function in Excel 
by selecting ratio values data array and bins data array and then the formula 
was entered as a multi-cell array by pressing Ctrl+Shift+Enter. The 
distributions of ratios in individual cells were then plotted in histogram. 
To calculate the average yellow fluorescence intensity the border of each cell 
was traced in the ImageJ using a polygon selection and the average pixel 
intensity of the selected region, including border, was calculated. Since the 
cells were stained with the plasma membrane stain all the cells were 
selected based on the red fluorescence signal outlining the membrane, 
including those that did not exhibit the yellow fluorescence signal. To account 
for the variability in transfection efficiency the images were acquired from 
multiple fields per well and used for analysis. The background signal in an 
area with no cells was subtracted from all values as described above. BiFC 
fluorescence intensity values from at least three independent experiments 
were averaged and used for statistical analysis. 
Data were analysed with ImageJ, Microsoft Excel and IBM SPSS Statistics 
22 software, using Kruskal-Wallis H test and Mann-Whitney U test. A P value 









Optimisation of the Bimolecular Fluorescence Complementation (BiFC) 




















The overall object of this thesis is to investigate receptor protein tyrosine 
phosphatases of R3 subgroup using bimolecular fluorescence 
complementation (BiFC) assay and in this chapter as a preliminary step the 
assay has been optimised and validated using a pair of well characterised 
interacting proteins. This assay enables direct visualisation of protein 
interactions in living cells, mimicking their normal cellular environment 
(Kerppola, 2006). The BiFC assay is based on the principle of protein 
fragment complementation, in which two non-fluorescent fragments from the 
Venus yellow fluorescent protein are fused to a pair of interacting partners. If 
these two proteins interact with each other they bring the two non-fluorescent 
fragments into close proximity, resulting in proper folding and assembly, thus 
reconstituting a fluorescent protein. Therefore the reconstituted fluorescence 
reflects the interaction of two proteins of interest (Kerppola, 2008). The 
assembled complex produces strong intrinsic fluorescence that can be 
detected by a confocal microscope without the need for staining with 
exogenous fluorogenic and chromogenic agents (Kerppola, 2006). 
However, this approach has some limitations. The main two limitations are 
self-assembly of the two non-fluorescent fragments and irreversibility that 
can contribute to the false-positive fluorescence and decreases the signal-to-
noise ratio, making data interpretation difficult (Kodama and Hu, 2010). To 
address the problem with self-assembly various mutants, such as V150L, 
I152L and T153M, have been introduced in fragments of a Venus yellow 
fluorescent protein in order to weaken the hydrophobic interaction between 
VN155 and VC155 and to reduce the background fluorescence (Kodama and 
Hu, 2010; Nakagawa et al, 2011). It has been previously reported that V150L 
resulted in very low fluorescence intensity in BiFC with bJunVN and bFosVC. 
The point mutation of T153M showed lower fluorescence intensity in BiFC 
with bJunVN and bFosVC but higher in BiFC with bJunVN and ∆bFosVC 
compared with I152L. However, the point mutation of I152L in VN155 of 
Venus significantly reduced self-assembly and decreased background 
fluorescence without significantly altering the overall structure (Kodama and 
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Hu, 2010). This improved Venus fragment should facilitate the study of 
protein interactions in living cells in this project. 
Numerous protein interactions have been visualised using the BiFC assay in 
many different cell types and organisms. For example, a study by Magliery et 
al (2006) used the GFP-based BiFC assay to study protein-peptide 
interactions in BL21 (DE3) Escherichia coli cells. In their study the 
interactions of TPR1 and TPR2A (tetratricopeptide repeat) domains with 
protein chaperones Hsc70 and Hsp90 were analysed. TPR1 binds to the C-
terminus of the human chaperone Hsc70 and TPR2A binds to the C-terminus 
of Hsp90 (Magliery et al, 2006). The BiFC results confirmed the known 
interactions and showed that protein-peptide or protein-protein interactions 
are clearly required for the reassembly of the GFP and that the BiFC 
approach was useful for discriminating strongly bound ligands from weakly 
bound ones (Magliery et al 2006).  
Another study by Walter et al (2004) adopted the BiFC approach to address 
its feasibility for visualisation of the basic leucine zipper (bZIP) transcription 
factor bZIP63 homodimerisation in living plant cells. It has been shown 
previously that nuclear bZIP63 transcription factor forms homodimers and 
heterodimers via the C-terminal leucine zipper domain (Siberil et al, 2001). 
The BiFC results showed that the epidermal cells infiltrated with bZIP63-
YFPN and bZIP63-YFPC-carrying Agrobacteria resulted in a strong 
fluorescence signal (Walter et al, 2004). The homodimerisation-induced YFP 
fluorescence appeared exclusively inside the nucleus which corresponded to 
the nuclear localisation of the bZIP63 (Walter et al, 2004). The same study 
by Walter et al (2004) also showed that the BiFC approach could be used to 
visualise cytoplasmic protein-protein interactions in plant cells. Previous 
experiments showed that the tobacco 14-3-3 protein T14-3c (T14) forms 
homodimers, which was also demonstrated by the BiFC experiments. The 
co-expression of T14-YFPN and T14-YFPC resulted in strong YFP 
fluorescence detected throughout the cytoplasm and the nucleus. The 
localisation of homodimer formation corresponded to the subcellular 
distribution of T14-3c, demonstrating that BiFC is a very efficient technology 
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for the analysis of protein–protein interactions in living plants cells (Walter et 
al, 2004).  
Some transmembrane protein interactions have also been studied using the 
BiFC approach. For example, a group led by de Virgilio et al (2004) used 
BiFC to define αIIbβ3 - tyrosine kinase interactions in living cells as well as to 
obtain subcellular localisation of αIIbβ3 - tyrosine kinase complexes.   
Transmembrane platelet integrin αIIbβ3 plays a critical role in platelet 
aggregation by binding to soluble ligands like c-Src. BiFC analysis revealed 
that the co-expression of αIIbYCβ3 (fused to the C-terminal part of YFP) with 
SrcYN (fused to the N-terminal part of YFP) resulted in a fluorescent signal 
within membrane ruffles, focal complexes and focal adhesions. The 
localisation of BiFC corresponded with where the proteins were previously 
co-localised with antibody-labelled αIIbβ3 and c-Src in fixed cells (de Virgilio 
et al, 2004). The same experiments showed that αIIbβ3 can also interact with 
spleen tyrosine kinase Syk. The co-expression of αIIbYCβ3 and SykYN 
detected BiFC signal confined primarily to ruffles and nascent adhesion 
structures close to the cell periphery. The above results were complemented 
with and corresponded to the results obtained with bioluminescence 
resonance energy transfer (BRET) (de Virgilio et al, 2004). 
 
Although the BiFC method has gained popularity in protein-protein 
interaction studies there is still a major downside that the non-fluorescent 
fragments of YFP are prone to self-assembly independent of a protein-
protein interaction event. To establish whether fluorescence observed in the 
BiFC assay reflects a specific protein interaction, it is essential to include 
negative controls in each experiment. A literature survey on recent BiFC 
studies carried out by Horstman et al (2014) revealed that most studies use 
inappropriate controls and rely on qualitative rather than quantitative read-out 
of fluorescence. The validity of results from BiFC analysis must be confirmed 
by examining fluorescence complementation by fusion proteins in which the 
interaction interface has been mutated (Kerppola, 2006). However, this is 
possible only if there is a prior knowledge of the structural nature of the 
interaction interface. It was suggested by Kerppola et al (2006) that multiple 
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combinations of fusion proteins need to be tested for BiFC. Amino- and 
carboxyl-terminal fusions can be used to test eight distinct combinations 
(refer to Figure 10; obtained and modified from Kerppola (2006)) in order to 
find a favourable combination that would reflect the precise structures and 














































Figure 10. Schematic representation of eight different combinations of 
fusion proteins to be tested for BiFC. These combinations of various 
fusion proteins were suggested by Kerppola (2006) to be used for BiFC in 
order to find a favourable combination that would reflect structures and 




































In addition, it is also recommended to use some of the numerous fusion 
proteins whose interactions have been visualised using the BiFC assay as 
positive controls. 
 
Because of the self-assembly capacity of the two halves of the YFP the 
qualitative analysis of the BiFC method has proved problematic. Thus BiFC 
quantification of protein-protein interactions in living cells has been proposed 
in order to distinguish between a fluorescence complementation by a true 
protein-protein interaction and a signal due to self-assembly of the two YFP 
fragments (Horstman et al, 2014). It is necessary to compare the quantitative 
data obtained from the protein combination of interest and from a negative 
control combination. One method for BiFC quantification is to determine the 
average fluorescence intensity from fluorescent images. However, this 
method requires measurement of cells on a one-by-one basis. In addition, in 
transient assays it is difficult to maintain relatively uniform and constant 
expression levels in the entire cell population and in replicate experiments. 
Therefore, to determine the statistical significance between experimental and 
control interaction pairs a large number of cells from random fields and 
multiple experiments have to be analysed (Kerppola, 2006; Horstman et al, 
2014). Additional quantification analyses performed in this thesis were 
adapted from Kodama and Hu (2010) and from Kerppola (2013). In previous 
studies the BiFC relative efficiency was quantified by determining the 
fluorescence intensity of BiFC complex and dividing it by the intensity of the 
control protein Cerulean. The distribution of ratios between the fluorescence 
intensities in individual cells was plotted in histogram (Kerppola, 2013). In 
this thesis the ratio of BiFC to cell membrane stain (rather than Cerulean) 
represented a measure of the efficiency of bimolecular fluorescence 
complementation. In addition the previous studies also looked at the signal-
to-noise (S/N) ratio as a measure of BiFC specificity. The higher the S/N ratio 
value the more specific the interaction. The S/N ratio was calculated by 
dividing a median of the BiFC efficiency with the positive interaction by a 
median of the BiFC efficiency with the negative interaction (Kerppola, 2013; 




In this chapter the objectives were to validate a novel quantification 
procedure using bJun, bFos and bFosΔZIP YFP fusion proteins and to 
optimise the assay to enhance the BiFC signal and to minimise background 
noise due to self-assembly of the YFP halves. It has been previously shown 
that two proteins bJun and bFos interact together. bFos directly modulates 
bJun function by formation of a heterodimer of bFos and bJun proteins 
(Ransone et al, 1990). In previous work Hu and colleagues (2002) used the 
basic region-leucine zipper (bZIP) family of transcription regulatory proteins 
bJun and bFos to establish BiFC assay. bFos-YC (fused to the C-terminal 
part of the yellow fluorescent protein) and bJun-YN (fused to the N-terminal 
part of the yellow fluorescent protein) fusion pair exhibited high fluorescence 
intensity when co-expressed together in COS-1 cells. Fluorophore formation 
by bFos-YC/bJun-YN fusion pair showed sigmoidal kinetics, consistent with 
bimolecular association of the two subunits followed by fluorophore formation 
at the rate comparable to that observed for intact YFP. The excitation and 
emission spectra of the bFos-YC/bJun-YN heterodimer were also identical to 
those of intact YFP (Hu et al, 2002). The introduction of a mutation into the 
interaction interface of bFos (bFosΔZIP-YC) has been shown to decrease 
significantly the fluorescence signal under the same experimental conditions, 
reflecting the specific interaction between bFos-YC/bJun-YN (Hu et al, 2002). 
Based on previous studies by Hu et al (2002) bFos-VC/bJun-VN (fused to C- 
and N-terminal parts of the Venus yellow fluorescent protein respectively) 
and bFosΔZIP-VC/bJun-VN fusion pairs were used as positive and negative 
control respectively. 
Figure 11 (A) shows the schematic representation of bFos-VC/bJun-VN 
bimolecular complex formation. Upon the interaction of these two proteins 
the non-fluorescent YFP fragments are brought into close proximity, 
reconstituting full-length functional yellow fluorescent protein. The resultant 
fluorescence is then detected by any confocal microscope. The mutated form 
of bFos-VC that lacks the interaction region (bFos∆ZIP-VC), in theory, would 
not be able to interact with bJun-VC. As a result there is no interaction and 
thus no bimolecular complex formation (Figure 11, B) and in theory there 






















Figure 11. Schematic representation of the formation of the bFos-
VC/bJun-VN bimolecular fluorescent complex. (A) Two non-fluorescent 
fragments (VC and VN) of a Venus yellow fluorescent protein (YFP) are 
fused to putative interaction partners bFos and bJun respectively. The 
association of the interaction partners allows formation of a bimolecular 
fluorescent complex. (B) Mutated bFos∆ZIP-VC lacks the interaction region 
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3.2.1 Western Blot analysis to confirm the expression of bJun-VN, 
bFos-VC and bFos∆ZIP-VC fusion proteins in HEK293T cells 
 
To confirm the expression of bJun-VN, bFos-VC and bFosΔZIP-VC fusion 
proteins following transient transfection into HEK293T cells Western blot 
analysis was performed using whole cell lysates. Single transfections of 
HEK293T cells were performed using 2.5 µg of each fusion construct and 
after a 24-hour incubation period the cell lysates were analysed.  
Western blot analysis confirmed the expression of bFos-VC and bFos∆ZIP-
VC (Figure 12, A) with the anticipated molecular weight of 24.77 and 23.02 
kDa respectively. The deletion of leucine zipper in bFos-VC did not affect the 
level of expression. As can be seen in Figure 12 (A) both bFos-VC and 
bFos∆ZIP-VC proteins are expressed at similar levels. The expression of 
bJun-VN was also confirmed with the anticipated molecular weight of 28.05 
kDa (Figure 12, B). The expression level for bJun-VN appeared to be much 
higher than for bFos-VC and bFos∆ZIP-VC. However, the comparison of 
relative expression levels of the above proteins may not be entirely reliable. 
A difference in band intensity could be caused by experimental variability, 
such as using different antibodies. Anti-myc antibody could be more sensitive 
in detecting myc tag compared with anti-HA antibody detecting HA tag. Using 
constructs fused to the same epitope tag that could be recognised by the 
same antibody would give a more accurate read-out of the true levels of 
each protein at the time of harvest and would better determine whether 



















Figure 12. Western blot analysis of bJun-VN, bFos-VC and bFos∆ZIP-
VC fusion proteins. Transfected HEK293T cells expressing fusion proteins 
































3.2.2 Comparison of HEK293 and HEK293T cell lines 
The human embryonic kidney 293 (HEK293) cell line is widely used in many 
transfection experiments due to the cells’ high transfection efficiency and 
rapid growth. HEK293T cells are derived from HEK293 cells but have been 
transduced with the SV40 large T antigen (Simian Vacuolating Virus 40 Tag) 
that can bind to SV40 enhancer of expression vectors, promoting plasmid 
replication, and thus considerably increase the expression levels obtained 
with transient transfection. 
In order to establish the cell line that results in higher BiFC signal both 
HEK293 and HEK293T cell lines were transiently co-transfected with bFos-
VC/bJun-VN and bFosΔZIP-VC/bJun-VN fusion pairs, using 0.25 µg of each 
DNA fusion construct using Lipofectamine® LTX Plus. After a 24-hour 
incubation live cells were examined under a confocal microscope to compare 
fluorescence signal.  
Both cell lines exhibited yellow fluorescence (Figure 13) after being co-
transfected with the bFos-VC/bJun-VN fusion pair. However, qualitative 
assessment of at least three randomly acquired images from two 
independent experiments showed that the co-expression of bFos-VC/bJun-
VN in HEK293T cells produced a stronger yellow fluorescence signal 
compared with the signal in HEK293 cells. HEK293T cells exhibited not only 
higher intensity of the fluorescent signal but also a higher number of cells 
producing the signal. Co-expression of bFos∆ZIP-VC/bJun-VN in either 
HEK293 or HEK293T cells did not produce any fluorescence emission 
(Figure 13).   
Based on qualitative results of this experiment it was considered that 
HEK293T cells exhibit higher protein expression efficiency since the 
transfection and confocal analysis were carried out under the same 
conditions and using the same parameters. In addition the experiment was 
repeated twice and resulted in the same outcome. Therefore the HEK293T 

















Figure 13. Confocal analysis of expression efficiency in HEK293 and HEK293T cells. Cells were co-transfected with either 
bFos-VC/bJun-VN or bFos∆ZIP-VC/bJun-VN fusion pairs using 0.25 µg of each DNA fusion construct and images were acquired 24 
















3.2.3 Optimising quantity of DNA for HEK293T cell transfection 
To minimise protein mislocalisation and formation of non-native complexes 
due to overexpression, the fusion proteins have to be expressed at levels 
comparable to the endogenous proteins. However, with transient 
transfections there is always a risk of overexpressing proteins. In order to 
establish the optimal DNA concentration HEK293T cells were transiently co-
transfected with bFos-VC/bJun-VN and bFos∆ZIP-VC/bJun-VN fusion pairs 
using 0.25 µg, 0.5 µg, 1.0 µg, 1.5 µg and 2.0 µg of each fusion construct with 
or without Plus (enhancer) reagent. Plus reagent is an optional reagent that 
was specifically designed for use in conjunction with Lipofectamine reagent 
and can improve transfection efficiency in adherent cell lines. After 24-hour 
incubation live cells were examined under a confocal microscope as 
indicated in Figure 14. 
Co-expression of bFos-VC and bJun-VN fusion proteins in HEK293T cells, 
where Plus reagent was used, resulted in fluorescence complementation at 
all the DNA concentrations used. However, cells co-transfected with 0.25 µg 
of each fusion construct exhibited very low transfection efficiency. There was 
a significant increase in fluorescence signal in cells co-expressing bFos-VC 
and bJun-VN fusion proteins at 0.5 µg, 1.0 µg, 1.5 µg and 2.0 µg with no 
visual difference in yellow fluorescence signal among these concentrations 
(Figure 14).      
Qualitative assessment of at least three randomly acquired images showed 
that without Plus reagent co-expression of bFos-VC and bJun-VN at 0.25 µg, 
0.5 µg and 1.0 µg resulted in fluorescence signal but the signal appeared to 
be reduced compared with images when Plus reagent was added at the 
same concentrations. There was no fluorescence complementation when 
cells were transfected with 1.5 µg of each fusion construct and only one cell 
exhibited fluorescence signal when cells were transfected with 2.0 µg of each 
fusion construct (Figure 14).  
bFos∆ZIP-VC, which lacks the interaction region, was used as a negative 
control to compare the BiFC efficiency between bFos-VC and bFos∆ZIP-VC 
when they were paired with bJun-VN fusion protein. There was no 
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fluorescence complementation produced when HEK293T cells were co-
expressed with bFos∆ZIP-VC/bJun-VN fusion pair at any concentration used 
when transfection was performed without Plus reagent. When HEK293T cells 
were transfected with the bFos∆ZIP-VC/bJun-VN fusion pair with Plus 
reagent there was some fluorescence complementation detected at 0.5 µg 
concentration. However, the BiFC signal was significantly reduced compared 
with the signal produced by the co-expression of bFos-VC/bJun-VN at the 
same concentration (Figure 14).  
Based on these results further experiments were conducted using 0.5 µg of 
each plasmid DNA with Plus reagent. This amount of DNA provided a good 




























Figure 14. BiFC and bright field images of HEK293T cells transfected with either bFos-VC/bJun-VN or bFos∆ZIP-VC/bJun-
VN fusion pairs at various concentrations. HEK293T cells were transfected with fusion pairs at different concentration with and 
without Plus reagent to determine the optimum concentration for further experiments. Confocal analysis was performed 24 hours 
post-transfection.                                 
Jun/Fos 
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3.2.4 Determining the optimal time-scale for expression of bFos-
VC/bJun-VN and bFosΔZIP-VC/bJun-VN fusion pairs in HEK293T cells 
In BiFC transient expression experiments fluorescence from specific 
interactions can generally be detected between 12 and 30 hours after 
transfection (Kerppola, 2006). A BiFC assay is not a “real-time” kinetic 
measurement of protein-protein association and the fluorescence signal 
increases with incubation time (Rose et al, 2010). However, caution must be 
taken as the fluorescence signal accumulates in time due to the irreversible 
nature of YFP complementation and the saturation of fluorescence signal 
influences the signal-to-noise ratio (Horstman et al, 2014). Therefore, it is 
essential to determine the optimal time-scale for expression of the BiFC 
fusion proteins.  
The initial BiFC assay validation experiments were analysed 24 hours post 
transfection. It was therefore decided to compare BiFC confocal analyses at 
24 and 48 hours. Longer time points (e.g. 72 hours) resulted in over-
confluent detached cells. All the other image acquisition parameters, such as 
laser power, pinhole and detection gain, were held constant within an 
experiment. The BiFC signal in cells transfected with bFos-VC/bJun-VN 
fusion pair was higher at 24 hours post-transfection when compared with 48 
hours (Figure 15, A). After 48 hours post-transfection there were fewer cells 
exhibiting the fluorescence signal and the signal was more saturated (Figure 
15, B). A 48-hour incubation period also resulted in some weak background 
fluorescence signal in the YFP channel due to nonspecific interactions in 
cells transfected with bFos∆ZIP-VC/bJun-VN fusion pair (Figure 15, B). This 
could be explained by the irreversible complex formation between two non-
fluorescent YFP fragments and the prolonged post-transfection incubation 
may result in the accumulation of the fluorescence signal, leading to false-
positive results and making the data interpretation difficult.  
Based on these results further BiFC experiments with bJun, bFos and 
bFosΔZIP fusion proteins as well as with all the membrane proteins of 















Figure 15. Visualisation of fluorescent signal after 24 and 48 hours post-transfection. HEK293T cells were transfected with 
bFos-VC/bJun-VN and bFos∆ZIP-VC/bJun-VN fusion pairs and analysed using confocal microscope after 24 and 48 hours post-
transfection. 
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3.2.5 Qualitative analysis and sub-cellular localisation of BiFC signal 
The well-characterised interaction between bFos and bJun was used in this 
thesis to validate the BiFC assay before applying it to membrane protein-
protein interaction studies. Mammalian expression plasmids encoding bFos-
VC and bJun-VN fused to C- and N-terminal fragments of a Venus yellow 
fluorescent protein respectively were transfected into HEK293T cells using 
0.5 µg of each plasmid. The BiFC signal was assessed by confocal 
microscopy 24 hours after transfection. As can be seen in Figure 16, bFos-
VC and bJun-VN do indeed interact together resulting in yellow fluorescence 
signal.  The transfected cells have been stained with CellMask™ DeepRed 
Plasma membrane stain prior to the visualisation to examine the localisation 
of bFos-VC/bJun-VN interaction. In agreement with the previous results by 
Hu and Kerppola (2002) fluorescence complementation by bFos-VC and 
bJun-VN exhibited distinct nuclear distribution. Expression of either bFos-VC 
or bJun-VN alone did not produce detectable fluorescence (Figure 17). 
To confirm that the interaction between bFos-VC and bJun-VN is specific 
and is not driven by the interaction force of the two non-fluorescent 
fragments of a Venus yellow fluorescent protein the negative protein-protein 
interaction pair was included in BiFC experiments. A deletion in the leucine 
zipper of Fos protein has been shown to prevent Fos/Jun dimerisation in vitro 
(Gentz et al, 1989). Therefore, co-expression bFos∆ZIP-VC with bJun-VN in 
cells should not result in any yellow fluorescence signal. HEK293T cells were 
co-transfected with equal amounts of each expression plasmid encoding 
bFos∆ZIP-VC, containing mutation of the leucine zipper, and bJun-VN. The 
BiFC efficiency was assessed by confocal microscopy 24 hours after 
transfection. All the transfection and confocal analysis parameters were kept 
















Figure 16. Visualisation of bFos-VC/bJun-VN protein interactions in living cells using BiFC analysis. Visualisation by 
confocal microscopy of interactions between bFos-VC and bJun-VN fusion pairs in live cells 24 hours after transfection. Confocal 
imaging of transiently transfected HEK293T cells obtained with a 63x objective of the Leica TCS SP2 confocal microscope shows 
plasma membrane (in red) stained with CellMask Deep Red plasma membrane stain and the localisation of protein – protein 
interaction (yellow fluorescent colour). (A) Confocal images of bFos-VC/bJun-VN interactions in cell populations. (B) Confocal 
images of a single cell, showing the localisation of bFos-VC/bJun-VN interactions. 
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Figure 17. Confocal analysis of single transfected HEK293T cells.  
Confocal images of HEK293T cells expressing the proteins indicated in each 
panel were acquired 24 hours after transfection. None of the above proteins 












































Figure 18. Visualisation of bFos∆ZIP-VC and bJun-VN interactions in living cells using BiFC analysis. Visualisation by 
confocal microscopy of interactions between bFos∆ZIP-VC and bJun-VN fusion pairs in live cells 24 hours after transfection. 
Confocal imaging of transiently transfected HEK293T cells obtained with a 63x objective of the Leica TCS SP2 confocal 
microscope shows plasma membrane (in red) stained with CellMask Deep Red plasma membrane stain and the localisation of 
protein – protein interaction (yellow fluorescent colour). (A) Confocal images of bFos∆ZIP-VC/bJun-VN interactions in cell 
populations. (B) Confocal images of a single cell, showing the localisation of bFos∆ZIP-VC/bJun-VN interactions 
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The mutation in the interacting region of bFos caused a significant reduction 
in the efficiency of fluorescence complementation. However, the negative 
bFos∆ZIP-VC and bJun-VN interaction pair did not eliminate entirely the 
yellow fluorescence signal, which was also enriched in the nucleus (Figure 
18). It has been shown previously that fluorescence complementation 
between bFos-VC and bJun-VN in cells required an intact leucine zipper 
dimerisation interface and that without this region the fluorescence signal 
was entirely eliminated (Hu et al, 2002). The results in Figure 18 contradict 
the previous finding, leading to the conclusion that perhaps the fluorescence 
complementation is formed as a result of YFP interactions, producing false-
positive results. The fluorescence signal could also be caused by high 
expression levels of proteins that lead to an increase in fluorophore 
concentrations. However, images in Figure 18 are only representatives of all 
the BiFC experiments that have been repeated at least three times and not 
all images show fluorescence complementation for bFos∆ZIP-VC and bJun-
VN interactions. Therefore, qualitative judgment is not sufficient to draw any 
concrete conclusions and quantitative analyses were performed (refer to 
section 3.2.6).  
 
3.2.6 Quantitative and statistical analysis 
In order to confirm that the results of BiFC experiments using bFos-VC, 
bJun-VN and bFosΔZIP-VC fusion proteins represent specific protein-protein 
interactions and are not driven by the self-assembly of the two non-
fluorescent YFP fragments the ImageJ software was used to analyse and 
quantitate the BiFC signal. 
After being transfected and stained with plasma membrane stain HEK293T 
cells were used for confocal analysis. For BiFC quantification multiple 
images were taken in a random distribution from each well. The confocal 
images were then used for quantitative analysis using ImageJ. In each image 
field the staining of the plasma membrane allowed the outlining of all 
individual cells and the border of each cell was selected on a cell-by-cell 
basis. The fluorescent intensity derived from bimolecular fluorescence 
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complementation (e.g. YFP-VN+YFP-VC) and the red fluorescence signal 
derived from the plasma membrane stain were measured in individual cells 
and expressed as yellow/red ratio. On average about 700 cells from at least 
three independent experiments for each fusion protein combination were 
analysed. The distributions of ratios in individual cells were then plotted in 
histogram (Figure 19). In addition the average yellow fluorescence intensity 
in each cell was determined by measuring the average pixel intensity of the 
selected region, including border. The background signal in an area with no 
cells was subtracted from all values. BiFC fluorescence intensity values from 
at least three independent experiments were averaged and used for 
statistical analysis (Figure 20).   
The efficiency of fluorescence complementation is determined from the 
fluorescence intensity. Two non-fluorescent YFP fragments are able to form 
fluorescent complexes at higher efficiency and at higher rate when fused to 
two interacting proteins. Spontaneous complementation, however, is 
possible but significantly reduced when the fragments are fused to proteins 
that do not interact with each other. Figure 19 shows the distribution of YFP 
fluorescence to red fluorescence signal from the plasma stain ratios, 
representing a measure of the efficiency of bimolecular fluorescence 
complementation. The interaction between bFos-VC and bJun-VN produced 
an increase in the efficiency of association between the fluorescent YFP 
fragments. HEK293T cells co-expressing bFos-VC and bJun-VN exhibit 
higher cell numbers that fall into a greater ratio value range compared with 
the cells co-expressing bFos∆ZIP-VC and bJun-VN negative interacting pair. 
Therefore it can be concluded that bFos-VC/bJun-VN complementation 
complex results in a stronger YFP fluorescence signal and is more prevalent 





Figure 19. The distribution of BiFC/DeepRed plasma stain ratios. Plasmids encoding bJun-VN and either bFos-VC or mutated 
bFos∆ZIP-VC (0.5 μg each) were transfected into HEK293T cells. Cells were stained with CellMask Deep Red plasma membrane 
stain 24 hours post-transfection. The fluorescence intensity produced by bimolecular fluorescence complementation (YN-YC) and 
the red fluorescence signal derived from the plasma membrane stain were measured in individual cells. The emission intensities 
were corrected for background fluorescence in an area of the field lacking cells. The distribution of ratios between the fluorescence 






















In addition, the graph in Figure 20 also confirms that bFos-VC/bJun-VN 
interacting pair resulted in significantly greater fluorescence intensity than the 
bFos∆ZIP-VC/bJun-VN negative interacting pair. The average fluorescence 
intensity for bFos-VC/bJun-VN interacting pair was 6.3 x greater than for 
bFos∆ZIP-VC/bJun-VN negative interacting pair. Although co-expression of 
the negative bFos∆ZIP-VC/bJun-VN pair also produced readily detectable 
fluorescence the average fluorescence intensity was significantly reduced 
compared with positive bFos-VC/bJun-VN pair (P˂0.01; Figure 20). 
False positive fluorescence resulting from self-assembly of the non-
fluorescent YFP fragments is defined by low (or reduced) signal-to-noise 
ratio (S/N). The S/N ratio can be used as a measure of BiFC specificity. To 
determine the specificity of the BiFC assay the S/N ratio was estimated using 
the following formula:  
 
 
The bFos-VC/bJun-VN fusion pair was used as positive fusion pair and the 
bFos∆ZIP-VC/bJun-VN as negative fusion pair. The S/N value for the BiFC 
assay with bFos-VC/bJun-VN was 7.7. This result agrees with previous 
results obtained by Kodama and Hu (2010) in BiFC optimisation studies, 








S/N = Median Y/R ratio value from positive interacting pair 







Figure 20. Validation of BiFC specificity. Quantification of fluorescence 
intensities that was determined with the ImageJ software using confocal 
images of bFos-VC/bJun-VN and bFosΔZIP-vc/bJun-VN interaction pairs in 
transiently transfected HEK293T cells. The mean and standard errors of 
three independent measurements are shown. *p<0.001 by the Mann-Whitney 







































To validate and optimise the BiFC assay two interacting proteins bFos and 
bJun were used as the positive interacting pair and bFosΔZIP and bJun as 
the negative interacting pair. The interaction between bFos and bJun is well 
documented and these proteins have been previously used in studies 
developing BiFC assays (Bos et al, 1989; Neuberg et al, 1989; Kerppola, 
2008; Hu et al, 2002). In this thesis fragments of a Venus YFP truncated at 
residue 155 (VN155 and VC155) were used as they exhibit a relatively high 
complementation efficiency when fused to interacting partners but produce 
low fluorescence when fused to non-interacting proteins. bJun was fused to 
the N-terminal part of YFP (bJun-VN) and bFos and bFosΔZIP were fused to 
the C-terminal part of YFP (bFos-VC and bFosΔZIP-VC) and were used first 
to select a cell line for BiFC experiments. In order to establish the cell line 
that results in a higher expression level both HEK293 and HEK293T cell 
lines were transiently co-transfected with bFos-VC/bJun-VN and bFosΔZIP-
VC/bJun-VN fusion pairs. These cell lines were chosen for the ease of 
expression of mammalian proteins, cells’ high transfection efficiency and 
ease of maintenance. The BiFC assay has been used for the analysis of 
protein interactions in many mammalian cells including HEK293, in which co-
expression of fusion proteins exhibited similar patterns of fluorescence 
compared with COS-7 and NIH 3T3 cells (Fang and Kerppola, 2004). The 
results showed that HEK293T cells, when co-expressing bFos-VC/bJun-VN 
fusion pair, exhibited not only higher intensity of the fluorescent signal but 
also a higher number of cells producing the signal compared with HEK293 
cells. This suggests that HEK293T cells exhibit higher protein expression 
levels, probably due to the presence of the SV40 large T antigen that can 
bind to SV40 enhancer of expression vectors and thus considerably increase 
the expression levels obtained with transient transfection. Based on these 
qualitative results the HEK293T cell line was chosen for further experiments 
with bFos and bJun as well as with transmembrane proteins discussed in 




To determine the optimal time-scale for expression of fusion proteins and 
BiFC complex formation the cells were analysed 24 and 48 hours post-
transfection. A longer incubation period (i.e. 72 hours) was also considered 
but resulted in the majority of cells being detached and, thus, was not 
included in experimental results. In transient expression experiments 
fluorescence from specific interactions can generally be detected between 12 
and 30 hours after transfection (Kerppola, 2006). The confocal analysis of 
the transfected HEK293T cells showed that the 24-hour incubation period 
resulted in an increased fluorescence signal. Fewer cells exhibited 
fluorescence signal after the 48-hour incubation period and the signal was 
more saturated. In addition the 48-hour incubation resulted in weak 
background fluorescence signal in cells co-expressing bFosΔZIP-VC/bJun-
VN negative interacting pair. This could be explained by the fact that the 
fluorescence complex formation is irreversible and longer incubation may 
result in accumulation of the signal from non-specific interactions driven by 
the YFP fragments. Longer incubation could result in higher expression of 
fusion proteins that could also contribute to complementation due to non-
specific interactions. Therefore, longer incubations should be avoided and, 
based on the qualitative analysis obtained from these experiments, it was 
decided that the 24-hour incubation is preferable for future experiments.  For 
the same reason it is advisable to keep the amount of DNA used for 
transfection low. Although previous studies reported that BiFC generally has 
very low background, very high expression of fusion proteins can result in 
BiFC between proteins that do not interact in vivo (Kerppola, 2006; Kerppola, 
2008). Over-expression of the fusion proteins may lead to the association of 
the tethered fluorescent protein fragments because of high local 
concentrations of the fusion proteins (Kodama and Hu, 2010). A paper on 
design and implementation of the BiFC assay by Kerppola (2008) 
recommended starting with 0.25 µg of DNA for transient transfections. 
However, in various papers on protein-protein interaction studies using BiFC 
a range of DNA amounts was used, ranging from 0.25 µg to 5.0 µg of each 
plasmid. To optimise the amount of DNA for transfections HEK293T cells 
were co-transfected with either bFos-VC/bJun-VN or bFosΔZIP-VC/bJun-VN 
fusion pairs, using a range of DNA amounts from 0.25 to 2.0 µg of each 
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plasmid. The cells transfected with bFos-VC/bJun-VN, using 0.25 µg of each 
plasmid, exhibited low expression efficiency and fluorescence signal. Higher 
amounts of DNA used for transfections produced an increase in expression 
efficiency and fluorescence signal compared with 0.25 µg of DNA. However, 
at higher amounts of DNA ranging from 0.5 to 2.0 µg, the expression 
efficiency and fluorescence intensity were comparable. The cells transfected 
with bFos-VC/bJun-VN at all the tested concentrations exhibited some 
background fluorescence signal. Since qualitative analysis showed no 
significant benefit of using higher amounts of DNA, 0.5 µg of each plasmid 
was used in all future experiments. This amount of DNA provided a good 
fluorescence signal and would save on using increased amount of 
transfection reagents.   
To validate the BiFC assay two proteins, bFos and bJun that are known to 
interact together, were chosen. The qualitative analysis of HEK293T cells co-
transfected with bFos and bJun, fused to C- and N-terminal fragments of a 
Venus yellow fluorescent protein respectively, exhibited a readily detectable 
fluorescence signal. The localisation of the fluorescence signal resulting from 
the bFos-VC/bJun-VN fusion pair interaction was predominantly in nuclei and 
some in cytoplasm. These results correspond to the previous studies by Bos 
et al (1989) and Neuberg et al (1989) that identified the location of bJun and 
bFos in the nucleus. Some of the complementation complex formation could 
probably occur during translocation of the proteins from the site of their 
synthesis in the cytoplasm to the nucleus. This could explain some of the 
fluorescence present in the cytoplasm. It has been previously reported that 
bFos is efficiently translocated to the nucleus when bound to bJun through 
their leucine zippers, and mainly by the use of the nuclear localisation signal 
of bJun (Chida et al, 1999). The negative bFosΔZIP-VC/bJun-VN interacting 
pair also produced a fluorescence signal when co-expressed in live cells but 
the signal and the BiFC efficiency were significantly reduced.  
The results of these experiments correspond to the previous findings from 
studies on design and optimisation of a Venus-based BiFC assay with bFos 
and bJun. Co-expression of bFos and bJun fused to C- and N-terminal 
fragments of a Venus yellow fluorescent protein in live cells exhibited readily 
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detectable fluorescence signal with good BiFC efficiency. Confocal analysis 
on the localisation of the bFos-VC/bJun-VN fusion pair interaction revealed 
that fluorescence signal was detected merely in nuclei, which corresponds to 
the results of Immunofluorescence studies showing that these proteins are 
localised in the nucleus (Bos et al, 1989; Neuberg et al, 1989). And although 
the negative bFos∆ZIP-VC/vJun-VN interaction pair also produced 
fluorescence signal when co-expressed in live cells, the signal and the BiFC 
efficiency appeared to be reduced. 
Spontaneous assembly of VC and VN fragments provides a source of false 
positive results, which makes qualitative data interpretation difficult. As 
already mentioned above, cells experiencing physiological distress, or cells 
assayed at late time points when fusion proteins are in high concentration, 
can accumulate high levels of mislocalised fluorescent signal (Kerppola, 
2008). Figures 16 and 18 show that it is not possible to rely on qualitative 
judgement to assess protein-protein interactions. Therefore, to reach valid 
conclusions on interactions, it is important to carry out quantitative and 
statistical analysis, comparing the intensities and numbers of fluorescent 
cells observed when the cells are transfected with the positive interaction 
pair with those observed when the cells are transfected with the negative 
interaction pair.  
In this study the quantitative analyses were carried out as described in 
Chapter 2, section 2.5.9. The distribution of the BiFC/Red plasma stain ratios 
in Figure 19 show that more cells co-expressing bFos-VC/bJun/VN fall into a 
higher range of ratio values than cells co-expressing bFosΔZIP-VC/bJun-VN. 
When the two proteins interact the fluorescence intensity of VC and VN YFP 
fragments will increase, resulting in a higher fluorescence ratio, as was 
observed with bFos-VC/bJun-VN interaction pair. This could be explained by 
the fact that when proteins do not interact, most cells will have a very low 
fluorescence ratio, as was observed with bFosΔZip-VC/bJun-VN. In a 
previous study on design and complementation of BiFC assay by Kerppola 
(2008) the efficiency of BiFC was defined by the ratio of YN-YC (N and C 
terminal fragments of YFP) to Cerulean (CFP; used as the internal control) 
fluorescence. Although in this study the plasma membrane was stained with 
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fluorescent dye instead of using an internal control, the results were 
comparable to previous findings. In addition, to confirm BiFC specificity the 
signal-to noise (S/N) ratio was measured as described in a study by Kodama 
and Hu (2010). The self-assembly of the YFP fragments can contribute to 
false-positive fluorescence and decrease the S/N ratio in the BiFC assay. It 
has been previously reported that introduction of I152L mutation in VN155 
YFP fragment dramatically reduces the self-assembly between the Venus N- 
and C- terminal fragments, resulting in a high S/N ratio in living cells 
(Kodama and Hu, 2010). The same Venus YFP fragments, containing I152L 
mutation in VN155, were used in this study and the S/N ratio value obtained 
from bFos-VC/bJun-VN interaction was 7.7. This value closely correlates to 
the S/N ratio value of 7 in the previous study by Kodama and Hu (2010), 
supporting the conclusion that the assay set-up and quantification procedure 
as used in this chapter are optimised and valid. 
Furthermore the average yellow fluorescence signal intensities were 
determined for positive and negative fusion pairs from confocal images, 
using ImageJ as described in Chapter 2, section 2.5.9. The results obtained 
not only complemented the results described above but provided a robust 
data interpretation. There was significant 6.3 fold decrease in the yellow 
fluorescence signal when cells were co-expressing bFosΔZip-VC/bJun-VN 
fusion pair compared with positive interacting pair bFos-VC/bJun-VN. The 
overall quantitative assessment of the fluorescence images obtained on co-
expression of either bFos-VC/bJun-VN or bFosΔZip-VC/bJun-VN constructs 
indicated a BiFC signal that is due to a specific interaction, rather than self-
assembly of constructs and background fluorescence.      
In this chapter a procedure for quantitative analysis of BiFC data was 
developed and validated, which could be further applied to studies of 
membrane proteins. This will be particularly important since the membrane 
protein-protein interaction studies would be more prone to self-assembly and 
false-positive results as the membrane proteins are “fixed” in the plane of the 
membrane rather than being free in cytoplasm. While it is recognised that 
there will be differences in expression of the membrane proteins the 
experiments with bFos and bJun proteins provided a good starting point, 
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showing that the BiFC assay is an efficient approach for visualisation of 
protein-protein interactions with a high specificity in live cells but further 









Validation and characterisation of the interaction between VE-PTP and 




















The functions of the extracellular domain for many RPTPs are not yet well 
characterised. The structure of the extracellular domain of VE-PTP suggests 
a role as an adhesion receptor (Barford et al, 1995). In fact, co-
immunoprecipitation studies by Nawroth and colleagues (2002) showed that 
VE-PTP interacts with the most prominent adhesion molecule of endothelial 
adherens junctions VE-cadherin. Interestingly the same research group 
demonstrated that VE-PTP and VE-cadherin interact together via their 
extracellular domains, independently of their cytoplasmic tails (Nawroth et al, 
2002). Furthermore it has been demonstrated that the single 17th Fibronectin 
III-like (FNIII) domain of VE-PTP and fifth cadherin domain of VE‐cadherin 
were sufficient for their association (Nawroth et al, 2002). It was proposed to 
be a cis interaction because of the membrane‐proximal position of both 
interacting domains, making VE‐PTP the first described candidate for a 
transmembrane protein that interacts in cis with a cadherin via an 
extracellular domain (Nawroth et al, 2002).  
Interestingly the 17th FNIII-like domain of VE-PTP is not homologous to the 
other 16 repeated domains. It is not only larger than the rest of the 
extracellular domains, consisting of 179 amino acids as supposed to 90 
amino acids for each of the 16 repeated domains, but it also contains a 
stretch of six prolines, which is similar to the hinge regions in immunoglobulin 
heavy chains. This characteristic perhaps provides the steric conformation, 
causing a kink in the peptide chain of the extracellular domain (Krueger et al, 
1990). 
Data from a study by Nawroth et al (2002) suggest the 17th membrane-
proximal FNIII-like repeat is the only domain required for the interaction with 
VE-cadherin. However, whether other regions of the VE-PTP extracellular 
domain are involved remains unknown. Therefore, the purpose of this 
chapter was first to validate the interaction between VE-PTP and VE-
cadherin via their extracellular domains in living cells using bimolecular 
fluorescence complementation (BiFC) assay in transiently transfected 
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HEK293T cells and then to investigate whether the deletion of the 17th FNIII-
like domain in VE-PTP would abolish any association.  
The constructs used in this study VEPTP-VN and VE-cadherin-VC, shown 
diagrammatically in Figure 21, consist of residues 1-1647 of VE-PTP and 1-
625 of VE-cadherin, with either the modified N- or C-terminal sequence of 
vYFP inserted five residues after the transmembrane domain and a flexible 
linker sequence, as used by Kodama & Hu (2010). This approach essentially 
replaced the intracellular region of these proteins with non-fluorescent 
fragments of vYFP enabling investigation of protein-protein interactions that 




























Figure 21. Schematic representation of the VE-PTP and VE-cadherin 
constructs used for BiFC. VE-PTP consists of multiple extracellular 
fibronectin III-like repeats (blue), a transmembrane domain and an 
intracellular protein tyrosine phosphatase domain (PTP). VE-cadherin 
consists of 5 extracellular cadherin domains (orange), a transmembrane 
sequence and an intracellular cadherin cytoplasmic region (grey). The 
constructs VE-PTP-VN, VE-PTP-VC and VE-cadherin-VC have a modified 
N- or C-terminal sequence of the Venus protein (a yellow fluorescent protein 
(YFP) variant; represented by a half cylinder) inserted five residues after the 
transmembrane domain. A myc tag (pink) has been inserted after the signal 
peptide of VE-PTP to facilitate analysis of expression. When brought into 
close proximity by a pair of interacting proteins, the fragments assemble to 
















4.1.1 Controls to determine the complementation specificity 
The BiFC assay is a useful technique for the direct visualisation of protein-
protein interactions in living cells. This approach allows one to study the sub-
cellular localisation of interactions with minimal perturbation of their normal 
environment. However, because the non-fluorescent fragments of the 
fluorescent protein are prone to self-assembly independent of a protein-
protein interaction event, leading to false positive results, it is crucial to 
include appropriate negative controls. In Chapter 3 (section 3.1) appropriate 
negative controls were discussed. Here two negative control fusion proteins 
were generated to determine the specificity and efficiency of BiFC. The first 
negative control was based on the transmembrane glycoprotein sialophorin 
(SPN; also known as leukosialin, CD43) and the other was a plasma 
membrane anchored fusion protein. 
SPN control was fused to either the C- or N-terminal part of the YFP (SPN-
VN or SPN-VC respectively). The SPN was chosen as a negative control 
since it shares no homology with any of the RPTPs of the R3 subgroup but it 
has an equally large extracellular domain that is highly glycosylated 
(Cordoba et al, 2013). It has been previously used as a control in studies 
with another R3 RPTP member DEP-1 (density enriched protein tyrosine 
phosphatase 1) to investigate the role of the DEP-1 extracellular domain in T 
cell receptor signalling (Cordoba, 2013). However, in the previous study the 
extracellular domain of the DEP-1 was substituted with the extracellular 
domain of the SPN. Therefore, there are no known possible interactions of 
SPN with any of the R3 RPTPs reported up to date. SPN fusion protein 
controls consisted of extracellular and transmembrane domains, either fused 
to the N-terminal part of a Venus YFP with a myc tag or the C-terminal part 
of Venus YFP with a HA tag (Figure 22).    
The second negative control consisted of either the C- or N-terminal 
fragment of a Venus YFP anchored to the plasma membrane via the 
membrane association sequence from Lck (lymphocyte-specific protein 
tyrosine kinase), Myr-VC and Myr-VN respectively (i.e. myristoylated C- and 
N-terminal YFP fragments). Negative controls Myr-VC and Myr-VN were 
108 
 
generated as a backup to eliminate any possible interactions between SPN 
and R3 RPTPs. These negative controls had all the possible interaction 
domains removed (i.e. they entirely lacked any extracellular and 
transmembrane domains) and in theory there should be no complementation 
complex formation when it is co-expressed with the fusion proteins of 
interest. The two fusion proteins Myr-VC and Myr-VN consisted only of C- 
and N-terminal YFP fragments respectively that were anchored to the 
plasma membrane via membrane association sequence from Lck protein 
kinase (Figure 22). An N-terminal dual acylation motif of Lck protein kinase is 
necessary for correct intracellular localisation to the plasma membrane. This 
sequence consists of MGCGCSSHPEDDW amino acids in which the 
cysteines (C) become post-translationally S-acylated and the glycine-2 (G), 
immediately after the initiator methionine, is myristoylated (Zlatkine et al, 
1997). Therefore, fusing this sequence to each YFP fragment should be 
sufficient to encode the correct lipid modification and to target the YFP 
fragments to plasma membrane. This dual acylation motif has been used 
previously to target cytosolic proteins to the plasma membrane (Zlatkine et 
al, 1997). Consequently, if any fluorescence complementation is observed 
after co-expressing Myr-VC or Myr-VN with any of the R3 RPTPs in 
mammalian cells, it is most likely due to the self-assembly of the YFP 
fragments. Therefore, the use of this control enables us to evaluate the 
specificity (i.e. whether the fluorescence complementation represents 
specific protein-protein interactions) and efficiency (i.e. fluorescence 
intensity) of association in positive interaction pairs as explained in Chapter 






















Figure 22. Schematic representation of BiFC negative controls. The full-
length extracellular and transmembrane domains of SPN were fused to 
either C- or N-terminal parts of a Venus YFP. SPN fused to the C-terminal 
YFP was HA tagged, whereas SPN fused to the N-terminal YFP was myc 
tagged. Myr-VC and Myr-VN represented negative interaction constructs 
lacking any interaction domains and comprised C- and N-terminal YFP 
fragment respectively, followed by myc tag and the plasma membrane 
anchoring sequence of Lck protein kinase. 
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4.1.2 Investigating association of a VE-PTP∆17FN mutant with VE-
cadherin 
Previous in vitro findings of Nawroth and colleagues (2002) showed that 
neither the cytoplasmic nor transmembrane domains of VE-PTP are required 
for the interaction with VE-cadherin and that the 17th FNIII-like domain was 
sufficient for co-immunoprecipitation with VE-cadherin. In order to examine 
this finding in a BiFC live cell assay a fusion construct in which the 17th FNIII-
like domain had been removed (VE-PTP∆17FN-VN) was generated (Figure 
23). The objective was to investigate whether this domain is important in 
association with VE-cadherin in live cells. It was hypothesised that deleting 
the 17th FNIII-like domain of VE-PTP would be sufficient to abolish the VE-


























Figure 23. Schematic representation of VE-PTP mutant fusion 
construct. The VE-PTP-VN BiFC construct consisting of transmembrane 
and extracellular domains fused to the N-terminal part of the YFP was used 
to generate mutated VE-PTPΔ17FN-VN fusion construct in which the 17th 
FNIII-like domain was removed, moving the 16th FNIII-like domain proximal 
to the transmembrane domain. The start and the end of the 17th FNIII-like 




















4.2 Results  
4.2.1 Cloning VE-PTP-VN and VE-cadherin-VC fusion proteins 
VE-PTP-VC and VE-PTP-VN fusion constructs were generated as outlined in 
the schema in Chapter 2 (Figure 8). For the VE-PTP-VN a synthetically 
generated signal peptide and myc tag (EQKLISEEDL) fragment (Genscript) 
was inserted into ApaI/XhoI restriction sites of pBiFC-VN155(I152L) vector. 
The transmembrane and extracellular (TM+ECD) domains of VE-PTP 
construct were amplified by PCR using Platinum Pfx polymerase (Figure 24, 
A). The PCR product corresponded to the predicted size of 5.8 kb. The 
primers used for the generation of the VE-PTP transmembrane and 
extracellular domains are listed in Table 10 and the PCR conditions are 
provided in Table 4 (Chapter 2). The resulting PCR product was purified, 
digested and subsequently inserted into XhoI restriction site of the pBiFC-
VN155(I152L) vector, which contained signal peptide and myc tag. Colony 
PCR was used to confirm the correct orientation of the insert to ensure that a 
fusion protein fused to the N-terminal part of YFP has been generated 
(Figure 25, A).  
To generate the VE-PTP-VC fusion construct a synthetically generated 
signal peptide and HA tag fragment (Genscript) was inserted into ApaI/XhoI 
restriction sites of pBiFC-VC155 vector. The TM+ECD domains of VE-PTP 
were cut out from the previously generated VE-PTP-VN fusion construct with 
XhoI restriction enzyme, purified and ligated into the pBiFC-VC155 vector, 
containing signal peptide and HA tag, to create a fusion protein fused to the 
C-terminal part of YFP. Colony PCR was used to confirm the correct 
orientation of the insert (Figure 25, B).  
The VE-cadherin-VC fusion construct was generated by using PCR to 
amplify signal peptide, transmembrane and extracellular domains of VE-
cadherin.  The PCR product corresponded to the predicted size of 1.9 kb for 
signal peptide, extracellular and transmembrane domains of VE-cadherin on 
an agarose gel (Figure 24, B). The resulting PCR product was ligated into 
ApaI/XhoI restriction sites of the corresponding pBiFC-VC155 vector and 
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transformed into XL1-Blue strain of E.coli. The presence of the correct DNA 
insert was determined by screening bacterial colonies by PCR using Bioline 
Red Taq with a combination of vector-specific and insert-specific primers 
(Table 11). PCR products were analysed by agarose gel (Figure 25, C) and 
the remaining portion of the colony containing vector with the correct insert 
was used to inoculate LB media with an appropriate antibiotic.  
The plasmid DNA for each fusion construct was purified and sequenced to 
verify that the insert gene has been ligated at the correct position within the 
vector backbone without any mutations. The sequenced plasmids were used 
to prepare larger quantities of high-quality plasmid DNA for mammalian cell 



























Figure 24. The generation of transmembrane and extracellular domains 
of VE-PTP and VE-cadherin by PCR. Electrophoresis on 0.8% agarose gel 
showing DNA bands corresponding to expected ECD+TM sizes for each 
construct: A) ~5.0 kb band for TM+ECD of VE-PTP. Running time was 35 
minutes at 110 V constant, B) ~1.9 kb DNA band for TM+ECD of VE-






















Figure 25. Colony PCR to screen for successful ligation. Following ligation and transformation colony PCR was performed with 
vector-specific and insert-specific primers to screen for successful ligation. (A) The DNA band corresponds to the predicted size of 
5897 bp of the VE-PTP TM+ECD inserted into a pBiFC-VN155 expression vector. (B) The DNA band corresponds to the predicted 
size of 5613 bp of the VE-PTP TM+ECD inserted into a pBiFC-VC155 expression vector. (C) The DNA band corresponds to the 
predicted size of 2225 bp of the VE-cadherin TM+ECD inserted into a pBiFC-VC155 expression vector. The circled bands indicate 
the clones selected for sequencing. 
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4.2.2 Generation of negative control SPN fusion construct 
To generate the SPN-VC fusion construct a synthetically generated signal 
peptide and HA tag fragment (Genscript) was inserted into ApaI/EcoRI 
restriction sites of pBiFC-VC155 expression vector. For the SPN-VN fusion 
construct a synthetically generated signal peptide and myc tag fragment was 
inserted into ApaI/EcoRI restriction sites of pBiFC-VN155(I152L) expression 
vector. Colony PCR was performed using REDTaq DNA Polymerase to 
confirm the presence of the correct insert with a combination of vector-
specific and insert-specific primers. The list of primers used for colony PCR 
is provided in Table 11 (Chapter 2). Figure 26 shows the DNA bands 
corresponding to the correct sizes of 482 bp for signal peptide and HA tag in 
pBiFC-VC155 vector and 677 bp for signal peptide and myc tag in pBiFC-
VN155(I152L) vector. 
Following insertion of the appropriate signal peptide and tags into the vector 
the sequence corresponding to the transmembrane and extracellular domain 
of SPN was amplified by PCR using Platinum Pfx polymerase (Figure 27). 
The oligonucleotide primer sequences and PCR conditions are listed in 
Tables 10 and 4 respectively.   
The resulting PCR product was subsequently digested, purified and inserted 
into EcoRI/XhoI restriction sites of the corresponding pBiFC-VC155 and 
pBiFC-VN155(I152L) vectors to create fusion protein fused to the C- and N-
terminal parts of YFP respectively. 
Colony PCR was used to confirm the presence of the correct insert (Figure 
28). The oligonucleotide primer sequences and PCR conditions are listed in 
Tables 11 and 6 respectively.   
The plasmid DNA for each fusion construct was purified and sequenced to 
verify that the insert gene has been ligated at the correct position within the 
vector backbone without any mutations. The sequenced plasmids were used 
to prepare larger concentrations of high-quality plasmid DNA for mammalian 














Figure 26. Colony PCR analysis. Synthetically generated signal peptide of 
SPN with either the HA or myc tag was ligated into ApaI/EcoRI restriction 
sites of the pBiFC-VC155 and pBiFC-VN155(I152L) vectors respectively. 
Colony PCR was performed with vector-specific and insert-specific primers 
to screen for successful ligation.  (A) The DNA band of 482 bp corresponds 
to the predicted size of SPN signal peptide and HA tag inserted into a pBiFC-
VC155 vector. (B) The DNA band of 677 bp corresponds to the predicted 































Figure 27. Generation of extracellular and transmembrane domains of 
SPN by PCR. Electrophoresis on 0.8% (w/v) agarose gel showing a DNA 
band of 771 bp that corresponds to the expected size of the SPN 
transmembrane and extracellular domain. Running time was 40 minutes at 























Figure 28. Colony PCR analysis. Colony PCR was performed with vector-
specific and insert-specific primers to screen for successful ligation. (A) The 
DNA band corresponds to the predicted size of 1693 bp of the SPN TM+ECD 
inserted into pBiFC-VN155 vector. (B) The DNA band corresponds to the 




















4.2.3 Cloning membrane anchored N- and C-terminal Venus-YFP fusion 
proteins 
A membrane anchored fusion protein that entirely lacked transmembrane 
and extracellular domains was generated for use as a control in BiFC studies 
(shown schematically in Figure 15). Overlapping primers (Table 15), 
containing sequences corresponding to ApaI and EcoRI restriction sites, the 
membrane association sequence (Myr) from the protein tyrosine kinase Lck 
and a myc tag, were annealed together and ligated into the ApaI/EcoRI 
restriction sites of pBiFC-VN155 and pBiFC-VC155 expression vectors. 
Colony PCR was performed using REDTaq DNA Polymerase to confirm the 
presence of the correct DNA insert with a combination of vector-specific 



























Figure 29. Colony PCR analysis for membrane anchored N- and C-
terminal Venus YFP fusion proteins. Annealed overlapping primers 
containing the membrane association (Myr) and myc tag sequences were 
ligated into pBiFC-VC155 and pBiFC-VN155 expression vectors. Colony 
PCR was performed with vector-specific (CMV-F) and insert-specific (Myr-R) 
primers to screen for successful ligation. (A) The DNA band corresponds to 
the predicted size of 417 bp of the Myr-myc inserted into pBiFC-VC155 
vector. (B) The DNA band corresponds to the predicted size of 426 bp of the 











4.2.4 Cloning a deletion mutant VE-PTP∆17FN 
A deletion mutant of VE-PTP in which the 17
th 
FNIII-like domain was 
removed was generated by PCR as shown schematically in Figure 23 for use 
in BiFC studies. Primers contained a non-complementary 5’ XmaI restriction 
enzyme site. The primer details are provided in Table 13 and the PCR 
parameters are listed in Table 14. Following PCR amplification the product 
was digested with DpnI/XmaI restriction enzymes and ligated to create the 












































Figure 30. Deletion of the 17th FNIII-like domain in VE-PTP-VN using a 
PCR based approach. PCR was performed to amplify the entire sequence 
of the pBiFC-VN155(VE-PTP)-SP-myc-TM-ECD except for the 17th FNIII-like 
domain that was to be deleted. The gel extracted PCR product was digested 
with DpnI/XmaI restriction enzymes and the plasmid was re-ligated together 
using T4DNA Ligase. (A) Gel electrophoresis analysis of the PCR product 
shows the band of the predicted size of ~9.0 kb. (B) Gel electrophoresis 




















































4.3 Western blot analysis of BiFC fusion proteins in HEK293T cells 
Western blotting of lysates from transiently transfected HEK293T cells 
confirmed the expression of all the fusion proteins close to their predicted 
molecular weight (Figure 31). Western blotting with anti-myc antibody for the 
VE-PTP-VN and VE-PTP∆17FN-VN mutant, which have a myc-tag inserted 
following the signal peptide sequence (Figure 31, A), detected proteins with a 
molecular weight of approximately 220 kDa. The predicted molecular weight 
for VE-PTP-VN was 203 kDa. The discrepancy in molecular weight is 
probably accounted for by extensive glycosylation. It has previously been 
shown that VE-PTP has 26 potential N-glycosylation sites in its extracellular 
domain (Krueger et al, 1990). VE-PTP∆17FN as a fusion with the N-terminal 
fragment of vYFP was expressed at lower levels than VE-PTP-VN (Figure 
31, A). Western blot experiments were performed at least twice and the 
results were consistent. 
Western blotting with the VE-cadherin antibody (ab7047) detected a 130 kDa 
band corresponding to VE-cadherin (Figure 31, B). The band is larger than 
the predicted 80 kDa but this is probably due to VE-cadherin being highly 
glycosylated. A study by Geyer et al (1999) showed that the VE-cadherin has 
seven potential N-glycosylation sites, all localised in its five cadherin 
ectodomains and it has been demonstrated that indeed VE-cadherin is 
accompanied by oligosaccharide side chains of reduced branching pattern, 
which are highly sialylated. This would largely increase the size of a protein 
and thus affect its migration so that the actual band size observed would be 
different from that predicted.  
Western blotting of lysates from transiently transfected HEK293T cells 
confirmed the expression of control proteins SPN and Myr-VC and Myr-VN at 
their predicted molecular weight (Figure 31, C-E). The predicted molecular 
weight for Myr-VC and Myr-VN was 15.3 kDa and 21.9 kDa respectively, 
which closely correspond to their migration points (Figure 31, C). The 
predicted molecular weight for SPN-VN was 48.4 kDa and 41 kDa for SPN-
VC. A high-molecular weight smear, reflecting extensive glycosylation, was 
apparent with the SPN constructs. All control proteins were expressed at 
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substantially higher levels than the VE-cadherin-VC protein (Figure 31, 
panels A, C, D and E). However, the difference in band intensities could also 
be explained by the lack of sensitivity of some antibodies. Anti-VE-cadherin 
antibody could be less sensitive in recognising VE-cadherin compared with 






















Figure 31. Protein expression analysis by Western blot. Western blotting of cell lysates from transfected HEK293T cells with 
either anti-myc, anti-HA or anti-VE-cadherin antibody confirmed the expression of the constructs at the expected molecular weight. 

















































4.4 Validation of VE-PTP and VE-cadherin interaction in live cells using 
the BiFC technique 
The involvement of the extracellular domains in the interaction between VE-
PTP and VE-cadherin has been demonstrated previously by co-
immunoprecipitation assay (Nawroth et al, 2002). However, no previous 
studies have been done in live cells to investigate the molecular basis of this 
interaction. To confirm that the interaction between these two proteins occurs 
via their extracellular domains in live cells the BiFC VE-PTP-VN and VE-
cadherin-VC fusion proteins were constructed (refer to section 4.2.1). The 
fusion proteins were expressed in HEK293T cells and 24 hours post-
transfection stained prior to confocal visualisation with the CellMas Plasma 
Membrane Stains (as detailed in method section 2.5.6). As predicted 
transfection of HEK293T cells with a single construct did not produce any 
detectable fluorescence signal, indicating that neither of the YN- and YC-
fusion proteins alone is fluorescent (Figure 32).  
Co-expression of the VE-PTP-VN and VE-cadherin-VC constructs in 
HEK293T cells resulted in the occurrence of BiFC fluorescence (Figure 33). 
BiFC fluorescence was observed in approximately 40% of the transfected 
cells. Comparison of the sub-cellular localisation of the Venus YFP (vYFP) 
signal with that of the CellMask deep red plasma membrane stain indicated 
that the fluorescence complementation signal was detected in the plasma 
membrane and intracellular structures, likely to be the endoplasmic reticulum 
or Golgi, of co-transfected cells. The localisation of the yellow fluorescence 
signal at the plasma membrane was also confirmed by the co-localisation 
analysis that was carried out using ImageJ software (Figure 34). The 
overlapping pixels from both signals are highlighted in white, showing that 
both yellow and red signals are co-localised at the plasma membrane (Figure 
34, A). The histogram in Figure 34 (B) also shows that both fluorescence 
signals overlap to some extent, confirming that some of the BiFC signal is 














Figure 32. Confocal analysis of single construct transfected HEK293T 
cells.  Confocal images of HEK293T cells expressing the proteins indicated 
in each panel were acquired 24 hours after transfection. None of the above 































Figure 33. BiFC analysis of interaction between VE-PTP-VN and VE-cadherin-VC. Fluorescence is regained as a result of 
reconstitution of YFP from two non-fluorescent N- and C-terminal fragments due to an interaction between VE-PTP-VN and VE-
cadherin-VC. Equal amount of expression vectors encoding VE-PTP-VN and VE-cadherin-VC were co-transfected into HEK293T 
cells and the resulting BiFC signal was analysed by confocal microscopy. (A) Confocal images of VE-PTP-VN/VE-cadherin-VC 
interactions in cell populations. (B) Confocal images of a single cell, showing the localisation of VE-PTP-VN/VE-cadherin-VC 
interactions.







































Figure 34. Co-localisation analysis of fluorescence signals from the 
BiFC and the red plasma membrane stain channels from HEK293T cells 
co-transfected with VE-PTP-VN/VE-cadherin-VC fusion pair. (A) 
Qualitative analysis highlights the overlapping pixels in white, showing that 
both the yellow BiFC and the red plasma membrane stain signals are co-
localised at the plasma membrane. The co-localisation analysis has been 
performed using ImageJ software. An overlap image has been created by 
selecting VE-PTP-VN and VE-cadherin-VC confocal images from yellow 
BiFC and red plasma stain channels and selecting Image, Color, Merge 
Channels. The co-localisation analysis on the overlay image has been 
carried out by selecting Analyse, Colocalisation Thresholds. (B) Histogram 
showing fluorescence signals from BiFC (yellow) and red plasma membrane 
stain (red) across a single cell. Co-localisation analysis has been performed 
using ImageJ by drawing a line across the same cell in both BiFC and red 
plasma membrane stain channels and selecting Plot Profile from the drop-
down menu Analyse. Fluorescence intensity values for both channels were 




































4.5 Comparison of the BiFC signal from the VE-PTP and VE-cadherin 
pairing with VE-PTP and control constructs 
In order to establish whether the BiFC signal resulting from co-expression of 
VE-PTP-VN and VE-cadherin-VC reflects a specific interaction between the 
proteins or is due to non-specific assembly of YFP fragments, the BiFC 
signal with VE-PTP-VN and control constructs, and pairs of control 
constructs, was compared with VE-PTP-VN/VE-cadherin-VC.  
Figures 35-37 show that all the negative interaction pairs resulted in a BiFC 
fluorescence signal. However, qualitative assessment of the images 
suggested that VE-PTP-VN with either negative control construct resulted in 
a lower fluorescence signal compared with the positive VE-PTP-VN and VE-
cadherin VC fusion pair (Figures 33, 35, 36 and 37). However, SPN-VN and 
Myr-VC exhibited a higher intensity of fluorescence signal and, in addition, 
more cells appeared to exhibit a BiFC signal (Figure 37) compared with VE-
PTP-VN/SPN-VC (Figure 35) and VE-PTP-VN/Myr-VC (Figure 36) fusion 
pairs. However, all the negative control pairing appeared to exhibit reduced 
fluorescence intensity and the number of fluorescent cells compared with 
VE-PTP-VN and VE-cadherin-VC fusion pair (compare Figures 33, 35, 36 
and 37). The BiFC signal appeared to be predominantly at the plasma 
membrane, as was predicted with membrane proteins, with some 
fluorescence in ER and Golgi. This was also confirmed by co-localisation 
analysis of BiFC and red plasma membrane fluorescence signals across a 
single cell (Figure 34). However, co-localisation analysis showed that the 
BiFC signal in cells co-expressing VE-PTP-VN with SPN-VC was mainly 
localised in the cytoplasm with only some signal at the plasma membrane 
(Figure 38, A). Cells co-expressing VE-PTP-VN and Myr-VC exhibited BiFC 
signal that was localised in the cytoplasm as there was minimum 
fluorescence signal overlap from both BiFC and red plasma membrane stain 















Figure 35. BiFC analysis of VE-PTP with control construct SPN-VC. To validate the specificity of the VE-PTP-VN and VE-
cadherin-VC interaction, VE-PTP-VN was co-transfected with equal amount of negative control construct SPN-VC into HEK293T 
cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal images of VE-PTP-VN/SPN-










































Figure 36. BiFC analysis of VE-PTP-VN with control construct Myr-VC. To validate the specificity of the VE-PTP-VN and VE-
cadherin-VC interaction, VE-PTP-VN was co-transfected with an equal amount of negative control construct Myr-VC into HEK293T 
cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal images of VE-PTP-VN/Myr-
VC interactions in cell populations. (B) Confocal images of a single cell, showing the localisation of VE-PTP-VN/Myr-VC 
interactions.  






































Figure 37. BiFC analysis of control constructs SPN-VN and Myr-VC. To validate the specificity of the BiFC fusion contructs 
interactions, an equal amount of negative control constructs SPN-VN and Myr-VC was co-transfected into HEK293T cells and the 
resulting BiFC signal was analysed by confocal microscopy after 24 hours.  
 





















Figure 38. Co-localisation analysis of fluorescence signals from the 
BiFC and the red plasma mambrane stain channels. (A) Histogram 
showing fluorescence signals from BiFC (yellow) and red plasma membrane 
stain (red) across a single HEK293T cell co-transfected with VE-PTP-
VN/SPN-VC fusion pair. (B) Histogram showing fluorescence signals from 
BiFC (yellow) and red plasma membrane stain (red) across a single 























































Red plasma membrane stain BiFC
A                             VE-PTP-VN/SPN-VC 
B                             VE-PTP-VN/Myr-VC 
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4.6 Quantitative analysis of BiFC data 
In order to obtain a more robust interpretation of the data and establish 
whether the results of BiFC experiments with VE-PTP-VN/VE-cadherin-VC 
represent true protein-protein interactions or are driven by the self-assembly 
of the two non-fluorescent YFP fragments, images were processed with 
ImageJ software to quantitate fluorescence signals. Quantitative 
comparisons of the fluorescence signal obtained with the cognate pairing 
and control pairings were performed. Quantitative analysis of BiFC data has 
previously been performed in other studies of cytosolic proteins by 
calculating the ratio of BiFC fluorescent intensity relative to an expressed 
Cerulean control protein to normalise for protein expression levels (Kerppola, 
2006; Kodama and Hu, 2010). In this chapter the BiFC fluorescent intensity 
of individual cells was measured and the CellMask Deep Red membrane 
stain was used as a reference (as described in the methods section 2.5.9). 
This quantitative analysis approach was validated in Chapter 3 using the well 
characterised transcription factors bJun and bFos, which are known to form a 
hetero-dimer (positive control), and bJun and the deletion mutant bFos∆ZIP, 
which lacks the interaction domain (negative control).  
Briefly, the quantitation procedure consisted of the following steps: confocal 
images from cells displaying a BiFC signal which had been stained with the 
CellMask Deep Red membrane stain were acquired in a random distribution. 
By tracing the outline of each cell in the ImageJ using a polygon selection the 
yellow fluorescent intensity derived from bimolecular fluorescence 
complementation and the red fluorescent signal derived from the plasma 
membrane stain of the selected region, including border, were calculated. 
The background signal in an area with no cells was subtracted from all 
values. The results for each cell (i.e. ImageJ region of interest) were 
expressed as a yellow/red ratio (i.e. vYFP fluorescence intensity/deep red 
fluorescence intensity). On average about 700 cells from at least three 
random fields from three or more independent experiments for each fusion 
protein combination were analysed. The ratio in individual cells was then 
plotted in a histogram (Figure 39). 
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The distribution of yellow/red ratios represents a measure of the efficiency of 
bimolecular fluorescence complementation. The efficiency of BiFC is defined 
by the fluorescent intensity that results upon bimolecular complex formation 
when specific fusion proteins are expressed in cells. The YFP fragments, 
however, have the tendency to associate with each other independently 
when expressed at sufficiently high concentrations but the BiFC efficiency is 
significantly reduced (Kerrpola, 2008).  As can be seen from the histogram in 
Figure 39 (A) co-expressing VE-PTP-VN and VE-cadherin-VC results in 
higher cell numbers that have higher ratio value range compared with cells 
co-expressing VE-PTP-VN and Myr-VC (Figure 39, B) or SPN-VN and Myr-
VC (Figure 39, D) negative interacting pairs. When comparing the distribution 
of ratios from VE-PTP-VN/VE-cadherin-VC and VE-PTP-VN/SPN-VC there 
appears to be little or no difference (Figure 39, C), suggesting that there is a 
possible interaction between VE-PTP and SPN.  However, just based on 
these results it is difficult to conclude with confidence that VE-PTP-VN/VE-
cadherin-VC co-expression results in higher yellow/red ratio values.  
In addition, to measure the BiFC specificity the signal-to-noise (S/N) ratio 
was calculated as described in previous studies by Kerppola (2010). A higher 
S/N ratio value reflects a more specific interaction. The S/N ratio was 
calculated by dividing the median value of BiFC efficiency for the positive 
interaction (i.e. VE-PTP-VN/VE-cadherin-VC) by the median value of BiFC 
efficiency for the negative interaction (VE-PTP-VN/Myr-VC) (Kerppola, 2010; 
Kodama and Hu, 2010). Since there are no previous documented reports 
about VE-PTP and SPN interactions and since the yellow/red ratio 
distributions for VE-PTP-VN/VE-cadherin-VC and VE-PTP-VN/SPN-VC 
appeared to be similar, the S/N ratio was also calculated for VE-PTP-
VN/SPN-VC and compared with VE-PTP-VN/VE-cadherin-VC. As can be 
seen from Figure 36, the VE-PTP-VN/VE-cadherin-VC pairing resulted in S/N 
value of 6.5 that was 2-fold higher when compared with VE-PTP-VN in 
combination with SPN-VC, indicating a specific interaction of VE-PTP-VN 
and VE-cadherin-VC.  
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An alternative approach to quantitate the data using only average 
fluorescence intensity was also used. The average yellow fluorescence 
intensity from at least three random fields and three or more independent 
experiments was calculated and used for statistical analysis (Figure 41). 
Quantitative analysis of the VE-PTP-VN and VE-cadherin-VC pairing 
resulted in an average BiFC fluorescent intensity that was significantly higher 
than control pairings even though control proteins appeared to be expressed 
at significantly higher levels than VE-PTP-VC (Figure 31). As can be seen 
from Figure 41 there was a significant decrease in fluorescence signal in all 
the control pairings (p<0.001). The average fluorescence signal for the VE-
PTP-VN/VE-cadherin-VC fusion pair was 8141.4 that was 2-fold higher than 
4099.6 for the VE-PTP-VN/SPN-VC fusion pair, 3-fold higher than 2688.5 for 




























































































Figure 39. Validation of VE-PTP-VN/VE-cadherin-VC interaction 
specificity. The fluorescence intensity from BiFC (yellow) and the 
fluorescent signal from the plasma membrane stain (red) were measured in 
individual cells. The distribution of ratios between the fluorescence intensity 
and red fluorescent signal in individual cells was plotted in a histogram. The 
yellow/red ratio has been plotted for each pair of constructs as indicated 










Figure 40. S/N ratio of BiFC assay in HEK293T cells. S/N for VE-PTP-
VN/VE-cadherin-VC was calculated by dividing its median values of BiFC 
efficiency by the median value of BiFC efficiency for VE-PTP-VN/Myr-VC. 
S/N for VE-PTP-VN/SPN-VC was calculated by dividing its median values of 
BiFC efficiency by the median values of BiFC efficiency for VE-PTP/Myr-VC. 
The median values from at least three images taken from three independent 



































Figure 41. Quantitation of BiFC fluorescence intensities in transiently 
transfected HEK293T cells. Pairs of constructs as indicated were 
transfected into HEK293T cells and the BiFC signal assessed. Average 
fluorescence intensity was determined using ImageJ software. The mean 
and standard errors from three images taken from three independent 
experiments were quantitated as described in the materials and methods. 
*p˂0.001 by the Kruskal-Wallis test was considered significant. Average 
fluorescence intensity from the positive interacting pair VE-PTP-VN/VE-
cadherin-VC was compared with average fluorescence intensity from 















































4.7 Analysis of the VE-PTP/VE-cadherin interface 
A VE-PTP deletion mutant, in which the 17th FNIII-like domain had been 
removed (VEPTP∆17FN), was used in the BiFC assay to examine the region 
that participates in interactions between VE-PTP and VE-cadherin. 
Qualitative analysis of BiFC images show that HEK293T cells co-expressing 
VE-PTP∆17FN-VN and VE-cadherin-VC still exhibit a strong fluorescence 
signal at the plasma membrane (Figure 42) which is comparable to the signal 
resulting from VE-PTP-VN/VE-cadherin-VC interaction (Figure 33). However, 
cells co-expressing VE-PTP∆17FN-VN and SPN-VC exhibited stronger 
fluorescence signal than the cells co-expressing VE-PTP-VN and SPN-VN 
(Figures 43 and 35), whereas cells co-expressing VE-PTP∆17FN-VN and the 
negative control Myr-VC showed no or weak fluorescence signal (Figure 43) 
which was comparable with the signal obtained from VE-PTP-VN and Myr-
VC co-expression (Figure 36). 
The average BiFC fluorescence intensity resulting from co-expression of VE-
PTP∆17FN-VN with VE-cadherin-VC was not significantly different from that 
obtained with VE-PTP-VN in combination with VE-cadherin-VC (Figure 43, 
A). A similar fold increase in fluorescent intensity relative to control pairings 
was observed with either VE-PTP-VN or VE-PTP∆17FN-VN. Although the 
BiFC qualitative analysis of VE-PTP∆17FN-VN/SPN-VC showed strong 
fluorescence signal, the quantitative results showed a significant reduction of 
signal by 1.9-fold compared with VE-PTP∆17FN-VN/VE-cadherin-VC 
(p˂0.001; Figure 43, A). There was a significant decrease in fluorescence 
signal by 6.4-fold when cells were co-expressing VE-PTP∆17FN-VN and 
Myr-VC compared with VE-PTP∆17FN-VN and VE-cadherin (p˂0.001; 
Figure 43, A). These results are comparable to the ones obtained with VE-
PTP-VN and VE-cadherin-VC.  
Figure 43 (B) shows that the VE-PTP-VN/VE-cadherin-VC pairing resulted in 
S/N value of 6.5 that was 1.4-fold higher than for VE-PTP∆17FN-VN/VE-
cadherin-VC and 2.4-fold higher than for VE-PTp∆17FN-VN/SPN-VC. S/N 
value for VE-PTP∆17FN-VN/VE-cadherin was 4.5, which was 1.6-fold higher 
than for VE-PTP∆17FN-VN/SPN-VC.  
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HEK293T cells co-expressing VE-PTP-VN and VE-cadherin-VC exhibit 
similar cell numbers falling into a greater ratio value range compared with 
VE-PTP∆17FN-VN and VE-cadherin-VC (Figure 46, A and B). Co-expression 
of VE-PTP∆17FN-VN and SPN-VC resulted in some reduction of cell 
numbers that fall into a greater ratio value range (Figure 46, C). However, 
co-expression of VE-PTP∆17FN-VN and Myr-VC resulted in the majority of 
cells falling into the lower ratio value range (Figure 46, D). Therefore it can 
be concluded that both VE-PTP-VN/VE-cadherin-VC and VE-PTP∆17FN-
VN/VE-cadherin-VC complementation complexes result in stronger 



























Figure 42. BiFC analysis of the deletion mutant VE-PTP∆17FN-VN and VE-cadherin-VC. To investigate VE-PTP-VN/VE-
cadherin-VC interaction interface the 17th FNIII-like domain of VE-PTP-VN was removed and the VE-PTP∆17FN-VN mutant was 
co-transfected with equal amounts of either VE-cadherin-VC into HEK293T cells and the resulting BiFC signal was analysed by 
confocal microscopy after 24 hours. (A) Confocal images of VE-PTP∆17FN-VN/VE-cadherin-VC interactions in cell populations. (B) 
Zoom in of HEK293T cells, showing the localisation of VE-PTP∆17FN-VN/VE-cadherin-VC interactions.  





















































Figure 43. BiFC analysis of the deletion mutant VE-PTP∆17FN-VN and control constructs SPN-VC and Myr-VC. To 
investigate the specificity of the VE-PTP∆17FN-VN and VE-cadherin-VC interaction, VE-PTP∆17FN-VN was co-transfected with 
equal amounts of either negative control construct SPN-VC or Myr-VC into HEK293T cells and the resulting BiFC signal was 
analysed by confocal microscopy after 24 hours. (A) Confocal images of VE-PTP∆17FN-VN/SPN-VC interactions. (B) Confocal 








































Figure 44. Co-localisation analysis of fluorescence signals from the 
BiFC and the red plasma membrane stain channels across a single cell. 























A            VE-PTP∆17FN-VN/VE-cadherin-VC           


















B                 VE-PTP∆17FN-VN/SPN-VC 

















C             VE-PTP∆17FN-VN/Myr-VC 




Figure 45. BiFC analysis of the VE-PTP/VE-cadherin interface. Pairs of constructs were transfected into HEK293T cells and the 
BiFC signal assessed. (A) Average fluorescence intensity was determined using ImageJ software. The mean and standard errors 
from three images taken from three independent experiments were quantitated as described in the materials and methods. 
*p˂0.001 by the Kruskal-Wallis test was considered significant. (B) S/N ratio of BiFC assay in HEK293T cells. S/N for VE-PTP-
VN/VE-cadherin-VC, VE-PTP∆17FN-VN/VE-cadherin-VC and VE-PTP∆17FN-VN/SPN-VC was calculated by dividing their median 




























































   
 
   
 
   
 




Figure 46. Validation of VE-PTP-VN/VE-cadherin-VC interaction 
specificity. BiFC (A) VE-PTP-VN/VE-cadherin-VC, (B) VE-PTP∆17FN-
VN/VE-cadherin, (C) VE-PTP∆17FN-VN/SPN-VC and (D) VE-PTP∆17FN-
VN/Myr-VC fusion pairs were co-expressed in HEK293T cells and 24 hours 
post-transfection were stained with CellMask Deep Red plasma membrane 
stain. The BiFC fluorescence intensity and the red fluorescent signal from the 
plasma membrane stain were measured in individual cells and yellow/red 
ratio values calculated. The distribution of ratios in individual cells was 




Vascular endothelial protein tyrosine phosphatase (VE-PTP) is recognised to 
be essential for the maintenance of the endothelial barrier between blood 
and tissue, maintenance and remodelling of blood vessels and control of 
blood vessel permeability and leukocyte extravasation during inflammation 
by potentially regulating the adhesive function of VE-cadherin in endothelial 
cells (Bäumer et al, 2006; Nottebaum et al, 2008). VE-PTP is the only RPTP 
reported to be expressed exclusively in endothelial cells and thus attracted 
attention as a potential regulator of VE-cadherin (Bäumer et al, 2006). Co-
immunoprecipitation studies by Nawroth et al (2002) showed that indeed VE-
PTP and VE-cadherin interact together and that this interaction occurs via 
their extracellular domains, independently of their cytoplasmic tails. The 
same group demonstrated using deletion mutants that the fifth cadherin 
domain of VE-cadherin and the 17th FNIII-like repeat of VE-PTP were 
sufficient to support their interaction. While there are many studies had been 
done on a whole protein (e.g. using knock-out mice) no studies to date had 
been done in live cells on a functional role of the extracellular domain of VE-
PTP in regulation of vascular permeability and angiogenesis. Here we used 
VE-PTP and VE-cadherin fusion constructs consisting of transmembrane 
and extracellular domains fused to the N- and C-terminal parts of a Venus 
yellow fluorescent protein (YFP) respectively to examine their interaction in 
live cells using the bimolecular fluorescence complementation (BiFC) assay. 
The qualitative BiFC analysis obtained on co-expression of VE-PTP and VE-
cadherin constructs containing the transmembrane and extracellular domains 
of these molecules showed a strong fluorescence signal that was localised at 
the plasma membrane with some fluorescence in endoplasmic reticulum and 
probably Golgi apparatus.  
To confirm that the yellow fluorescent signal originated as a result of VE-
PTP-VN and VE-cadherin-VC interaction and not from self-assembly of YFP 
fragments we employed several controls. Although it is recommended to 
negate a positive interaction by introducing a point mutation, it was not 
practical in this project since the exact interaction site of VE-PTP and VE-
cadherin is not known. One of the controls was Sialophorin (SPN) that is not 
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homologous to any proteins investigated in this project and has a completely 
different extracellular domain composition (Figure 15). It consists of a mucin-
like 235-residue extracellular region highly rich in serine, threonine and 
proline uniformly distributed throughout the ECD region. It is also highly 
glycosylated, containing one N-linked carbohydrate unit and approximately 
84 O-linked units (Shelley et al, 1989). The expression of SPN is restricted to 
haematopoietic cells, especially leukocytes (Fukuda and Tsuboi, 1999). The 
fact that the extracellular domains of SPN and VE-PTP are so different and 
that the two proteins are expressed in different cells made SPN a good 
candidate for a control. Furthermore, it has previously been used by Cardoba 
et al (2013) as a control. Fusing one of the YFP fragments to an unrelated 
protein that does not interact with the protein of interest should, in theory, 
reduce the background signal intensity. However, to eliminate any possible 
interactions between SPN and VE-PTP an unfused YFP fragment anchored 
to the plasma membrane via the membrane associated sequence from Lck 
(Myr-VC and Myr-VN) was generated as additional control. Since Myr-VC 
and Myr-VN entirely lack any transmembrane and extracellular domain 
sequences it was predicted that the fluorescent signal would be abolished 
when co-expressed with VE-PTP. Interestingly the co-expression of VE-PTP-
VN with either SPN-VC or Myr-VC negative controls also resulted in 
fluorescence signal. Although the signal appeared to be reduced and less 
intense, it was not possible to conclude that the fluorescence obtained with 
negative interaction pairs was due to non-specific interactions or self-
assembly of the two non-fluorescence YFP fragments.  Due to the nature of 
the BiFC method the two non-fluorescence YFP fragments are able to 
assemble spontaneously into a functional YFP, resulting in yellow 
fluorescence. This could be caused by an overexpression of proteins. Under 
normal physiological conditions membrane (integral) proteins are molecularly 
dispersed and their two-dimensional translational diffusion (i.e. movement of 
proteins perpendicular to the plane of the membrane) occurs freely (Singer 
and Nicolson, 1972). However, overexpression of proteins could result in 
somewhat tightly packed and ordered protein molecules with limiting spacing 
in the plane of the membrane, thereby restricting planar diffusion. Such 
clustering within the membrane could enhance spontaneous collisions of the 
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YFP fragments and increase the probability of irreversible bimolecular 
fluorescent complexes and the false-positive fluorescence signal.  
As reported by Horstman et al (2014) the vast majority of published BiFC 
studies report only qualitative results and show representative examples of 
detected interactions. Here we adapted three different quantitative analyses 
that were performed using ImageJ software and statistically validated data. 
First, the distribution of yellow/red ratio values has been determined for each 
interaction pair to validate the BiFC efficiency as was recommended by 
Kerppola (2008). Second, based on studies by Kodama and Hu (2010), the 
signal-to-noise ratio was calculated to validate the BiFC specificity. In 
addition, the average yellow fluorescence intensity for the positive interacting 
pair was compared with that of the negative interacting pair. The full detailed 
quantitative and statistical analyses are described in Chapter 2, section 
2.5.9. All three quantitative methods showed similar results, complementing 
each other. Co-expression of VE-PTP-VN and VE-cadherin resulted in more 
cells exhibiting higher yellow/red ratio values, higher S/N value and a 
significant increase in average yellow fluorescence signal compared with all 
the negating interacting pairings. The fact that the VE-cadherin-VC was 
expressed at lower level compared with negative controls SPN-VC and Myr-
VC (Figure 31, C and E) suggests that the BiFC signal from VE-PTP-VN and 
VE-cadherin-VC was not an artefact of overexpression. Therefore, the 
quantitative assessment of the fluorescence images obtained on co-
expression of VE-PTP and VE-cadherin constructs indicated a BiFC signal 
that is due to a specific interaction, rather than self-assembly of the YFP 
fragments and background fluorescence. However, the disadvantage of the 
quantitative analyses used in this project is the measurement of whole cell 
fluorescence as they do not allow for the evaluation of intracellular versus 
membrane-localised BiFC signal. Nonetheless, the quantitation methods 
were based on previous BiFC studies by various research groups who used 
flow cytometry or ImageJ for fluorescence signal quantification (Kodama and 
Hu, 2010; Sung and Huh, 2010; Wong and O’Bryan, 2011). 
The cells were stained with plasma membrane stain to facilitate comparison 
between images and identification of distinct BiFC signal localisation 
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patterns. Co-transfection of VE-PTP-VN and VE-cadherin-VC revealed a 
strong YFP fluorescence that predominantly localised at the plasma 
membrane as indicated by co-localisation with red plasma membrane stain 
(overlay image in Figure 33 and Figure 34). The BiFC signal from VE-PTP-
VN/SPN-VC, VE-PTP-VN/Myr-VC and SPN-VN/Myr-VC fusion pairs also 
predominantly localised to the plasma membrane (overlay images in Figures 
35-37). However, some BiFC signal was also detected in the cytoplasm, 
most likely in the endoplasmic reticulum (ER) and Golgi, for all the tested 
fusion pairs. Although in this study no organelle markers have been used to 
confirm the BiFC signal co-localisation at the ER and Golgi, the confocal 
images closely resemble the images from other studies that used BiFC 
assay to investigate membrane protein-protein interactions. For example, 
similar results have been demonstrated with receptor tyrosine kinases 
Anks1a/EphA2 in a BiFC study by Lee et al (2016). Most of the BiFC signal 
was detected in the plasma membrane but some was also present in the ER, 
which was confirmed by the ER marker. Interestingly a deletion of Anks1a 
phosphotyrosine binding domain (PTB) resulted in an increased intracellular 
staining for the Anks1a/EphA2 complex, suggesting that perhaps some 
domains are not required for the interaction but instead are needed for the 
correct cellular localisation (Lee et al, 2016). A study by Chen et al (2006) 
used the BiFC method to investigate the interaction between membrane 
proteins Notch2 and amyloid precursor protein (APP) in live cells. They 
showed that C-terminally truncated Notch2 and APP formed heterodimers 
that localised to the plasma membrane, ER and Golgi. The co-localisation of 
BiFC signal at the ER and Golgi was shown using ER CFP and Golgi-DsRed 
markers.  
There are various reasons why the BiFC signal is present in the ER. Some 
domains may not be required for the interaction but might be needed for cell 
surface localisation (as in the case of Anks1a/EphA2 mentioned above) and 
without the required domain proteins would not pass quality control and thus 
would be retained in ER. The BiFC complex formation may also take place in 
the ER where the newly synthesised proteins are modified before being 
translocated to the plasma membrane, thereby bringing the YFP fragments 
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into close proximity and resulting in a fluorescence signal. Perhaps some 
fusion proteins are not fully processed to the cell surface and are trapped in 
the ER, most likely not passing the protein quality control. In addition, some 
proteins may be retained inactive in the ER and eventually degraded if they 
are not required. This was shown for the receptor tyrosine kinases (RTKs). If 
there is a need for high levels of RTKs on the plasma membrane, a cell 
may direct the ER membranes to rapidly release mature RTKs and send 
them towards the cell surface (Lee et al, 2016). As shown by Nottebaum et 
al (2008) a large fraction of the VE-PTP – containing vesicles co-localised 
with endocytic vesicles. Comparison with a marker for the endocytic 
recycling compartment (Rab11) also showed a partial overlap with the 
staining for VE-PTP. Their results suggested that VE-PTP resides in an 
endocytic compartment until it is translocated to endothelial cell contacts 
once the endothelial cell junctions have matured (Nottebaum et al, 2008). 
Further validation would be critical to ensure that these localisation patterns 
of the bimolecular fluorescent complex are physiologically relevant. To 
confirm the subcellular localisation of the BiFC signal numerous 
fluorescent organelle markers, such as KDEL-mCerulean3 fusion protein 
for ER or VE-cadherin-mApple fusion protein for tight junctions (both from 
Addgene), can be used. As the subcellular localisation of a protein is often 
tied to its function the comparison of localisation of full-length VE-PTP 
fused to the full-length YFP with that of the interaction between VE-PTP 
and VE-cadherin fused to the N- and C-terminal fragments of YFP would 
provide some information about the molecular mechanism of VE-PTP/VE-
cadherin interaction.  
Some proteins have been shown to internalise from the cell surface into 
internal membrane compartments upon interaction with other proteins, 
which is an important part of trafficking events in the regulation of cell 
signalling, receptor turnover and magnitude, duration and nature of 
signalling events. For example, the internalisation of the endothelial growth 
factor receptor (EGFR) system upon ligand stimulation has been 
previously demonstrated (Wilde et al, 1999). Epidermal growth factor 
(EGF) binds to its receptor epidermal growth factor receptor (EGFR), 
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inducing EGFR dimerisation and intracellular autophosphorylation of key 
tyrosine residues in the activation loop of its catalytic domain 
(Schlessinger, 2002). This, in turn, initiates clathrin-mediated 
internalisation of the EGFR, which is mediated by a RING-finger E3 
ubiquitin ligase (Cbl) that binds to activated EGFR, targeting it for 
endocytosis (Le Roy and Wrana, 2005). Endosomally localised EGFR was 
shown to associate with many down-stream effectors, such as SH2-
domain-containing transforming protein (SHC), leading to the recruitment 
and activation of signal transduction proteins Ras, Raf, MEK1 and MAPK 
cascade (Le Roy and Wrana, 2005). EGFR can clearly signal from 
endosomes, therefore showing that trafficking can control both the nature 
and magnitude of molecular signalling events. Furthermore VE-cadherin 
itself was shown to internalise upon interaction with β-arrestin. Interleukin 
8 (IL9) stimulation was also shown to induce VE-cadherin internalisation in 
response to PAK-mediated phosphorylation of S665 on VE-cadherin 
(Kuppers et al, 2014). Therefore, it would be interesting to investigate 
whether the interaction between VE-PTP and VE-cadherin results in their 
internalisation.      
Protein-protein interactions are essential for cellular functions and the 
majority of proteins in the cell exist as part of multicomponent assemblies. 
Experimentally determining and characterising VE-PTP and VE-cadherin 
binding interface would give a better understanding of the mechanism of their 
specific recognition and function. It was hypothesised, based on Nawroth et 
al study (2002), that deleting the 17th FNIII-like domain from the ectodomain 
of VE-PTP would be sufficient to abolish the VE-PTP interaction with VE-
cadherin. However, in this study this was not observed and a similar BiFC 
signal was obtained with both constructs even though VE-PTP∆17FN-VN 
was expressed at lower levels than VE-PTP-VN (Figure 31, A and B). One 
possibility that may account for this is that both constructs were expressed at 
levels in excess of VE-cadherin (Figure 31, A and B). Another routine 
possibility that may explain the difference between these findings and the 
Nawroth et al (2002) study is that there are species-dependent differences in 
the interaction of VE-PTP and VE-cadherin, as in this study the human cDNA 
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was used and the earlier study used mouse. This seems unlikely given that 
the human and mouse full-length amino acid sequences are 83% identical 
and the mechanism of interaction is likely to be conserved. To generate the 
VE-PTP mutant construct (VEPTP∆17FN-VN) the 17th FNIII-like domain of 
VE-PTP was deleted, which brought the 16th FNIII-like domain proximal to 
the transmembrane domain, whereas the earlier study used either a 
construct in which FNIII domains 1-16 had been deleted or a construct which 
expressed only the 17th domain. If the FNIII-like domain proximal to the 
membrane is the only region involved in interaction between the two 
molecules, the results obtained in this study would suggest that despite the 
low sequence identity between the 16th and 17th domains, the 16th domain 
when artificially moved proximal to the membrane, is able in effect to replace 
the 17th domain in this position, and as a consequence the interaction is 
maintained. Alternatively other regions, in addition to the 17th FNIII domain, 
such as the transmembrane domain, of VE-PTP may be involved in the 
interaction with VE-cadherin. This may not have been apparent in the co-
immunoprecipitation studies with detergent solubilised proteins but is of 
significance when performing BiFC protein-protein interaction studies in live 
cells as carried out in this study. There are many examples of membrane 
proteins forming homo- and hetero-oligomers via transmembrane domains 
(Strous and Gent, 2002), including receptor-type phosphatases (Tertoolen et 
al, 2001). A study by Tertoolen et al (2001) demonstrated that RPTPα 
dimerises in live cells and that the transmembrane domain alone was 
sufficient to drive this dimerisation. Interestingly a study by Coon et al (2015) 
showed through immunoprecipitation that VE-cadherin directly interacts with 
vascular endothelial growth factor receptors (VEGFR) 2 and 3 and that these 
interactions are mediated by their transmembrane domains (TMDs). Their 
results suggest that VE-cadherin contributes to the flow signalling pathway 
downstream of SFKs (Src family kinases) and upstream of PI3K 
(phosphoinositide 3-kinase) through its role as an adaptor for VEGFRs 
(Coon et al, 2015). This raises a question of whether VE-PTP also 
contributes to VEGFR signalling since it directly binds to VE-cadherin. Co-
precipitation studies by Fachinger et al (1999) revealed that VE-PTP does 
not associate directly with VEGFR2. Nonetheless, these proteins could be 
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part of a functional complex involved in maintenance of blood vessels and 
endothelial cell barrier.     
Future experiments are required to establish regions of VE-PTP that are 
involved in interaction with VE-cadherin. The molecular binding interface of 
VE-PTP and VE-cadherin interaction could be studied by generation of 
various deletion mutants of VE-PTP to analyse the interaction of VE-cadherin 
with each of the mutants. Whether the ECD drives the interaction or is 
required only for the initial contact and whether the TMD maintains the 
interaction is yet to be determined and further studies are necessary to 
define the relative roles of the extracellular domain and transmembrane 
domain in interaction of VE-PTP with VE-cadherin as well as to elucidate the 
precise mechanism of this interaction. 
Dysregulation of PTPs is often associated with many inherited or acquired 
human diseases and in many cases the immune system is affected (Mustelin 
et al, 2005). Both PTKs and PTPs have been shown to have activating and 
inhibitory effects and the actions of both types of enzyme are required for a 
physiological immune response. The role of the adherens junctions and its 
key proteins VE-PTP and VE-cadherin and the associated signalling events 
in leukocyte transendothelial migration are not entirely defined. During 
inflammation leukocytes have to pass from the blood to the surrounding 
tissue through the endothelial barrier of the blood vessel wall (leukocyte 
extravasation or diapedesis). It is a multistep process in which many proteins 
are involved. VE-cadherin has been shown previously to act as a barrier in 
leukocyte diapedesis but it was also shown that it moves away from 
endothelial cell contacts to allow leukocyte extravasation. Adhesion 
molecules ICAM1 (intercellular adhesion molecule 1) and PECAM-1 (platelet 
endothelial cell adhesion molecule 1) then form a ring-like structure 
surrounding leukocytes at cell contact sites (Nottebaum et al, 2008). 
Tyrosine phosphorylation was also shown to play a key role in this process 
and tyrosine phosphorylation of adherens junction proteins has been 
correlated with the loosening of cadherin-mediated adhesion in various cell 
types (McLachlan and Yap, 2007). In contrast VE-PTP was shown to be 
directly implicated in the regulation of endothelial barrier, enhancing the 
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adhesive function of VE-cadherin and reducing leukocyte extravasation 
(Nottebaum et al, 2008). Broermann et al (2011) demonstrated that 
leukocyte docking and stimulation of endothelial cells with VEGF influence 
the dissociation of VE-PTP from VE-cadherin in vivo, resulting in the opening 
of the endothelial cell contacts and in increased leukocyte extravasation. The 
results of previous studies indicate that the VE-PTP makes an attractive 
candidate as a novel therapeutic target for the treatment of pathological 
vascular permeability and inflammation. Therefore it is essential to elucidate 
its physiological function, its substrates, regulation and its importance in 
physiological processes.  
 
4.9 Conclusion 
The quantitative data show that the BiFC signal obtained from HEK293T 
cells co-expressing VE-PTP-VN/VE-cadherin-VC and VE-PTP∆17FN-
VN/VE-cadherin-VC was not due to non-specific YFP-fragments interactions 
in the plasma membrane since the negative control fusion pairs showed a 
significantly reduced BiFC signal even though they were expressed at much 
higher levels compared with positive interaction pairs. Therefore, based on 
these findings it can be concluded that VE-PTP and VE-cadherin have the 
potential to interact together via their extracellular domains. In addition, the 
17th FNIII-like domain of VE-PTP is not the only domain required for the 
interaction and the removal of this domain did not abolish the interaction with 
VE-cadherin. Further work is required to determine the molecular interface of 








Investigation of a potential interaction between DEP-1, SAP-1 and 
























Originally the sequences of receptor-type protein tyrosine phosphatases 
(RPTP) cytoplasmic domains were thought to be highly conserved and 
ectodomains more divergent between different subgroups. Further, the 
extracellular domains within each subgroup were thought to be homologous 
(for the PTPs classification refer to Figure 3) and, thus, it was suggested that 
members within a subgroup would share similar receptor functions. The four 
members of the R3 RPTP subgroup, namely VE-PTP, DEP-1, SAP-1 and 
GLEPP1 share structural homology of their extracellular domains, which are 
comprised solely of long chains of FNIII-like repeats (Tonks, 2006). However, 
the number of such repeats varies (Chapter 1, Figure 4). It was previously 
suggested that extracellular domains of R3 RPTPs could be involved in cis- 
and trans-interactions with extracellular domains of other receptors (e.g. 
RTKs) and ligands, although this has not been demonstrated in most cases 
(Jeon and Zinn, 2015). Most of the known substrates for the R3 RPTPs are 
receptor tyrosine kinases (RTKs) and Src family kinases but their interaction 
occurs via cytoplasmic (i.e. catalytic) domains (Jeon and Zinn, 2015). Thus 
the function of the extracellular domains of the R3 RPTPs is not fully 
understood. Co-immunoprecipitation studies by Nawroth et al (2002) showed 
that VE-PTP directly interacts with VE-cadherin via their extracellular 
domains (ECD). Their interaction via ECD in live cells was addressed in this 
project as described in Chapter 4 and it was found that VE-PTP and VE-
cadherin do have the potential to interact via their extracellular domains in 
live cells and that the 17th FNIII-like domain of VE-PTP is not the only domain 
required for this interaction. Here I aimed to investigate whether other R3 
RPTPs, in addition to VE-PTP, have the potential to interact with VE-
cadherin, which could provide insight into the specificity and/or molecular 
basis of interactions with VE-PTP.  
Although extracellular ligand binding has not been defined yet for all the 
members of R3 RPTP subgroup, some members were shown to interact with 
their ligands or co-receptors via their extracellular domains. DEP-1 was 
shown to interact with Syndecan-2. As was shown by Whiteford et al (2011) 
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DEP-1 and Syndecan-2 associate through their N-terminal extracellular parts 
and this interaction plays a key role in fibroblast adhesion to Syndecan-2. 
Affinity purification and mass spectrometry studies by Takahashi et al (2012) 
have revealed another putative ligand, a trimeric glycoprotein 
Thrombospondin-1 (TSP1), that binds with a high affinity and specificity to 
the extracellular domain of the DEP-1 in endothelial cells. Transfection 
experiments confirmed this association as the deletion of the DEP-1 
extracellular domain abolished the interaction with TSP1 (Takahashi et al, 
2012). The binding of the TSP1 appears to increase the catalytic activity of 
DEP-1 as the dephosphorylation of the DEP-1 substrates, EGFR and 
ERK1/2, was increased upon treatment of DEP-1 transfected cells with 
TSP1, which resulted in the inhibition of the endothelial cell proliferation. 
Interestingly, though, the TSP1 is synthesised by endothelial cells in 
response to injury or growth factors and thus it is likely that TSP1 acts as a 
ligand for DEP-1 in pathological conditions (Takahashi et al, 2012). The 
same experiments revealed that other members of R3 RPTPs did not 
interact with TSP1 despite having homologous extracellular domains 
(Takahashi et al, 2012). On the other hand, co-immunoprecipitation studies 
by Murata et al (2015) revealed that mouse SAP-1 associates with a 
transmembrane protein CEACAM20 (Carcinoembryonic Antigen-Related Cell 
Adhesion Molecule 20). What is more, the SAP-1 and CEACAM20 appeared 
to form a complex via their extracellular domains, resulting in 
dephosphorylation of the CEACAM20 and attenuating the CEACAM20-
induced IL-8 production and thus regulating intestinal immunity (Murata et al, 
2015). However, it is not known whether this is also the case with the human 
SAP-1. Co-immunoprecipitation studies by Kim et al (2010) showed that 
mouse GLEPP1 associates with extracellular cell-cell signalling molecules 
Wnt (Wnt-3a and Wnt1) but only when the ECD of GLEPP1 is present. The 
interaction of mouse GLEPP1 with Wnt via its extracellular domain resulted 
in inhibition of Wnt/β-catenin signalling (Kim et al, 2010). The activation of 
this signalling pathway has been linked to several human cancers (Cadigan, 
2008). Therefore, GLEPP1 has been suggested to act as a tumour 
suppressor by inhibiting Wnt/β-catenin signalling pathway through interaction 
with Wnt ligand. However, whether human GLEPP1 also associates with Wnt 
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or it interacts with any other ligands via its extracellular domain had not been 
tested to date.  
R3 RPTP members are comprised of repetitive fibronectin like III repeats in 
their extracellular domains, the physiological role of which has not been fully 
defined yet. Numerous studies indicate that the extracellular domain could be 
involved in interaction with substrates or ligands but the molecular basis of 
these interactions is not entirely understood. Since the members of this 
subfamily share similar extracellular structures, it has been proposed that 
they share similar physiological functions. This gives rise to some questions.  
Do all the R3 RPTP members have the potential to interact with the same 
ligands via their extracellular domains? What role does the extracellular 
domain of R3 RPTPs play in substrate specificity? Therefore, the purpose of 
this chapter was to investigate whether DEP-1, SAP-1 and GLEPP1 also 
have the potential to interact with VE-cadherin via their extracellular domains 
in living cells using bimolecular fluorescence complementation (BiFC) assay 
in transiently transfected HEK293T. The principle of the BiFC assay is 
described in Chapter 4.  
To determine the specificity and efficiency of BiFC complementation two 
negative controls were generated: sialophorin (SPN) and either C- or N-
terminal fragment of a Venus YFP anchored to the plasma membrane via the 
membrane association sequence from Lck (lymphocyte-specific protein 
tyrosine kinase), Myr-VC and Myr-VN respectively. The rationale for using 



















Figure 47. Schematic representation of BiFC fusion proteins. DEP-1, 
SAP-1 and GLEPP1 consist of multiple extracellular fibronectin III-like 
repeats (blue) and a transmembrane domain. The intracellular protein 
tyrosine phosphatase domain (PTP) was removed. The constructs DEP-1-
VN, SAP-1-VN and GLEPP1-VN have a modified N-terminal sequence of the 
Venus protein (a yellow fluorescent protein (YFP) variant. The constructs 
DEP-1-VC, SAP-1-VC and GLEPP1-VC have a modified C-terminal 
sequence of YFP. The YFP fragments are represented by a half cylinder 
inserted five residues after the transmembrane domain. Constructs 
containing N-terminal YFP had a myc-tag (pink) and constructs containing C-
terminal YFP had a HA-tag (both represented by a pink line) inserted after 



































5.2.1 Cloning fusion proteins 
The constructs used in this study DEP-1, SAP-1 and GLEPP1, shown 
diagrammatically in Figure 47, consist of residues 1-996 of DEP-1, 1-775 of 
SAP-1 and 1-843 of GLEPP1, with either the modified N- or C-terminal 
sequence of vYFP inserted five residues after the transmembrane domain 
and a flexible linker sequence, as used by Kodama & Hu (2010). This 
approach essentially replaced the intracellular region of these proteins with 
non-fluorescent fragments of vYFP enabling investigation of protein-protein 
interactions that involve only the extracellular and transmembrane domains. 
DEP-1, SAP-1 and GLEPP1 fusion constructs were generated as outlined in 
the schema in Chapter 2 (Figure 8). For the DEP-1-VN, SAP-1-VN and 
GLEPP1-VN synthetically generated signal peptides and myc tag 
(EQKLISEEDL) fragment (Genscript) were inserted into ApaI/XhoI restriction 
sites of pBiFC-VN155(I152L) vector. The presence of the correct DNA insert 
was determined by screening bacterial colonies by PCR using Bioline Red 
Taq with a combination of vector-specific and insert-specific primers (Table 
11). PCR products were analysed on agarose gel (Figure 48). The 
extracellular and transmembrane (ECD+TM) domains of DEP-1, SAP-1 and 
GLEPP1 constructs were amplified by PCR using Platinum Pfx polymerase. 
The PCR products corresponded to the predicted sizes of 2934 bp, 2295 bp 
and 2493 bp for DEP-1, SAP-1 and GLEPP1 respectively (Figure 49). The 
primers used for the generation of the transmembrane and extracellular 
domains are listed in Table 10 and the PCR conditions are provided in Table 
4 (Chapter 2). The resulting PCR product was purified, digested and 
subsequently inserted into XhoI restriction site of the pBiFC-VN155(I152L) 
vector, which contained signal peptide and myc tag. Colony PCR was used 
to confirm the correct orientation of the insert to ensure that a fusion protein 



















Figure 48. Colony PCR analysis. Synthetically generated signal peptides of 
DEP-1, GLEPP1 and SAP-1 with the myc tag were ligated into ApaI/XhoI 
restriction sites of the pBiFC-VN155(I152L) vector. Colony PCR was 
performed with vector-specific and insert-specific primers to screen for 
successful ligation. The DNA band of 712 bp corresponds to the predicted 
size of DEP-1 signal peptide and myc tag inserted into a pBiFC-
VN155(I152L) vector. The DNA band of 691 bp corresponds to the predicted 
size of GLEPP1 signal peptide and myc tag inserted into a pBiFC-
VN155(I152L) vector. The DNA band of 685 bp corresponds to the predicted 
size of SAP-1 signal peptide and myc tag inserted into a pBiFC-












































































































Figure 49. The generation of transmembrane and extracellular domains 
of DEP-1, SAP-1 and GLEPP1 by PCR. Electrophoresis on 0.8% (w/v) 
agarose gel showing DNA bands corresponding to expected ECD+TM sizes 
for each construct: A) 2934 bp band for ECD+TM of DEP-1, B) 2295 bp DNA 
band for ECD+TM of SAP-1 and C) 2493 bp for ECD+TM of GLEPP1. 























































Figure 50. Colony PCR to screen for successful ligation of ECD+TM domains of DEP-1, SAP-1 and GLEPP1 into pBiFC-
VN155 expression vectors. Following ligation and transformation colony PCR was performed with vector-specific and insert-
specific primers to screen for successful ligation. (A) The DNA band corresponds to the predicted size of 2453 bp of the DEP-1 
ECD+TM inserted into a pBiFC-VN155 expression vector. (B) The DNA band corresponds to the predicted size of 2164 bp of the 
SAP-1 ECD+TM inserted into a pBiFC-VN155 expression vector. (C) The DNA band corresponds to the predicted size of 3184 bp 













C-terminal YFP fragment fusions were generated in essentially the same 
way as N-terminal YFP fragment fusions. To generate DEP-1-VC, SAP-1-VC 
and GLEPP1-VC fusion constructs a synthetically generated signal peptide 
and HA tag fragment (Genscript) was inserted into ApaI/XhoI restriction sites 
of pBiFC-VC155 vector. The successful ligation was confirmed by PCR, 
using vector- and insert-specific primers, and analysed on agarose gel 
(Figure 51). The primers used for the Colony PCR are listed in Table 11 
(Chapter 2).  The previously generated ECD+TM domains of DEP-1, SAP-1 
and GLEPP1 were digested with XhoI restriction enzyme, purified and ligated 
into the pBiFC-VC155 vector, containing corresponding signal peptide and 
HA tag, to create a fusion protein fused to the C-terminal part of YFP. Colony 
PCR was used to confirm the correct orientation of the insert, using either 
vector specific primers or a combination of vector and insert specific primers 
(Figure 52). The primers used for the Colony PCR are listed in Table 11 
(Chapter 2).  
Although each construct was generated as an N- and C-terminal fusion, only 
the N-terminal fusion constructs were used in combination with either VE-
cadherin-VC, SPN-VC or Myr-VC in order to keep all the conditions and 
parameters of each experiment constant. The generation process of the VE-
cadherin-VC fusion construct as well as negative control fusion constructs 



















Figure 51. Colony PCR analysis to screen for successful ligation of signal peptide and HA tag of DEP-1, SAP-1 and 
GLEPP1 into pBiFC-VC155 expression vectors. Synthetically generated signal peptides of DEP-1, SAP-1 and GLEPP1 with the 
HA tag were ligated into ApaI/XhoI restriction sites of the pBiFC-VC155 vector. Colony PCR was performed with vector-specific and 
insert-specific primers to screen for successful ligation. A) The DNA band of 514 bp corresponds to the predicted size of DEP-1 
signal peptide and HA tag inserted into a pBiFC-VC155 vector. B) The DNA band of 490 bp corresponds to the predicted size of 
SAP-1 signal peptide and HA tag inserted into a pBiFC-VC155 vector. C) The DNA band of 475 bp corresponds to the predicted 


























      
Figure 52. Colony PCR to screen for successful ligation of ECD+TM of DEP-1, SAP-1 and GLEPP1 into pBiFC-VC155 
expression vectors. Following ligation and transformation colony PCR was performed with vector-specific and insert-specific 
primers to screen for successful ligation. (A) The DNA band corresponds to the predicted size of 2264 bp of the DEP-1 ECD+TM 
inserted into a pBiFC-VC155 expression vector. (B) The DNA band corresponds to the predicted size of 3125 bp of the SAP-1 
ECD+TM inserted into a pBiFC-VC155 expression vector. (C) The DNA band corresponds to the predicted size of 2968 bp of the 
GLEPP1 ECD+TM inserted into a pBiFC-VC155 expression vector.                                                                    










5.3 Western Blot analysis of BiFC fusion proteins in HEK293T cells 
Western blotting of lysates from transiently transfected HEK293T cells 
confirmed the expression of all the fusion proteins close to their predicted 
molecular weight (Figure 53). Western blotting with anti-myc antibody for the 
DEP-1-VN, SAP-1-VN and GLEPP1-VN, which have a myc-tag inserted 
following the signal peptide sequence, detected two bands for each protein. 
For DEP-1-VN the bands with a molecular weight of approximately 180 kDa 
and 240 kDa were detected (Figure 53, A). For SAP-1 the bands with a 
molecular weight of approximately 160 kDa and 220 kDa were detected 
(Figure 53, A). For GLEPP1 the bands with a molecular weight of 
approximately 160 kDa and 230 kDa were detected (Figure 53, A). The 
bands for GLEPP1 appeared lighter compared with other fusion proteins on 
the same blot (Figure 53, A). The Western blot was repeated for the GLEPP1 
fusion construct, producing the same result (Figure 53, C). The predicted 
molecular weights for DEP-1-VN, SAP-1 and GLEPP1 were 107 kDa, 84 kDa 
and 95 kDa respectively. The discrepancy in molecular weight is probably 
accounted for by extensive glycosylation. A study by de la Fuente et al 
(1998) confirmed that DEP-1 is highly glycosylated. Western blot analysis of 
DEP-1 before and after the treatment with N-linked deglycosylation enzyme 
N-glycosidase F detected the shift in molecular weight from 240 kDa to about 
160 kDa. The treatment with O-linked deglycosylation enzyme O-Glycanase 
also resulted in decreased molecular weight of about 200 kDa. These results 
showed that the molecular weight of DEP-1 was modified by extensive 
glycosylation (de la Fuente et al, 1998). It has been previously shown that 
SAP-1 and GLEPP1 have 24 and 15 potential N-linked glycosylation sites 
respectively (Matozaki et al, 1994; Thomas et al, 1993). Western blot 
analyses carried out by Matozaki et al (1994) detected a band for SAP-1 with 
molecular weight of 200 kDa instead of the predicted 120 kDa. Western blot 
analyses of GLEPP1 from a study by Thomas et al (1993) also detected a 
higher molecular weight band of 235 kDa compared with predicted 132 kDa. 
In both studies the differences were accounted for by extensive 
glycosylation.   
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The double bands for DEP-1, SAP-1 and GLEPP1 could possibly represent 
differentially glycosylated forms of these proteins. Interestingly the higher 
molecular weight bands (~220 kDa) of each protein appear to be less 
prominent and could be due to some non-specific antibody binding.   
Western blotting with anti-HA antibody for the DEP-1-VC, SAP-1-VC and 
GLEPP1-VC, which have a HA-tag inserted following the signal peptide 
sequence, detected bands with molecular weight of approximately 180, 160 
and 150 kDa respectively (Figure 53, B and D). Similar to anti-myc blots the 
molecular weights were much higher than predicted, probably due to post-
translational modification of these proteins. Both GLEPP1-VN and GLEPP1-
VC fusion proteins were expressed at lower levels compared with all other 
fusion proteins (Figure 53, A-D). The expression of control fusion proteins 
SPN-VN, SPN-VC, Myr-VN and Myr-VC was shown and discussed in 































Figure 53. Protein expression analysis by Western blot. Western blotting of cell lysates from transfected HEK293T cells with 
either anti-myc or anti-HA antibody confirmed the expression of the constructs at close to expected molecular weight. β-actin () 











































5.4 Investigation of DEP-1, SAP-1 and GLEPP1 interactions with VE-
cadherin in live cells using the BiFC technique  
To investigate whether DEP-1, SAP-1 and GLEPP1 could have the potential 
to interact with VE-cadherin via their extracellular domains in live cells, in a 
similar manner to VE-PTP, the BiFC DEP-1-VN, SAP-1-VN and GLEPP1-VN 
fusion proteins were generated as described above (section 5.2.1). Each 
fusion protein was co-expressed with VE-cadherin-VC in HEK293T cells and 
24 hours post-transfection stained prior to confocal visualisation with 
CellMaskTM Plasma Membrane Stain (as detailed in method section 2.5.6). 
All the transfection conditions and parameters of confocal analyses were 
kept constant for all the experiments.  
Co-expression of all three DEP-1-VN/VE-cadherin-VC, SAP-1-VN/VE-
cadherin-VC and GLEPP1-VN/VE-cadherin-VC fusion pairs resulted in the 
occurrence of BiFC fluorescence (Figures 54, 57 and 60). For each fusion 
pair the comparison of the sub-cellular localisation of the Venus YFP signal 
with that of the CellMask deep red plasma stain indicated that the 
fluorescence complementation signal was detected in the plasma membrane 
and intracellular structures, likely to be the endoplasmic reticulum or Golgi, of 
co-transfected cells (Figures 56, 59 and 62). 
In order to establish that the BiFC signal resulted from the interaction of 
DEP-1-VN/VE-cadherin-VC, SAP-1-VN/VE-cadherin-VC and GLEPP1-
VN/VE-cadherin-VC fusion pairs and was not due to the non-specific 
assembly of YFP fragments, the R3 RPTP fusion constructs were co-
expressed with each control construct. The co-expression of DEP-1-VN with 
either SPN-VC or Myr-VC both resulted in a BiFC fluorescence signal (Figure 
55, A and B).  However, the qualitative assessment of the images suggested 
that DEP-1-VN with a negative control construct SPN-VC appeared to exhibit 
a slightly reduced fluorescence signal and the number of fluorescent cells 
compared with the DEP-1-VN and VE-cadherin-VC fusion pair (Figures 54 
and 55 (A)). In addition, the fluorescence signal that resulted from the 
interaction of negative fusion pairs appeared to be localised more in the 
cytoplasm and not in the plasma membrane. The cells co-expressed with 
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DEP-1-VN and Myr-VC appeared to exhibit a greater reduction in 
fluorescence signal compared with DEP-1-VN/VE-cadherin-VC and with 
DEP-1-VN/SPN-VC fusion pairs (Figures 54 and 55). The qualitative 
analyses of confocal images show that, similar to DEP-1-VN, SAP-1-VN and 
GLEPP1-VN also formed fewer complexes when co-expressed with either 
negative control than they did with VE-cadherin-VC. The BiFC signal 
resulting from the SAP-1-VN/SPN-VC complex assembly appeared to be 
weaker than the BiFC signal resulting from the SAP-1-VN/VE-cadherin-VC 
combination (Figures 57 and 58 (A)). The SAP-1-VC/Myr-VC combination 
appeared to result in even greater reduction of fluorescence signal compared 
with SAP-1-VN/VE-cadherin-VC and with SAP-1-VN/SPN-VC combinations 
(Figures 57 and 58). The same results were observed with the GLEPP1-VN 
fusion protein. The BiFC fluorescence signal appeared to be reduced when 
GLEPP1-VN was co-expressed with SPN-VC compared with the BiFC signal 
resulting from GLEPP1-VN/VE-cadherin co-expression (Figures 60 and 61 
(A)). When GLEPP1-VN was co-expressed with Myr-VC the fluorescence 
signal appeared to be even more reduced compared with co-expression of 
either GLEPP1-VN/VE-cadherin-VC or GLEPP1-VN/SPN-VC fusion pairs 
(Figures 60 and 61 (B)). As with VE-PTP-VN and VE-cadherin co-expression 
(discussed in Chapter 4) the BiFC signal resulting from all the fusion pairs 
tested in this chapter was predominantly detected at the plasma membrane 
with some fluorescence in ER and Golgi (Figures 54, 55, 57, 58, 60 and 61). 
This was also confirmed by the co-localisation analysis of the fluorescence 
signals from BiFC and CellMask red plasma membrane stain (Figures 56, 59 
and 62). 
The qualitative results described in this chapter show that the BiFC signals 
for a given protein complex are difficult to interpret and a more robust 
quantitative analysis is required. Although the fluorescence signal with 
control fusion proteins appeared to be reduced it is difficult to conclude 
whether there is any significant difference in fluorescence intensity. In 
addition, the confocal images presented in Figures 54-61 are only the 
representatives and the number of cells exhibiting the BiFC signal and its 















Figure 54. BiFC analysis of interaction between DEP-1-VN and VE-cadherin-VC. To investigate the potential interaction 
between DEP-1-VN and VE-cadherin-VC equal amounts of expression vectors encoding DEP-1-VN and VE-cadherin-VC were co-
transfected into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of DEP-1-VN/VE-cadherin-VC interactions in cell populations. (B) Zoom in of HEK293T cells, showing the localisation of 
DEP-1-VN/VE-cadherin-VC interactions. 


















































Figure 55. BiFC analysis of DEP-1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the DEP-1-
VN and VE-cadherin-VC interaction, DEP-1-VN was co-transfected with equal amounts of negative control constructs SPN-VC and 
Myr-VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of DEP-1-VN/SPN-VC interactions in cell populations. (B) Confocal images of DEP-1-VN/Myr-VC interactions in cell 
populations.






























Figure 56. Co-localisation analysis of fluorescence signals across a 
single cell from the BiFC and the red plasma mambrane stain channels. 
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Figure 57. BiFC analysis of interaction between SAP-1-VN and VE-cadherin-VC. To investigate the potential interaction 
between SAP-1-VN and VE-cadherin-VC equal amounts of expression vectors encoding SAP-1-VN and VE-cadherin-VC were co-
transfected into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of SAP-1-VN/VE-cadherin-VC interactions in cell populations. (B) Zoom in of HEK293T cells, showing the localisation of 
SAP-1-VN/VE-cadherin-VC interactions. 
11.75 µm 11.75 µm 


















































Figure 58. BiFC analysis of SAP-1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the SAP-1-
VN and VE-cadherin-VC interaction, SAP-1-VN was co-transfected with equal amounts of negative control constructs SPN-VC and 
Myr-VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of SAP-1-VN/SPN-VC interactions in cell populations. (B) Confocal images of SAP-1-VN/Myr-VC interactions in cell 
populations.






























Figure 59. Co-localisation analysis of fluorescence signals across a 
single cell from the BiFC and the red plasma mambrane stain channels. 
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Figure 60. BiFC analysis of interaction between GLEPP1-VN and VE-cadherin-VC. To investigate the potential interaction 
between GLEPP1-VN and VE-cadherin-VC equal amounts of expression vectors encoding GLEPP1-VN and VE-cadherin-VC were 
co-transfected into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of GLEPP1-VN/VE-cadherin-VC interactions in cell populations. (B) Zoom in of HEK293T cells, showing the localisation of 
GLEPP1-VN/VE-cadherin-VC interactions. 

















































Figure 61. BiFC analysis of GLEPP1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the 
GLEPP1-VN and VE-cadherin-VC interaction, GLEPP1-VN was co-transfected with equal amounts of negative control constructs 
SPN-VC and Myr-VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) 
Confocal images of GLEPP1-VN/SPN-VC interactions in cell populations. (B) Confocal images of GLEPP1-VN/Myr-VC interactions 
in cell populations. 
 






























Figure 62. Co-localisation analysis of fluorescence signals across a 
single cell from the BiFC and the red plasma mambrane stain channels. 
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5.5 Quantitative analysis of BiFC data 
In order to complement the qualitative BiFC interactions between DEP-1-VN, 
SAP-1-VN, GLEPP1-VN and VE-cadherin-VC described above quantitative 
analyses were carried out using ImageJ software. The principle and 
validation of the quantitative analyses with putative interacting partners bJun 
and bFos were described in Chapter 3. The same quantitative analyses were 
applied to VE-PTP-VN and VE-cadherin-VC interaction study and described 
in Chapter 4.  
To analyse the BiFC specificity of interactions between DEP-1-VN/VE-
cadherin-VC, SAP-1-VN/VE-cadherin-VC and GLEPP1-VN/VE-cadherin-VC 
fusion pairs the distribution of yellow/red ratios in individual cells was plotted 
in a histogram. If the fluorescence signal resulting from DEP-1-VN/VE-
cadherin-VC, SAP-1-VN/VE-cadherin-VC or GLEPP1-VN/VE-cadherin-VC 
fusion pair interaction is due to specific protein-protein interactions and not 
due to the YFP fragments, then more cells would have higher yellow/red ratio 
value range compared with negative controls.  
The histogram in Figure 63 (A) shows that co-expression of DEP-1-VN and 
VE-cadherin-VC resulted in a slightly higher number of cells that fall into 
higher ratio value range between 0 and 4 compared with cells co-expressing 
DEP-1-VN and SPN-VC (Figure 63, B) or DEP-1-VN and Myr-VC (Figure 63, 
C) negative interacting pairs. When comparing the distribution of ratios from 
DEP-1-VN/VE-cadherin-VC and DEP-1-VN/SPN-VC there appear to be 
fewer cells that exhibit higher yellow/red ratio values. The yellow/red ratio 
values for DEP-1-VN/SPN-VC mainly fall into a range between 0 and 2 
(Figure 63, B). However, there appears to be little difference in yellow/red 
ratio distribution between DEP-1-VN/SPN-VC and DEP-1-VN/Myr-VC (Figure 
63, B and C). Similar results were observed with SAP-1-VN and GLEPP1-VN 
fusion proteins. When SAP-1-VN was co-transfected with VE-cadherin-VC 
there was a higher number of cells that have higher ratio value range 
(between 0 and 4) than for cells co-expressing SAP-1-VN and SPN-VC or 
SAP-1-VN and Myr-VC control pairs (Figure 64, A-C). When cells were co-
transfected with SAP-1-VN and SPN-VC there appeared to be fewer cells 
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exhibiting higher ratio values, falling into the distribution range between 0 
and 3, than for cells co-expressing SAP-1-VN and VE-cadherin-VC fusion 
pair (Figure 64, A and B). When cells were co-transfected with SAP-1-VN 
and Myr-VC there appeared to be even greater reduction in cell numbers 
with higher ratio values compared with SAP-1-VN/VE-cadherin-VC or SAP-1-
VN/SPN-VC fusion pairs. The majority of cells expressing SAP-1-VN and 
Myr-VC exhibited yellow/red ratio values that ranged from 0 to 1 (Figure 64, 
C). Co-expression of GLEPP1-VN and VE-cadherin-VC resulted in a higher 
number of cells with higher ratio value range (between 0 and 3) compared 
with co-expression of GLEPP1-VN/SPN-VC that resulted in cells with lower 
ratio value range (between 0 and 2) or GLEPP1-VN/Myr-VC that resulted in 
cells with even lower ratio value range (between 0 and 1) (Figure 65, A-C). 
However, it is difficult to conclude whether the reduction in cells exhibiting 
higher ratio value range is significant.  
To supplement the above results and to measure the BiFC specificity the 
signal-to-noise (S/N) ratio was calculated as described in Chapters 3 and 4. 
A higher S/N ratio value reflects a more specific interaction. S/N ratio was 
calculated for each interacting fusion pair, including control fusion pairs to 
establish how much fluorescence signal was formed due to YFP fragments 
self-assembly. S/N ratio for DEP-1-VN/VE-cadherin-VC, DEP-1-VN/SPN-VC 
and DEP-1-VN/Myr-VC fusion pairs was calculated by dividing their median 
values by the median value of DEP-1-VN/Myr-VC. The same was done for all 
the other fusion pairs, dividing their median values by the median value of 
the corresponding Myr-VC-containing fusion pair.   
There are no previous documented reports about R3 RPTPs and SPN 
interactions. Interestingly, while the S/N ratio value for SAP-1-VN/VE-
cadherin-VC was 3.5-fold higher than for SAP-1-VN/SPN-VC and for 
GLEPP1-VN/VE-cadherin-VC was 2-fold higher than for GLEPP1-VN/SPN-
VC, the S/N for DEP-1-VN/VE-cadherin-VC was slightly lower than for DEP-
1-VN/SPN-VC control pair (Figure 66). This could suggest possible 
interaction between DEP-1-VN and SPN-VC. S/N value for DEP-1-VN/VE-
cadherin-VC was 3-fold higher than for DEP-1-VN/Myr-VC. S/N value for 
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SAP-1-VN/VE-cadherin-VC was 6-fold higher compared with SAP-1-VN/Myr-
VC. The S/N value for GLEPP1-VN/VE-cadherin-VC was 4.5-fold higher than 
for GLEPP1-VN/Myr-VC (Figure 66). These results suggest that interactions 
between DEP-1-VN and VE-cadherin-VC, SAP-1-VN and VE-cadherin-VC 
and GLEPP1-VN and VE-cadherin-VC are specific and not due to self-



















Figure 63. Validation of DEP-1-VN/VE-cadherin-VC interaction specificity. The fluorescence intensity from BiFC (yellow) and 
the fluorescent signal from the plasma membrane stain (red) were measured in individual cells. The distribution of ratios between 
the fluorescence intensity and red fluorescence signal in individual cells was plotted in a histogram. The yellow/red ratio has been 















Figure 64. Validation of SAP-1-VN/VE-cadherin-VC interaction specificity. The fluorescence intensity from BiFC (yellow) and 
the fluorescent signal from the plasma membrane stain (red) were measured in individual cells. The distribution of ratios between 
the fluorescence intensity and red fluorescence signal in individual cells was plotted in a histogram. The yellow/red ratio has been 
















Figure 65. Validation of GLEPP1-VN/VE-cadherin-VC interaction specificity. The fluorescence intensity from BiFC (yellow) and 
the fluorescent signal from the plasma membrane stain (red) were measured in individual cells. The distribution of ratios between 
the fluorescence intensity and red fluorescence signal in individual cells was plotted in a histogram. The yellow/red ratio has been 
plotted for each pair of constructs: (A) GLEPP1-VN/VE-Cadherin-VC, (B) GLEPP1-VN/SPN-VC and (C) GLEPP1-VN/Myr-VC.




Figure 66. S/N ratio of BiFC assay in HEK293T cells. S/N for each interacting fusion pair was calculated by dividing its median 
value by the median value from the corresponding Myr-VC-containing fusion pair. The median value for each fusion pair was 















An alternative approach to quantitate the data using only average 
fluorescence intensity was also used. The average yellow fluorescence 
intensity from at least three random fields and three or more independent 
experiments was calculated for each fusion pair and used for statistical 
analysis (Figure 67). Quantitative analysis of the DEP-1-VN and VE-
cadherin-VC fusion pair showed that there was no significant difference in an 
average BiFC fluorescence intensity compared with DEP-1-VN and SPN-VC. 
However, when DEP-1-VN was co-expressed with Myr-VC there was a 
significant reduction in average fluorescence intensity by 2.5-fold and 2.2-
fold than for DEP-1-VN/VE-cadherin-VC and DEP-1-VN/SPN-VC fusion pairs 
respectively (Figure 67). When SAP-1-VN was co-expressed with VE-
cadherin-VC the average fluorescence intensity was significantly higher than 
for all the control pairings (p<0.001). As can be seen from Figure 67 there 
was a significant decrease in fluorescence signal by about 2- and 3-fold in 
SAP-1-VN/SPN-VC and SAP-1-VN/Myr-VC respectively compared with SAP-
1-VN/VE-cadherin-VC fusion pair. Similarly, when HEK293T cells were co-
transfected with GLEPP1-VN and VE-cadherin-VC the resulting fluorescence 
intensity was significantly higher than for all the control pairings (p<0.001). 
There was a significant decrease in fluorescence signal by 1.7- and 3.5-fold 
in GLEPP1-VN/SPN-VC and GLEPP1-VN/Myr-VC respectively than for 
GLEPP1-VN/VE-cadherin-VC fusion pair (Figure 67). The results of this 
quantitative approach correspond to results from distribution of yellow/red 





















Figure 67. Quantitation of BiFC fluorescence intensities in transiently transfected HEK293T cells. Pairs of constructs as 
indicated were transfected into HEK293T cells using equal amounts of each expression vector and the BiFC signal assessed. 
Average fluorescence intensity was determined using ImageJ software. The mean and standard error from at least three 



































Protein tyrosine phosphatases of the R3 subgroup (R3 RPTPs) share similar 
structure and it has been suggested that they may share similar physiological 
functions. The single intracellular catalytic domain of these proteins has 
received much attention and it has been shown that the members of this 
subgroup have developmental and physiological functions in several tissues 
including the vascular and nervous systems (Sakuraba et al, 2013). 
However, the function of the extracellular domains of R3 RPTPs that is 
composed of fibronectin III-like (FNIII) repeats is less well defined. Although 
the extracellular domains of these proteins are structurally similar, the 
number of FNIII-like repeats varies and some previous studies have reported 
little homology. Comparison of the amino acid sequence of each FNIII-like 
repeat in ECD performed by Matozaki et al (1994) revealed that SAP-1 and 
VE-PTP share only 24% similarity, which, in contrast to other studies, 
suggested that they may have different functions. Despite such low similarity, 
R3 RPTP extracellular domains may have similar functions. Interestingly 
immunofluorescence staining experiments on frozen sections from human 
and mouse performed by Takahashi et al (1999) showed that DEP-1 was 
expressed on luminal membranes of capillary and arterial endothelium of 
mature human and mouse kidney, where it accumulates at points of inter-
endothelial contact. Furthermore double-labelling studies demonstrated that 
DEP-1 expression overlaps with localisation of VE-cadherin (Takahashi et al, 
1999).  These observations raise some speculation that perhaps DEP-1 has 
similar physiological functions to VE-PTP in vascular development and in 
endothelial cell-cell interactions through association with VE-cadherin. 
 In this chapter DEP-1-VN and VE-cadherin-VC fusion constructs consisting 
of transmembrane and extracellular domains fused to the N- and C-terminal 
parts of a Venus yellow fluorescent protein (YFP) respectively were used to 
examine their potential interaction in live cells using the bimolecular 
fluorescence complementation (BiFC) assay. In addition SAP-1-VN and 
GLEPP1-VN fusion constructs fused to the N-terminal part of YFP were also 
used to investigate whether all the members of R3 RPTP subgroup have the 
potential to interact with VE-cadherin. The qualitative BiFC analysis obtained 
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on co-expression of DEP-1-VN/VE-cadherin-VC, SAP-1-VN/VE-cadherin-VC 
or GLEPP1-VN/VE-cadherin-VC fusion pairs showed a strong fluorescence 
signal for each interacting pair that was localised at the plasma membrane 
with some fluorescence in endoplasmic reticulum and probably Golgi 
apparatus. These results correlate with the results obtained with VE-PTP-
VN/VE-cadherin-VC interacting pair discussed in Chapter 4. To confirm the 
specificity of the BiFC fluorescence signal negative controls described in 
Chapter 4 were used with each R3 RPTP fusion. However, the co-
expression of DEP-1-VN, SAP-1-VN or GLEPP1-VN with either SPN-VC or 
Myr-VC negative controls also resulted in fluorescence signal. Although the 
signal appeared to be reduced and less intense using qualitative analysis it 
was not possible to conclude that the fluorescence obtained with negative 
interaction pairs was due to non-specific interactions or self-assembly of the 
non-fluorescent YFP fragments that could be caused by an overexpression 
of proteins.  
In this chapter three different quantitative analyses were performed using 
ImageJ software and statistically validated data as described in previous 
Chapters 2-4. Each quantitative analysis validates the BiFC efficiency and 
specificity, complementing each other to produce more robust data. The 
quantitative analyses demonstrated that co-expression of each member of 
R3 RPTP subgroup with either VE-cadherin or negative control construct 
resulted in a similar trend of BiFC complex formation. Co-expression of  
either SAP-1-VN/VE-cadherin-VC or GLEPP1-VN/VE-cadherin-VC fusion 
pair resulted in more cells exhibiting higher yellow/red ratio values, higher 
S/N value and a significant increase in average yellow fluorescence signal 
compared with all the negative interacting pairings. Considering that the 
GLEPP1-VN was expressed at lower level than for negative controls SPN-
VC and Myr-VC and that DEP-1-VN and SAP-1-VN were expressed at lower 
level than for SPN-VC (Figures 31 and 53) suggests that the BiFC signal 
from either SAP-1-VN/VE-cadherin-VC or GLEPP1-VN/VE-cadherin-VC was 
not an artefact of overexpression. These results suggest that the interactions 
between SAP-1-VN and VE-cadherin-VC and between GLEPP1-VN and VE-
cadherin-VC are bona fide protein-protein interactions rather than non-
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specific assembly of the YFP fragments. Interestingly the fluorescence 
intensity obtained with the DEP-1-VN and VE-cadherin-VC pairing, although 
significantly different from DEP-1 with the Myr-VC control, was not 
significantly different from DEP-1-VN and the SPN-VC control (Figure 67) as 
discussed further below. In addition, the S/N value for DEP-1-VN/SPN-VC 
was higher than for DEP-1-VN/VE-cadherin-VC (Figure 66). These 
quantitative assessments of the fluorescence images obtained for each 
interacting pair indicated a BiFC signal that is due to a specific interaction, 
rather than self-assembly of the YFP fragments and background 
fluorescence.  
In this chapter analysis of the potential of other R3 RPTPs (DEP-1, SAP-1 
and GLEPP1) to interact with VE-cadherin revealed that the series of 8-9 
extracellular FNIII-like domains from any of the R3-PTPs has the potential to 
mediate a direct interaction with VE-cadherin. This is of particular interest 
with regard to DEP-1 since it is expressed in endothelial cells together with 
VE-cadherin. It has been shown previously that DEP-1 localisation at inter-
endothelial cell contacts overlaps with VE-cadherin, where it interacts with 
other endothelial cell tight junction proteins and, thus, it has been suggested 
to play a role in regulation of endothelial cell permeability (Takahashi et al, 
1999; Sallee and Burridge, 2009; Spring et al, 2012). It has been previously 
shown that the cytoplasmic domain of VE-cadherin forms complexes with cell 
adhesion catenin proteins, such as plakoglobin (also known as gamma-
catenin), p120-catenin and β-catenin (Lampugnani et al, 1995). A schematic 
representation of VE-cadherin/catenin complex is shown in Figure 68. This 
complex serves to strengthen adhesion forces and allows dynamic contacts 
(Azzi et al, 2013). Interestingly DEP-1 was also shown to associate with and 
dephosphorylate plakoglobin, p120-catenin and β-catenin through its 
cytoplasmic domain (Holsinger et al, 2002). But whether DEP-1 interacts 
directly with VE-cadherin in the same manner as VE-PTP has not been 
defined previously. Even if DEP-1 and VE-cadherin do not interact via their 
extracellular domains, the cumulative previous results suggest that these two 
proteins function as part of one complex. Close localisation of DEP-1 and 
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VE-cadherin was possibly enough for BiFC complementation to occur, 
















Figure 68. VE-cadherin adhesive complex. Schematic representation of 
VE-cadherin/catenin complex formation. This figure was adopted and 
modified from Azzi et al (2013). The cytoplasmic domain of VE-cadherin 
interacts with p120-catenin (p120) and β-catenin (β-cat.). Actin cytoskeleton 
is anchored to VE-cadherin via α-catenin (α-cat.) or plakoglobin. VE-cadherin 
was also shown to interact with VEGF-R2 (vascular endothelial growth factor 














The observation that co-expression of DEP-1-VN with the SPN-VC control 
was not significantly different from the DEP-1-VN/VE-cadherin-VC 
combination but gave significantly higher levels of fluorescence than DEP-1-
VN with the Myr-VC control could be interpreted as a bona fide interaction 
between DEP-1 and SPN. Both DEP-1 and SPN proteins are expressed in 
leukocytes. However, I am not aware of any previous reports documenting 
this interaction. Nonetheless, both DEP-1 and SPN have been shown to 
share similar physiological functions in regulation of immune responses and 
especially in regulation of T cell receptor (TCR) signalling. DEP-1, together 
with another RPTP glycoprotein CD45, was suggested to regulate TCR 
signalling by passive segregation from engaged TCR (kinetic-segregation 
model). It has been proposed that DEP-1, due to its large extracellular 
domain, is excluded from the vicinity of the engaged TCR, allowing 
TCR/MHC (major histocompatibility complex) interaction and the consequent 
phosphorylation of TCR ITAMs (immunoreceptor tyrosine-based activation 
motifs) and other substrates to take place that result in TCR signalling 
pathway activation (Cordoba et al, 2013). Fluorescent imaging revealed that 
truncation of DEP-1 and CD45 extracellular domains enhanced co-
localisation with TCR and, as was confirmed by immunoblot analysis, 
enabled phosphatases to dephosphorylate membrane-proximal molecules 
(such as LAT) in the TCR triggering pathway (Corboda et al, 2013). 
Therefore, these results suggest that the large extracellular domain of DEP-1 
prevents its tyrosine phosphatase domain from inhibiting TCR signalling. 
Interestingly SPN was also shown to be highly expressed in T cells and to 
interact with the T cell receptor to initiate signalling events (Clark and Baum, 
2012). Furthermore it has been suggested that the glycosylation of SPN 
plays a key role in this interaction. SPN has about 80 O-linked, as well as 
some N-linked, glycans dispersed over the entire extracellular domain. Some 
studies demonstrated that the glycosylation of SPN’s extracellular domain is 
regulated by T cells and that this differential glycosylation of SPN regulates 
interactions with the extracellular environment that, in turn, regulate T cell 
receptor signalling (Clark and Baum, 2012). As the results of this Chapter 
and of some previous observations suggest, there is a possibility that DEP-1 
and SPN interact together via their extracellular domains. However, further 
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experiments are required to confirm their interaction and to investigate its 
molecular basis. In addition it would be interesting to examine what role the 
glycosylation plays in interaction between DEP-1 and SPN, as well as 
between R3 RPTPs and VE-cadherin. Additional experiments could be 
performed by enzymatically removing N- and O-linked glycans, using 
PNGase and O-Glycosidase.          
On the other hand the physiological importance of either SAP-1 or GLEPP1 
interaction with VE-cadherin is not clear.  I am not aware of any reports of 
SAP-1 and GLEPP1 expression in endothelial cells and, since VE-cadherin 
expression is restricted to this cell type, the observed interaction is unlikely to 
be of physiological relevance. Nonetheless, the results provide insight into 
the molecular basis of the interaction suggesting that the interaction of VE-
PTP and VE-cadherin, or other R3 RPTPs with VE-cadherin, can be 
mediated by several different FNIII domains and, potentially, their 
transmembrane domains. This finding is consistent with studies in Chapter 4 
of the deletion mutant suggesting that the FNIII domains could be 
interchangeable. Controversially, as mentioned above, the interaction could 
occur through the extensive glycosylation of these proteins in the same 
manner as SPN interacts with proteins involved in T cell receptor regulation. 
Since the overall sequence identity of R3 RPTPs is very low the investigation 
of glycosylation involvement in protein-protein interactions would be of 
particular interest in future experiments. Additionally, further experiments are 
required to investigate mechanisms involved in regulation of R3 RPTPs’ 







The results of this Chapter suggest that all members of R3 RPTP subgroup 
have the potential to interact with VE-cadherin via their extracellular domains 
in live cells. Although the physiological importance of these interactions is not 
yet defined, the observations of this Chapter demonstrate the importance of 
the extracellular domain of R3 RPTPs in regulation of their function. Perhaps 
substrate specificity is due not to structural similarity but to restricted 
expression and localisation of these proteins or could be determined by the 
extensive glycosylation of their extracellular domains. Conceivably a protein 
could combine selectivity for specific ligands with the flexibility and possibility 
for interaction with other ligands that would have different binding affinity and 
signalling outcomes. Further experiments would be required to confirm the 





























Dimerisation has been proposed as one of the regulatory mechanisms of 
receptor protein tyrosine phosphatases (RPTPs) but its regulatory role is still 
controversial. This proposed regulatory mechanism was based on many 
studies showing that receptor protein tyrosine kinases (RPTKs) transduce 
signals by ligand-initiated extracellular domain dimerisation to promote in 
trans cytoplasmic domain tyrosine phosphorylation and subsequent 
assembly of multicomponent signalling complexes. It appeared that ligand-
induced receptor dimerisation brought kinase molecules into close proximity 
so that they could phosphorylate one another, leading to stimulation of the 
kinase activity (Lemmon and Schlessinger, 1998). In contrast to RPTKs, the 
function of RPTPs was shown to be inhibited by dimerisation. For example, 
receptor protein tyrosine phosphatase alpha (RPTPα) was shown to exist on 
the cell surface as monomers and dimers in equilibrium (Jiang et al, 1999). 
RPTPα was shown to form spontaneous dimers and that the dimerisation 
was mediated by the N-terminal D1 (active) catalytic domain and 
transmembrane region (Jiang et al, 1999). In addition, immunoblotting 
analysis revealed that the dimerised form of RPTPα was not able to 
dephosphorylate its biological substrate c-Src, suggesting that RPTPα is 
negatively regulated by dimerisation (Jiang et al, 1999).  
Several studies have explored the potential of R3 subgroup PTPs to homo-
dimerise or form homophilic interactions. However, from the available data it 
is difficult to develop a unifying scheme. Some members of R3 RPTPs, such 
as GLEPP1 and SAP-1, do show potential dimerisation but the mechanism 
of this dimerisation is not well defined. A study by Hower et al (2009) using a 
chimeric approach showed that GLEPP1 can form dimers in live cells and 
that this dimerisation results in a strong decrease of its intrinsic PTPase 
activity, as was confirmed using a biological substrate for GLEPP1,  
tropomyosin receptor kinase C (TrkC; a receptor for neurotrophin (NT)-3). In 
a similar way to RPTPα, the transmembrane and intracellular domains of 
GLEPP1 were sufficient for the observed dimerisation (Hower et al, 2009). 
Another member of R3 RPTP subgroup SAP-1 was also shown to form 
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stable homodimers, but in contrast to GLEPP1 the dimerisation of SAP-1 
was mediated by its extracellular domain, independently of cytoplasmic and 
transmembrane regions. The dimerisation was suggested to be formed 
through at least one cysteine (but possibly more, since it has 13 cysteines in 
its extracellular domain) that forms disulfide bridges between two SAP-1 
proteins (Walchli et al, 2005). Moreover, the same study by Walchli et al 
(2005) also showed that SAP-1 efficiently activates its biological substrate c-
Src, but only when SAP-1 is in monomeric form, therefore suggesting that 
dimerisation results in reduced catalytic activity of this enzyme (Walchli et al, 
2005). The same study by Walchli et al (2005) found no evidence for 
dimerisation of other R3 RPTP members. Immunoprecipitation and Western 
blot analyses by Takahashi et al (2006) revealed that DEP-1 can also form 
dimers as a result of ligand stimulation. It has been demonstrated that 
bivalent, but not monovalent, antibody (Ab1) was accompanied by an 
increase in CD148-associated PTP activity resulting in significant inhibition of 
cell proliferation. Therefore, in contrast to previous observations for GLEPP1 
and SAP-1, DEP-1 catalytic activity seems to increase upon ligand-induced 
extracellular domain dimerisation. But further work is needed to elucidate the 
mechanism of antibody-mediated dimerisation of DEP-1 (Sorby et al, 2001; 
Takahashi et al, 2006). VE-PTP did not show any dimerisation under similar 
experimental conditions and thus it remains unclear how the function of this 
protein is regulated (Walchli et al, 2005).  
All the above studies were carried out using immunoprecipitation assays. 
The mechanisms regulating R3 RPTPs’ activity are still not fully defined and 
further experiments are required to investigate whether the previously used 
experimental procedures fully mimic natural regulation of these proteins. It 
still remains unclear whether the dimerisation does occur for all R3 RPTPs 
and whether it could be induced by an extracellular ligand binding. Based on 
studies described above it is becoming apparent that the extracellular 
domain and/or transmembrane of these phosphatases plays an important 
role in the regulation (either through dimerisation or by any other means) of 
their catalytic activities. Thus, further experiments are required to establish 
the role of R3 RPTP extracellular domains in dimerisation. Therefore, the aim 
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of this Chapter is to examine whether R3 RPTP members can form dimers 
via their extracellular and/or transmembrane domains in live cells using BiFC 








6.2.1 Fusion proteins 
VE-PTP, DEP-1, SAP-1 and GLEPP1 fusion constructs were generated as 
outlined in the schema in Chapter 2 (Figure 8). Each construct for each 
protein was generated as N- and C-terminal YFP fragment fusion as 
described in result sections of Chapters 4 and 5. The generation process of 
the negative control fusion constructs SPN-VC and Myr-VC is shown in 
Chapter 4. Throughout all BiFC experiments the same negative controls 
fused to the C-terminal part of the YFP were used in order to keep all the 
conditions constant as the position of the fused YFP fragment can affect the 
interaction of proteins and thus make data interpretation difficult. R3 RPTP 
fusion constructs are schematically shown in Figure 47 (Chapter 5). 
 
6.3 Western blot analysis of BiFC fusion proteins in HEK293T cells 
Expression of the constructs used in this chapter has been previously 
assessed in Chapters 4 and 5 (refer to Figures 31 and 53). Western blotting 
of lysates from transiently transfected HEK293T cells confirmed the 
expression of all the fusion proteins above their predicted molecular weight, 
indicating the presence of extensive glycosylation in their extracellular 
domains. VE-PTP-VN, DEP-1-VN, SAP-1-VN, GLEPP1-VN, SPN-VN 
appeared to be expressed at higher levels compared with their 
corresponding –VC fusions, (Figures 31 and 53). Both GLEPP1-VN and 
GLEPP1-VC fusion proteins appeared to be expressed at lower levels 
compared with all other fusion proteins (Figure 53, A-D). Western blotting 
was performed at least three times for each fusion construct and the results 






6.4 Investigation of homodimerisation of R3 RPTPs in live cells using 
BiFC technique 
To investigate the role of the extracellular domain in dimerisation each 
construct consisting of extracellular and transmembrane domains was 
generated as N- and C-terminal YFP fragment fusions (as described in 
Chapters 4 and 5). Although the dimerisation of R3 RPTPs has been studied 
before, no previous studies have been done in live cells to investigate the 
molecular basis of dimer formation. In addition, no studies had been carried 
out on the specific role of R3 RPTP extracellular domain in dimerisation. 
Each N-terminal YFP fragment fusion protein was co-expressed with the 
corresponding C-terminal YFP fragment fusion protein (e.g. DEP-1-VN and 
DEP-1-VC) in HEK293T cells and 24 hours post-transfection stained prior to 
confocal visualisation with the CellMaskTM Plasma Membrane Stain (as 
detailed in method section 2.5.6). In addition, to establish the specificity of 
BiFC signal, each N-terminal R3 RPTP fusion construct was co-expressed 
with each control C-terminal fusion construct (SPN-VC and Myr-VC). All the 
transfection conditions and parameters of confocal analyses were kept 
constant for all the experiments.  
Co-expression of VE-PTP-VN and VE-PTP-VC resulted in a strong 
fluorescence signal (Figure 69). Co-expression of VE-PTP-VN with either 
SPN-VC or Myr-VC also resulted in a fluorescence signal, but the intensity of 
the signal and the number of cells exhibiting the signal appeared to be 
reduced (Figure 70, A and B). The same pattern was also observed with 
other members of R3 RPTPs. Co-expression of DEP-1-VN/DEP-1-VC, SAP-
1-VN/SAP-1-VC or GLEPP1-VN/GLEPP1-VC resulted in an abundant 
fluorescence signal and the signal appeared to be reduced when either DEP-
1-VN, SAP-1-VN or GLEPP1-VN was co-expressed with either SPN-VC or 
Myr-VC (Figures 71, 72, 73, 74, 75 and 76). Comparison of the sub-cellular 
localisation of the yellow fluorescence signal with that of the red fluorescence 
signal from plasma membrane stain indicated that the fluorescence 
complementation signal was detected in the plasma membrane and some 
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intracellular structures, likely to be the endoplasmic reticulum and Golgi, of 

















Figure 69. BiFC analysis of VE-PTP dimerisation. To investigate whether VE-PTP forms dimers in live cells, equal amounts of 
VE-PTP-VN and VE-PTP-VC fusions were used to co-transfect HEK293T cells and the resulting BiFC signal was analysed by 
confocal microscopy after 24 hours. (A) Confocal images of VE-PTP-VN/VE-PTP-VC interactions in cell populations. (B) Zoom in of 
HEK293T cells, showing the localisation of VE-PTP-VN/VE-PTP-VC interactions. 
 










































Figure 70. BiFC analysis of VE-PTP-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the VE-
PTP-VN and VE-PTP-VC interaction, VE-PTP-VN was co-transfected with equal amounts of negative control constructs SPN-VC 
and Myr-VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal 
images of VE-PTP-VN/SPN-VC interactions in cell populations. (B) Confocal images of VE-PTP-VN/Myr-VC interactions in cell 
populations. 
 








































Figure 71. BiFC analysis of DEP-1 dimerisation. To investigate whether DEP-1 forms dimers in live cells, equal amounts of DEP-
1-VN and DEP-1-VC fusions were used to co-transfect HEK293T cells and the resulting BiFC signal was analysed by confocal 
microscopy after 24 hours. (A) Confocal images of DEP-1-VN/DEP-1-VC interactions in cell populations. (B) Zoom in of HEK293T 
cells, showing the localisation of DEP-1-VN/DEP-1-VC interactions. 










































Figure 72. BiFC analysis of DEP-1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the DEP-1-
VN and DEP-1-VC interaction, DEP-1-VN was co-transfected with equal amounts of negative control constructs SPN-VC and Myr-
VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal images of 
DEP-1-VN/SPN-VC interactions in cell populations. (B) Confocal images of DEP-1-VN/Myr-VC interactions in cell populations. 
 







































Figure 73. BiFC analysis of SAP-1 dimerisation. To investigate whether SAP-1 forms dimers in live cells, equal amounts of SAP-
1-VN and SAP-1-VC fusions were used to co-transfect HEK293T cells and the resulting BiFC signal was analysed by confocal 
microscopy after 24 hours. (A) Confocal images of SAP-1-VN/SAP-1-VC interactions in cell populations. (B) Zoom in of HEK293T 








































Figure 74. BiFC analysis of SAP-1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the SAP-1-
VN and SAP-1-VC interaction, SAP-1-VN was co-transfected with equal amounts of negative control constructs SPN-VC and Myr-
VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) Confocal images of 










































Figure 75. BiFC analysis of GLEPP1 dimerisation. To investigate whether GLEPP1 forms dimers in live cells, equal amounts of 
GLEPP1-VN and GLEPP1-VC fusions were used to co-transfect HEK293T cells and the resulting BiFC signal was analysed by 
confocal microscopy after 24 hours. (A) Confocal images of GLEPP1-VN/GLEPP1-VC interactions in cell populations. (B) Zoom in 
of HEK293T cells, showing the localisation of GLEPP1-VN/GLEPP1-VC interactions. 











































Figure 76. BiFC analysis of GLEPP1-VN with control constructs SPN-VC and Myr-VC. To validate the specificity of the 
GLEPP1-VN and GLEPP1-VC interaction, GLEPP1-VN was co-transfected with equal amounts of negative control constructs SPN-
VC and Myr-VC into HEK293T cells and the resulting BiFC signal was analysed by confocal microscopy after 24 hours. (A) 
Confocal images of GLEPP1-VN/SPN-VC interactions in cell populations. (B) Confocal images of GLEPP1-VN/Myr-VC interactions 
in cell populations. 





























6.5 Quantitative analysis of R3 RPTP homodimerisation BiFC data 
In order to complement the qualitative BiFC dimerisation results for each R3 
RPTP fusion described above quantitative analysis was carried out using 
ImageJ software, as described in Chapters 2 and 3.  
To analyse the BiFC specificity of R3 RPTP homodimerisation the 
distribution of yellow/red ratios in individual cells for each fusion pair was 
plotted in a histogram. In contrast to the qualitative analysis, co-expression of 
VE-PTP-VN and VE-PTP-VC resulted in fewer cell numbers exhibiting higher 
ratio values compared with cells co-expressing VE-PTP-VN and SPN-VC 
negative interacting pairs (Figure 77, A and B). There was very little 
difference in yellow/red ratio distribution between VE-PTP-VN/VE-PTP-VC 
and VE-PTP-VN/Myr-VC fusion pairs (Figure 77, A and C). Similarly, when 
comparing DEP-1-VN/DEP-1-VC and DEP-1-VN/SPN-VC interaction pairs 
there appears to be little difference in yellow/red ratio distribution between 
them (Figure 78, A and B). Co-expression of DEP-1-VN and Myr-VC resulted 
in more cells with lower ratio values than for DEP-1-VN/DEP-1-VC and DEP-
1-VN/SPN-VC fusion pairs (Figure 78). Also, co-expression of SAP-1-
VN/SAP-1-VC and SAP-1-VN/SPN-VC pairings gave rise to comparable 
results (Figure 79, A and B). Cells co-expressing SAP-1-VN and Myr-VC 
exhibited more cells with lower ratio values than for SAP-1-VN/SAP-1-VC 
and SAP-1-VN/SPN-VC fusion pairs (Figure 79). However, when GLEPP1-
VN was co-expressed with GLEPP1-VC there were higher cell numbers with 
higher ratio value range in the region between 1 and 3 compared with cells 
co-expressing GLEPP1-VN and SPN-VC or GLEPP1-VN and Myr-VC control 
pairs (Figure 80). Cells co-expressing GLEPP1-VN and Myr-VC appeared to 
exhibit greater cell numbers with lower ratio values than for GLEPP1-
VN/GLEPP1-VC or GLEPP1-VN/SPN-VC fusion pairs (Figure 80). However, 
it is difficult to conclude whether the reduction in cells exhibiting higher ratio 













Figure 77. Validation of VE-PTP dimerisation. The fluorescence intensity from BiFC (yellow) and the fluorescent signal from the 
plasma membrane stain (red) were measured in individual cells. The distribution of ratios between the fluorescence intensity and 
red fluorescence signal in individual cells from at least three independent experiments was plotted in a histogram. The yellow/red 

















Figure 78. Validation of DEP-1 dimerisation. The fluorescence intensity from BiFC (yellow) and the fluorescent signal from the 
plasma membrane stain (red) were measured in individual cells. The distribution of ratios between the fluorescence intensity and 
red fluorescence signal in individual cells from at least three independent experiments was plotted in a histogram. The yellow/red 
ratio has been plotted for each pair of constructs: (A) DEP-1-VN/DEP-1-VC, (B) DEP-1-VN/SPN-VC and (C) DEP-1-VN/Myr-VC.  
 













Figure 79. Validation of SAP-1 dimerisation. The fluorescence intensity from BiFC (yellow) and the fluorescent signal from the 
plasma membrane stain (red) were measured in individual cells. The distribution of ratios between the fluorescence intensity and 
red fluorescence signal in individual cells from at least three independent experiments was plotted in a histogram. The yellow/red 
ratio has been plotted for each pair of constructs: (A) SAP-1-VN/SAP-1-VC, (B) SAP-1-VN/SPN-VC and (C) SAP-1-VN/Myr-VC.  
 












Figure 80. Validation of GLEPP1 dimerisation. The fluorescence intensity from BiFC (yellow) and the fluorescent signal from the 
plasma membrane stain (red) were measured in individual cells. The distribution of ratios between the fluorescence intensity and 
red fluorescence signal in individual cells from at least three independent experiments was plotted in a histogram. The yellow/red 
ratio has been plotted for each pair of constructs: (A) GLEPP1-VN/GLEPP1-VC, (B) GLEPP1-VN/SPN-VC and (C) GLEPP1-
VN/Myr-VC.  
 
A B C GLEPP1-VN/GLEPP1-VC GLEPP1-VN/SPN-VC GLEPP1-VN/Myr-VC 
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The BiFC specificity was also determined by measuring signal-to-noise (S/N) 
ratio as described in Chapters 3 and 4 by dividing the median value of the 
positive interacting pair by that of the negative interacting pair. Therefore, for 
the Myr-VC-containing interacting pair the S/N ratio value was always 1, 
representing the background fluorescence. A higher S/N ratio value reflects a 
more specific interaction. The S/N ratio value was calculated for each 
interacting fusion pair, including control fusion pairs, to establish how much 
fluorescence signal was formed due to YFP fragments self-assembly. In 
addition, the average fluorescence intensities were compared in all 
interacting pairs as described in Chapters 3 and 4.  
The S/N ratio value for VE-PTP-VN/VE-PTP-VC was 2.4 (Figure 81). 
Unexpectedly, although the S/N ratio value decreased to 1.5 in VE-PTP-
VN/SPN-VC control pair, there was no significant difference in average 
fluorescence intensity between both fusion pairs (Figures 81 and 82). The 
S/N for VE-PTP-VN/Myr-VC control pair was 2.4 x lower than for VE-PTP-
VN/VE-PTP-VC fusion pair (Figure 81). The average fluorescence intensity 
for VE-PTP-VN/Myr-VC was significantly reduced compared with VE-PTP-
VN/VE-PTP-VC and VE-PTP-VN/SPN-VC fusion pairs (Figure 82). However, 
these results are considerably lower when comparing with VE-PTP-VN/VE-
cadherin interacting pair, suggesting that perhaps VE-PTP does not form 
homodimers. The average fluorescence intensity for VE-PTP-VN/VE-
cadherin-VC was 1.9 x higher and the S/N was 2.7 x higher than for VE-PTP-
VN/VE-PTP-VC (Figures 40 and 41). These results suggest that VE-PTP 
does not homodimerise via its extracellular domain and the fluorescence 
signal was more likely due to non-specific YFP fragments interactions.  
Interestingly the average fluorescence intensity in cells co-expressing DEP-
1-VN/DEP-1-/VC was significantly lower (about 1.6 x) compared with cells 
co-expressing DEP-1-VN/SPN-VC (Figure 82). However, the average 
fluorescence intensity for both DEP-1-VN/DEP-1-VC and DEP-1-VN/SPN-VC 
interacting pairs was significantly higher than for DEP-1-VN/Myr-VC control 
pair (Figure 82). Both DEP-1-VN/DEP-1-VC and DEP-1-VN/SPN-VC fusion 
pairs resulted in the same S/N ratio value of 3.7, which was 3.7 x higher than 
222 
 
for DEP-1-VN/Myr-VC control pair (Figure 81). Similarly to VE-PTP, DEP-1-
VN/DEP-1-VC co-expression resulted in a significantly lower average 
fluorescence intensity than for DEP-1-VN/VE-cadherin-VC (Figures 67 and 
82). These results suggest that perhaps DEP-1 does not readily form 
homodimers.  
On the other hand, S/N ratio value and average fluorescence intensity for 
SAP-1-VN/SAP-1-VC were significantly higher than for negative interacting 
pairs SAP-1-VN/SPN-VC and SAP-1-VN/Myr-VC by 1.85- and 1.6-fold 
respectively (Figures 81 and 82). The average fluorescence intensity in cells 
co-expressing SAP-1-VN/SAP-1-VC appears to be similar to fluorescence 
intensity in cells co-expressing SAP-1-VN/VE-cadherin/VC (Figures 67 and 
82). However, S/N ratio value for SAP-1-VN/Sap-1-VC appears to be much 
lower than for SAP-1-VN/VE-cadherin-VC (Figures 66 and 81). These results 
suggest that SAP-1 has the potential to form homodimers via its extracellular 
domains.  
S/N ratio value for GLEPP1-VN/GLEPP1-VC was 4.8-fold higher than for 
GLEPP1-VN/SPN-VC and 10.5-fold higher compared with GLEPP1-VN/Myr-
VC (Figure 81). The average fluorescence intensity in cells co-transfected 
with GLEPP1-VN/GLEPP1-VC was significantly higher compared with cells 
co-transfected with GLEPP1-VN/SPN-VC and GLEPP1-VN/Myr-VC. The 
average fluorescence intensity for GLEPP1-VN/GLEPP1-VC was 2.2 x 
higher than for GLEPP1-VN/SPN-VC and 4.5 x higher than GLEPP1-
VN/Myr-VC (Figure 82). S/N ratio value and average fluorescence intensity 
for GLEPP1-VN/GLEPP1-VC were both higher than the values obtained for 
GLEPP1-VN/VE-cadherin-VC (Figures 66, 67, 81 and 82).  All three methods 
of analysis complement each other, suggesting that GLEPP1 has the 






Figure 81. S/N ratio of BiFC assay in HEK293T cells in R3 RPTP dimerisation study. S/N for each interacting fusion pair was 
calculated by dividing its median value by the median value from the corresponding Myr-VC-containing fusion pair. The median 















Figure 82. Quantitation of BiFC fluorescence intensities in transiently transfected HEK293T cells. Pairs of constructs as 
indicated were transfected into HEK293T cells using equal amounts of each expression vector and the BiFC signal assessed. 
Average fluorescence intensity and error bars of at least three independent experiments was determined using ImageJ software as 
described in the materials and methods. At least three random fields were analysed in experiments for each fusion pair tested. 



































6.6 Evaluating the fraction of BiFC constructs in the plasma membrane 
Since generation of fusion proteins and deletion of the intracellular 
sequence, as in this study, may affect the sub-cellular localisation of the 
protein, I assessed the fraction of the DEP-1-VN construct present in the 
plasma membrane relative to total cell expression and compared this with a 
full-length DEP-1 expression construct. This was achieved essentially as 
described in van der Wijk et al (2005). Briefly, using cells transfected with 
either DEP-1-VN or DEP-1 full-length constructs, the constructs were 
immunoprecipitated from whole cell lysates or immunoprecipitated after 
adding the anti-myc antibody to intact cells, to detect cell-surface expression 
only. The amount of immunoprecipitated protein was assessed by Western 
blotting. So far the results were obtained only for DEP-1-VN fusion construct 
due to availability of the corresponding full-length expression vector. 
Nonetheless the results could be potentially extrapolated to other similar R3 
RPTP constructs. 
Comparison of the fraction of cell-surface expression of the DEP-1-VN 
construct, relative to total DEP-1-VN expression, with the fraction of cell-
surface expression of full-length DEP-1 (Fig. 83) indicated that the BiFC 
construct exhibited a similar fraction of cell-surface expression as DEP-1, 
suggesting that the generation of the fusion protein did not detract from 
effective trafficking of the protein. Degradation was not evident (Figure 77), 
indicating the cell-surface localisation and protein stability were not 
significantly affected by creating the fusions, although it is possible that some 
degradation products lacking a myc tag are not detected by this analysis. As 
observed in studies investigating interactions with VE-cadherin, in the studies 
of homodimerisation in this chapter, a BiFC signal was observed in both the 
plasma membrane and an intracellular structure. This is likely to be the rough 
endoplasmic reticulum revealing that formation of the BiFC complex between 
proteins of interest can occur in the endoplasmic reticulum during the post-
translation modifications prior to trafficking to the plasma membrane. 
However, further experiments are required to confirm surface localisation of 














Figure 83. Evaluating the fraction of the DEP-1 BiFC construct in the plasma membrane. Comparison of DEP-1-VN construct 
cell surface expression relative to the full-length DEP-1 protein. HEK293T cells transfected with either DEP-1-VN or full-length 
DEP-1(WT). (A) Cell-surface protein was immunoprecipitated with an anti-myc antibody and detected in an anti-myc Western blot. 




























Dimerisation of R3 RPTPs has been previously studied by co-
immunoprecipitation experiments, though it still remains unclear whether all 
R3 RPTP members homodimerise (Hower et al, 2009; Walchli et al, 2005; 
Sorby et al, 2001; Takahashi et al, 2006). It has not to date been studied in 
live cells and it is not known whether all the members of the R3 subgroup 
have the potential to form homodimers. In addition the role of the 
extracellular domain of R3 RPTPs in dimerisation remains undefined. 
Using the bimolecular fluorescence complementation technique the potential 
of R3 RPTPs to homodimerise via their extracellular and transmembrane 
domains was examined in live cells. Each BiFC construct consisted of the 
ectodomain and transmembrane domain of these molecules (as shown in 
Figures 21 and 47). Qualitative and quantitative assessments of the 
fluorescence images obtained on co-expression of either VE-PTP-VN/VE-
PTP-VC, DEP-1-VN/DEP-1-VC, SAP-1-VN/SAP-1-VC or GLEPP1-
VN/GLEPP1-VC fusion pairs suggested potential homodimerisation of SAP-1 
and GLEPP1 but not VE-PTP and DEP-1. Quantitative assessment of these 
interacting pairs indicated that the co-expression of either SAP-1-VN/SAP-1-
VC or GLEPP1-VN/GLEPP1-VC fusion pairs resulted a BiFC signal that was 
due to a specific interaction, rather than self-assembly of constructs and 
background fluorescence.  
The results of this chapter complement previous co-immunoprecipitation 
studies that demonstrated SAP-1 homodimerisation is mediated by its 
extracellular domain (Walchli et al, 2005). The finding that the extracellular 
domain of SAP-1 potentially forms homodimers is reminiscent of the previous 
reports on some other transmembrane proteins. For example, it has been 
demonstrated that RPTPα exists predominantly as homodimers and that 
both its extracellular and transmembrane domains were independently able 
to form homodimers though the exact contribution of each of the individual 
dimerisation domains has not yet been determined (Jiang et al, 2000). 
Interestingly, different isoforms of the same protein can undergo differential 
homodimerisation. A study by Xu and Weiss (2002) demonstrated that a 
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smaller isoform of CD45 formed homodimers more rapidly and efficiently 
compared with a larger CD45 isoform. The dimerisation was mediated by the 
extracellular domain, independently of cytoplasmic tail (Xu and Weiss, 2002). 
However, in this chapter the SAP-1 construct consisted of extracellular and 
transmembrane domain and there is a possibility that the observed 
dimerisation could be mediated by its transmembrane region. Dimerisation of 
PTPσ via its transmembrane domain was reported by Lee et al (2015). It has 
been demonstrated that the transmembrane was sufficient for at least some 
of the homodimerisation, though the intracellular and, to a lesser extent, the 
extracellular domain of the protein could also contribute (Lee et al, 2015). 
The above results suggest that the dimerisation of RPTPs could be 
modulated by multiple domains and the dimerisation does not fit one model. 
However, it is becoming apparent that extracellular and/or transmembrane 
domains of RPTPs play an important role in their regulation and may have 
physiological significance if regulated by ligands leading to changes in 
phosphatase activity.   
It has been previously shown that GLEPP1 can potentially form homodimers 
mediated by its transmembrane and intracellular domains but not 
extracellular domain (Walchli et al, 2005; Hower et al, 2009). In a co-
immunoprecipitation study by Hower et al (2009) a GLEPP1 construct was 
used in which the extracellular domain had been replaced by a NGF receptor 
TrkA and, thus, they could not conclude whether the extracellular domain 
has a role in dimerisation or not. In this chapter, however, we show that there 
is a potential involvement of the extracellular and transmembrane domains 
but not intracellular domain. Both studies (i.e. the study by Hower et al 
(2009) and the study of this chapter) were carried out using different 
constructs; however in both cases the transmembrane domain of GLEPP1 
was present. This suggests that perhaps homodimerisation of GLEPP1 is 
mediated by its transmembrane domain. As already mentioned above, there 
are many examples of membrane proteins forming homo- and hetero-
oligomers via transmembrane domains, including receptor-type 
phosphatases. Dimerisation of sialoglycoprotein in human erythrocyte 
membranes glycophorin A (GpA) was extensively studied. A pattern of seven 
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amino acids (L75IXXGVXXGVXXT87 (L, leucine; I, isoleucine; X, any amino 
acid; G, glycine; V, valine; T, threonine)) in the transmembrane of GpA was 
shown to be sufficient to drive its dimerisation (Lemmon et al, 1994). The 
right-handed parallel transmembrane domain α-helices cross at an angle of 
40° and form a supercoil with a closely packed interface (ridges-into-grooves 
structure). The GXXXG motif (two glycines separated by any three residues) 
within the pattern of seven amino acids of GpA was shown to facilitate 
specific protein-protein dimerisation as glycine residues stabilise the 
structure through Van der Waals interactions and/or hydrogen bonding with 
residues on the opposite helix. This brings the interacting helices into close 
proximity of each other (Strous and Gent, 2002).  Mutation of glycine to 
alanine was shown to distract dimerisation. The insertion of this motif into 
other hydrophobic sequence backgrounds also led to dimerisation. Genetic 
and statistical data suggested that the GXXXG motif is a common framework 
for transmembrane domain helix-helix interactions (Strous and Gent, 2002). 
These findings propose that many transmembrane domains may contain 
information that regulates specific interactions, perhaps common to many 
proteins, with functionally important consequences. Indeed, it has been 
reported that GXXXG motifs are present in about 12 % of transmembrane 
helices (Teese and Langosch, 2015). However, some previous observations 
demonstrated that the presence of GXXXG motif is not an indicator of 
dimerisation but influenced by sequence context presumably to ensure that 
non-specific interactions of transmembrane helices are avoided. Instead, the 
conserved transmembrane residues (such as GXXXG motif) could play a 
role in a variety of functions, ranging from enhancing helix flexibility, lipid 
interactions and cell localisation (Teese and Landosch, 2015). Interestingly, 
alignment of the membrane-spanning sequences performed by Chin et al 
(2005) revealed that VE-PTP, DEP-1 and SAP-1, but not GLEPP1, contain 
such GXXXG motif in their transmembrane domains. In the same study Chin 
et al (2005) showed that the transmembrane of DEP-1 was able to self-
interact in the membrane. What is more, G979L and G983L mutations in 
GXXXG motif were found the most disruptive (Chin et al, 2005). In the same 
study GLEPP1 resulted in the strongest dimerisation signal despite the lack 
of GXXXG motif in its transmembrane domain (Chin et al, 2005). This 
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confirmed that more than one sequence motif in one or more domains could 
influence the interaction between proteins. In this Chapter, in agreement with 
previous findings, the quantitative analysis revealed that the co-expression of 
GLEPP1 fusion constructs resulted in the highest average fluorescence 
intensity as well as S/N ratio value, suggesting homodimerisation of this 
protein. Interestingly though, sedimentation velocity measurements carried 
out by Barr et al (2009) showed that GLEPP1 and DEP-1 were entirely 
monomeric in solution. The presence of GXXXG motif in the transmembrane 
domains of VE-PTP and SAP-1 does not seem to be involved in their 
dimerisation as shown by Chin et al (2005). As outlined above, the GXXXG 
motif is only a weak predictor of a dimerisation. Based on results obtained in 
this project, the dimerisation of SAP-1 is more likely mediated by its 
extracellular domain. This is in agreement with previous results obtained by 
Walchli et al (2005), showing that the extracellular domain of SAP-1 was 
sufficient to facilitate dimerisation, independently of its cytoplasmic and 
transmembrane regions. On the other hand, the results on VE-PTP 
dimerisation was consistent with the previous study by Chin et al (2005), 
showing that this phosphatase does not dimerise.  However, similarly to 
DEP-1, the dimerisation could still occur on a physiological level as a result 
of some ligand binding.  
The results obtained in this project also suggest that DEP-1 does not 
dimerise, which contradicts some previous findings. As mentioned in the 
introduction of this Chapter, the study by Takahashi et al (2006) showed that 
the extracellular domain of DEP-1 can form homodimers and that this forced 
dimerisation mediated by bivalent antibody increases its activity. A study by 
Sorby et al (2001) also demonstrated that DEP-1 activity can be increased 
as a result of ligand stimulation. Stimulation of DEP-1 with MatrigelTM (a 
preparation of extracellular matrix proteins secreted by Englebreth - Holm - 
Swarm mouse sarcoma) had a direct agonistic effect on DEP-1, which was 
mediated through interaction with the extracellular domain of DEP-1 (Sorby 
et al, 2001). Therefore, despite the results of this Chapter, DEP-1 could still 
have the potential to form extracellular ligand-mediated dimers in vivo. 
Ligand-induced dimerisation was shown for a cell surface receptor 
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glycoprotein CD36. A study by Daviet et al (1997) demonstrated that CD36 
exists predominantly as a monomer, but undergoes homodimerisation upon 
extracellular binding of Thrombospondin-1. Thrombospondin-1-induced 
dimerisation of CD36 was shown to be implemented in signal transduction of 
angiogenic pathways (Daviet et al, 1997). 
Dimerisation, whether it is homodimerisation or heterodimerisation, 
represents a powerful regulatory mechanism that can have a variety of 
functional consequences. Dimerisation between the same members of a 
family could have distinct functional specificity, whereas dimerisation 
between different members of a protein family can result in functional 
diversity, when different protein combinations have distinct regulatory 
properties. It is an attractive idea that RPTPs could be regulated by 
dimerisation similarly to RPTKs. Understanding the molecular mechanisms 
of the regulation of R3 RPTP would potentially assist in drug development for 
R3 RPTPs for some diseases, such as some immune, cardiovascular and 
neurological disorders or some types of cancers. For example, ligand-fusion 
proteins or antibodies to the extracellular domain of R3 RPTPs could be 
potentially used to regulate their activity. R3 RPTPs have been described as 
tumour suppressors and dysregulation of these phosphatases has been 
implicated in a variety of diseases. For example, GLEPP1 has been found to 
be lost in malignant cells in colon cancer and in hepatocellular carcinomas 
(Tautz et al, 2006). GLEPP1 was shown to play a role in terminal 
differentiation, apoptosis and cell cycle arrest, which are some of the 
hallmarks of tumour suppressor (Aguiar et al, 1999; Seimiya and Tsuruo, 
1998). Using restriction landmark genome scanning (RLGS) in an animal 
model of multistage tumorigenesis induced by folate/methyl-deficiency 
revealed that GLEPP1 gene was silenced due to immediate promoter 
methylation during hepatocarcinogenesis progression resulting in significant 
reduction of GLEPP1 expression (Motiwala et al, 2003). These findings 
suggested that the silencing of PTPRO in the liver could facilitate tumour 
promotion either by relaxing cell cycle arrest, preventing cell contact 
inhibition or developing resistance to apoptosis (Motiwala et al, 2003). A 
truncated isoform of GLEPP1 (PTPROt) is expressed in B-lymphoid cells. 
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More recent study by Motiwala et al (2015) showed that PTPROt is 
significantly down-regulated in the most common adult leukaemia, Chronic 
Lymphocytic Leukaemia (CLL). The expression of PTPROt was shown to 
prevent infiltration of inflammatory cells, such as monocytes and T-
lymphocytes that support the growth of CLL cells, into the spleen (the study 
was concentrating on spleen tissue as an increased spleen weight and 
accumulation of leukaemic CD5/CD19 cell population are the characteristics 
of CLL) (Motiwala et al, 2015). In addition, the expression of PTPROt 
appeared to suppress the leukaemic phenotype by mediating activation of a 
cellular tumour protein p53 and the resultant suppression of an oncogenic 
transcription factor Foxm1 expression (Motiwala et al, 2015). The collective 
results suggest that GLEPP1 could be a good therapeutic target for novel 
drugs against some types of cancer. 
SAP-1 expressed in intestinal epithelial cell was shown to be involved in the 
regulation of the intestinal immunity, partially by controlling the expression of 
proinflammatory cytokines and chemokines, such as interferon-γ and IL-17, 
in the colonic mucosa (Kotani et al, 2016). It has been suggested that SAP-1 
regulates the intestinal immunity through its physiological substrate 
CAECAM20 (carcinoembryonic antigen-related cell adhesion molecule 
20).  Tyrosine phosphorylation of CAECAM20 is an intestinal microvilli-
specific membrane protein that was shown to promote the binding of spleen 
tyrosine kinase (Syk) and activation of nuclear factor-κB (NF-κB) in cultured 
cells. This leads to the production of IL-8 chemokine that, in turn, results in 
neutrophil infiltration, both of which were shown to be characteristics of 
inflammatory bowel disease (Murata et al, 2015). It has been shown that 
SAP-1 and CAECAM20 can associate together via their extracellular 
domains, independently of their cytoplasmic tails. However, full-length of 
SAP-1 is required to exert its effect on CAECAM20 as it has been shown to 
dephosphorylate CAECAM20 and, thus, counteract CAECAM20-mediated 
proinflammatory effects (Murata et al, 2015). Therefore, SAP-1 represents a 
therapeutic potential in inflammatory bowel diseases. The therapeutic 
potential of VE-PTP and DEP-1 as targets for anti-inflammatory drugs was 
discussed in previous Chapters 4 and 5 with regards to their regulatory roles 
233 
 
in leukocytes extravasation and T-cell receptor signalling respectively. DEP-1 
also represents an attractive therapeutic target for the treatment of the 
cardiovascular diseases associated with diabetes and obesity. A study by 
Shintany et al (2015) demonstrated that R3 RPTPs suppressed the insulin-
induced tyrosine phosphorylation of the insulin receptor (IR), inhibiting insulin 
signalling and negatively regulating energy metabolism. However, DEP-1 is 
the only R3 RPTP that is expressed in insulin target tissues such as the 
skeletal muscle, liver and adipose tissue, where it was shown to co-localise 
with insulin receptor in the plasma membrane (Shintany et al, 2015). 
Selective DEP-1 inhibitors could have the potential to enhance the insulin-
induced activation of IR and the downstream Akt signalling, thus improving 
glucose and insulin tolerance in type 2 diabetes patients.  
Although R3 RPTPs represent an attractive drug target many difficulties limit 
the development of PTPs’ inhibitors due to a highly charged and highly 
conserved active site. Highly potent inhibitors often target multiple PTPs that 
can lead to tremendous adverse effects. Despite this major drawback, there 
was an influx of new strategies in developing competitive orthosteric and 
allosteric PTP inhibitors to target specific PTPs (Stanford and Bottini, 2017). 
One of the exciting developments in the PTP field is the development of the 
first-in-class selective orthosteric small molecule VE-PTP inhibitor AKB-9778 
(Campochiaro et al, 2015). This small molecule was shown to be effective in 
diabetic retinopathy and retinal vein acclusion treatments as well as other 
eye diseases, including neovascular age-related macular degeneration, 
characterised by excessive vascular permeability and ocular 
neovascularisation and it is now in clinical trials (Shen et al, 2014). VE-PTP 
was shown to negatively regulate the activity of the angiopoietin-1 receptor 
Tie2, which together with VE-cadherin and plakoglobin play a role in 
maintaining the integrity of endothelial junctions (Fachinger et al, 1999). VE-
PTP regulation of vascular integrity via Tie2 and VE-cadherin appear to be 
independent of each other. VE-PTP was shown to inhibit Tie2, resulting in 
increased vascular leakage and, thus, inhibiting VE-PTP would represent an 
attractive therapeutic target to decrease vascular leakage associated with 
certain eye diseases as well as type 2 diabetes. Small molecule AKB-9778 
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appeared to inhibit VE-PTP catalytic activity, leading to the increased 
phosphorylation of Tie2 and activation of downstream Akt signalling and 
subsequent reduction in vascular leakage and occular neovascularisation 
(Shen et al, 2014).   
In most cases the ligands for the R3 RPTPs, the regulation of their 
dimerisation state and the effects of dimerisation on their activity are not fully 
defined. Nonetheless, increasing evidence shows that dimerisation can 
determine enzyme activity and growing data demonstrates that generally 
protein tyrosine phosphatases are inhibited by dimerisation. However, in 
some cases, as was seen with DEP-1, the catalytic activity was enhanced by 
artificial dimerisation. Therefore, the correlation between dimerisation and 
regulation of catalytic activity should be established specifically for each 
RPTP and cannot be extrapolated even to members of the same sub-type of 
RPTPs. Understanding regulatory mechanisms of R3 RPTPs will shed light 
on physiological roles of this subfamily and aid in development of novel 
therapeutic targets. Further studies are required to define the relative roles of 
the extracellular and transmembrane domains in R3 RPTP dimerisation and 
perhaps explore other possible mechanisms of their regulation, such as 
extracellular ligand binding or reversible oxidation.  
 
6.8 Conclusion 
Although there is growing evidence that the dimerisation of R3 RPTPs can 
regulate their functions and that their extracellular and/or transmembrane 
domains could be involved in the formation of dimers, the results of this 
chapter clearly demonstrate that the phosphatases of this subgroup do not 
behave in similar ways and, thus, it is difficult to present a unifying theme. 
Based on the results obtained in this project GLEPP1 and SAP-1 have a 
potential to dimerise, which is mediated by their extracellular and/or 
transmembrane domains. However, the exact molecular interface of such 
interactions remains unclear and requires further investigation. VE-PTP and 
DEP-1 did not show the potential to dimerise via their extracellular and 
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transmembrane domains, though dimerisation can perhaps still occur under 
physiological conditions through different domains (e.g. cytoplasmic domain 
or full-length protein is required) or as a result of extracellular ligand binding. 
There could be another regulatory mechanism altogether. Therefore, further 
experiments are required to establish the potential of these phosphatases to 
dimerise and to investigate other means of their regulation in order to gain 




































This thesis uses a live cell bimolecular fluorescence complementation (BiFC) 
assay and the results provide insight into functional roles and the importance 
of the extracellular and transmembrane domains of protein tyrosine 
phosphatases of the R3 subgroup (R3 RPTPs). This method enabled me to 
confirm the interaction between VE-PTP and VE-cadherin via their 
extracellular domains in live cells, representing a major step forward from 
previous immunoprecipitation studies. In addition this method was used to 
investigate extracellular domain interactions of other members of the R3 
subgroup, namely DEP-1, SAP-1 and GLEPP1 with VE-cadherin. Despite 
little homology within their extracellular domains all members of the R3 
subgroup showed the potential to interact with VE-cadherin via their 
extracellular and/or transmembrane domains in live cells, although the 
physiological importance of these interactions remains to be defined. The 
molecular basis of these interactions has to be further investigated. It is 
possible that the extensive glycosylation of their extracellular domains could 
also play a role in the interaction with other proteins. This project also 
demonstrated that the 17th FNIII-like domain of VE-PTP is not the only 
domain involved in interaction with VE–cadherin as was reported by previous 
studies by Nawroth et al (2002). This raises a question whether these 
protein-protein interactions are specific. Collective results over the decade 
showed that phosphatases appear to exhibit high specificity towards their 
substrates (Zhang et al, 1993; Zhang et al, 2002). However, whether the 
specificity applies towards ligand binding is not fully defined. Based on the 
expression analysis of R3 RPTPs it has been proposed that the ligand 
binding specificity is determined by specific tissue and/or cell type 
expression. More recent studies highlight the importance of extracellular and 
transmembrane domains of R3 RPTPs in protein-protein interaction. In itself 
extracellular ligand binding was proposed to be one of the regulatory 
mechanisms that governs substrate specificity of RPTPs, thus regulating 
their catalytic activity (den Hertog et al, 2008). Perhaps there are 
combinatorial factors that determine specificity of R3 RPTP interactions. 
Homophilic binding interactions have been shown for some R3 RPTPs in 
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previous immunoprecipitation studies and have been proposed as another 
regulatory mechanism. 
The results of this project showed that fusion constructs SAP-1 and GLEPP1 
indeed have the potential to form dimers via their extracellular and/or 
transmembrane domains. On the other hand, fusion constructs VE-PTP and 
DEP-1 appeared not to homodimerise. However, in this project the 
generated BiFC fusion constructs consisted of extracellular and 
transmembrane domains fused to either N- or C-terminal part of a yellow 
fluorescent protein, lacking the intracellular domain entirely. Perhaps, VE-
PTP and DEP-1 still have the potential to form homodimers in their normal 
physiological environment via their intracellular domains or every domain is 
required for the dimerisation to occur. In addition, the dimerisation could 
occur in response to extracellular ligand binding. Based on the results of this 
project and on many previous studies it appears that the regulation of R3 
RPTP could be specific to each member and the results for one phosphatase 
cannot be extrapolated to another even though they belong to one subgroup. 
Further work is necessary to investigate the detailed molecular basis of 
interactions between R3 RPTP and VE-cadherin as well as the molecular 
basis of homodimerisation. We have already begun further experiments with 
VE-PTP and VE-cadherin, using the same methodology. In order to 
understand what particular region is essential for this interaction various 
mutants of VE-PTP are being generated, each lacking two different 
extracellular domains, which would be then co-expressed with VE-cadherin. 
Moreover, it would be of particular interest to investigate the role of 
glycosylation of the extracellular domains of R3 RPTPs in protein-protein 
interactions.    
The BiFC assay remains a popular tool for direct visualisation of protein-
protein interactions in live cells due to its simplicity and the ability to carry out 
experiments with regular confocal microscopy. Despite many improvements 
of BiFC assay the results require careful evaluation. Due to the nature of this 
method split fragments of a yellow fluorescent protein (YFP) have the 
tendency to self-associate spontaneously without the interaction between 
proteins fused to the YFP fragments resulting in false-positive fluorescence 
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signal, especially if proteins are overexpressed, which is common in transient 
transfections (Kerppola, 2006). Therefore it is advisable not to rely on only 
the qualitative confocal analysis but carry out thorough quantitative and 
statistical analysis that would provide more robust data. Here I adapted three 
different ways of quantitative analysis to measure the average fluorescence 
intensity, signal-to-noise (S/N) ratio and the distribution of yellow/red 
fluorescence signal ratio. All three methods gave very similar results, 
complementing each other and confirming the specificity of the BiFC method.  
Furthermore, as this thesis highlights, I believe the choice of appropriate 
negative controls is essential. As a control in the BiFC experiments a 
transmembrane protein sialophorin (SPN) (also termed leukosialin and 
CD43) was used as a fusion with the N- or C-terminal YFP sequence 
(designated SPN-VN and SPN-VC respectively). The SPN protein is similar 
to R3 RPTPs in that it has a large highly glycosylated extracellular domain 
and a single transmembrane spanning region; however, it has no homology 
to any R3 RPTPs and for these reasons has previously been used as a 
control in other studies of DEP-1 function (Cordoba et al, 2013). Moreover, a 
control construct that entirely lacked the extracellular domain and 
transmembrane regions and was associated with the cell membrane via the 
Lck myristoylation sequence (designated Myr-VC) was used as an additional 
negative control. Despite negative interacting pairs exhibiting some 
fluorescence signal the quantitative analysis revealed that the signal was 
significantly reduced compared with positive interacting fusion pairs, 
indicating specific interactions. However, one exception was the interaction 
of DEP-1 with SPN control. It is interesting to note that the fluorescence 
intensity obtained with the DEP-1 and VE-cadherin pairing, although 
significantly different from DEP-1 with the Myr-VC control, was not 
significantly different from DEP-1 and the SPN-VC control. And the 
fluorescence intensity obtained from DEP-1 and SPN interaction was higher 
compared with DEP-1 and DEP-1 interaction. These observations could be 
interpreted as a bona fide interaction between DEP-1 and SPN. Although 
both proteins are expressed in leukocytes I am not aware of any previous 
reports documenting this interaction. Further experiments would be required 
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to investigate whether the interaction between DEP-1 and SPN has any 
physiological significance. The findings highlight the importance of using 
several controls in BiFC studies with membrane proteins which are more 
prone to artefactual results than studies of freely diffusing cytoplasmic 
proteins, since the sub-cellular location of these proteins is restricted to the 
plane of the membrane. 
An important area of future investigation in the field of R3 RPTPs is 
identification of potential ligands and exploration of ligand-induced 
dimerisation. With respect to R3 RPTPs, since ligands have been 
documented for DEP-1 (Takahashi et al, 2012; Whiteford et al, 2011), it is 
reasonable to assume that ligands exist for other R3 RPTP family members. 
One approach to identify ligands involves the receptor alkaline phosphatase 
(RAP) assay. This method provides a direct indicator of extracellular domain 
binding and it is heat stable and, thus, can be differentiated from the heat 
labile alkaline phosphatases of most tissues (Stoker, 2005). We have already 
generated R3 RPTP alkaline phosphatase (AP) fusion proteins and 
confirmed their expression by Western blotting. These AP fusion proteins 
can be used as affinity probes to identify ligand- or receptor-expressing cells 
in tissue culture or in tissue sections and the binding can be directly 
visualised through simple chromogenic assays without purification, 
radioactive labelling or secondary reagents. However, these results are not 
included in this thesis since the experiments are still at the preliminary stage 
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